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Abstract
Phospholipase D (PLD) is a phospholipid hydrolyzing enzyme, the activation o f 
which has effects on cellular events including cell growth and membrane trafficking in 
mammalian cells. In a reconstitution assay consisting o f permeabilised HL-60 cells 
(human myeloid leukemic cells), experiments confirmed that members o f the ADP- 
ribosylation factor (ARF) family proteins including ARF1 and ARF6  were efficient 
PLD activators. However, ARF1 was a stronger activator o f PLD than ARF6 , a result 
that was also found in in vitro PLD assays. Moreover, the myristoylated amino 
terminal a-helix o f  ARF was essential for the activation o f PLD.
The activation o f ARF is in turn regulated by a specific family o f small guanine 
nucleotide exchange factors (GEFs) comprising ARNO, GRP-1 and cytohesin-1. The 
GEFs catalyze the release o f bound GDP and its replacement by GTP, leading to ARF 
activation. Using the reconstitution assay, the PLD activation mediated by ARF was 
enhanced by the GEFs. However, the GEFs did not improve the stimulation o f PLD by 
ARF in vitro. Interestingly, these GEFs activated PLD with high potency but none o f 
the three GEFs was more potent than the others in their regulation o f PLD in cell- 
based assays. It seems that this pattern o f PLD activation does not reflect differential 
interactions with major phosphoinositides (PIP2 and PIP3) since these molecules bind 
equally well to the GEFs.
Importantly, PIP2 and PIP3 increased the potency o f PLD activation mediated by 
the coordinated actions o f ARF and its exchange factors indicating the involvement o f
3
other pathways in the regulation o f PLD in vivo. In particular, it emerged that PIP3 is a 
more potent activator o f  PLD than PIP2 in the presence and absence of ARF-GEFs.
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Chapter one
General introduction
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1.1. Cell signalling
Correct cell growth and differentiation in multicellular organisms depends on the 
ability o f the cells to communicate with each other. The mechanisms for such 
communication include secretion o f soluble signalling molecules and direct contacts 
between cells. Generally, extracellular signalling molecules interact with a receptor 
embedded within the plasma membrane which transduces the signal across the 
membrane. Then distinct intracellular signal tranduction pathways are initiated that 
lead to the generation o f so-called second messengers within the cell. The second 
messengers then trigger a series o f molecular interactions that lead to specific cellular 
responses.
The molecular mechanisms o f signal transduction pathways have been intensely 
investigated over the years. The purpose o f this introduction is to give an overview o f 
the various receptor-mediated signalling pathways involved in the control and 
regulation o f intracellular events such as gene transcription, protein synthesis and 
transport, protein phosphorylation and phospholipid metabolism. The latter will be 
discussed in more details with respect to the regulation o f an important enzyme named 
phospholipase D (PLD).
1.2. Signal transduction via cell surface receptors
Cell surface receptors are integral membrane proteins. They have regions that 
contribute to three basic domains: extracellular domains, transmembrane domains and 
cytoplasmic domains. Receptors containing extracellular domains expose some 
residues to the outside o f the cell, interact with and bind to ligands. Receptors with 
transmembrane domains span the membranes hydrophobic stretches o f amino acids in
19
the lipid bilayer. The cytoplasmic domains o f cell surface receptors are tails or loops 
o f the receptor that are within the cytoplasm that react to ligand binding by interacting 
in some way with other molecules, leading to the generation o f second messengers. 
Cytoplasmic residues o f the receptor are thus the effector region o f the molecule.
There are four major classes o f cell-surface receptors: G-protein-coupled 
receptors (GPCRs), tyrosine kinase-linked receptors, ion-channel receptors, and 
receptors with intrinsic enzymatic activity such as receptor tyrosine kinases (RTKs) 
(Figure 1.1).
Ligand binding to ion-channel receptors changes the conformation o f the 
receptor so that specific ions flow through it. The resultant ion movements alter 
electric potential across the cell membrane. The acetylcholine receptor at the nerve- 
muscle junction is an example.
Stimulation o f tyrosine kinase-linked receptors leads to the formation o f  a 
multimeric receptor, which then interacts with and activates one or more cytosolic 
protein-tyrosine kinases. The receptors for many cytokines, the interferons, and human 
growth factor are o f this type. These tyrosine kinase-linked receptors sometimes are 
referred to as the cytokine-receptor superfamily.
The GPCRs and the RTKs will be considered in more details in the following 
sections with a particular stress on the signalling pathways initiated by these receptors.
1.2.1. Signalling through GPCRs
Many different mammalian cell-surface receptors are coupled to a heterotrimeric 
signal-transducing GTP-binding protein (G protein). Ligand binding to these receptors 
activates their associated heterotrimeric G protein, which then activates an effector
20
Figure 1.1. Four major classes o f cell-surface receptors. Common ligands for each 
receptor type are listed in parentheses (Taken from Molecular Cell Biology, 
http://www.ncbi.nlm.nih.gov/books).
enzyme to generate intracellular second messenger (Figure 1.1). All GPCRs contain 
seven membrane-spanning regions with their N-terminal segment on the exoplasmic 
face and their C-terminal segment on the cytosolic face o f the plasma membrane 
(Figure 1.2).
Figure 1.2. Schematic diagram o f the general structure o f G protein- 
linked receptors. All receptors of this type contain seven 
transmembrane a-helical regions. (Taken from Molecular Cell Biology, 
http://www.ncbi.nlm.nih.gov/books).
This large receptor family comprises light-activated receptors (rhodopsins) in the eye 
and literally thousands of odorant receptors in the mammalian nose, as well as 
numerous receptors for various hormones and neurotransmitters (a-adrenergic 
receptors, p-adrenergic receptors). Although these receptors are activated by different 
ligands and may mediate different cellular responses, they all activate a seemingly 
similar signaling pathway (Figure 1.3).
All heterotrimeric G proteins contain a, p, and y subunits. Prior to activation, the 
a subunit is bound to GDP. Binding of a trimeric G protein to an activated receptor
22
Figure 1.3. Schematic overview oj common signalling pathways 
downstream from GPCRs and RTKs. SM, second messenger. (Taken 
from Molecular Cell Biology, http://www.ncbi.nlm.nih.gov/books).
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leads to dissociation of GDP, binding o f GTP to Ga, and dissociation o f Ga-GTP from 
Gpy. Gq-GTP and Gpy can specifically interact with effector proteins such as enzymes, 
ion channels or receptors leading to changes in their activity. There are four general 
families o f  heterotrimeric G proteins: Gs, G„ Gq, and Go (Neer, 1995).
The best-characterized effector regulated by Gs and G* proteins is adenylyl 
cyclase, which catalyzes the formation o f cAMP from ATP. For instance, many o f the 
very different tissue-specific responses induced by binding o f adrenaline to p- 
adrenergic receptors are mediated by a rise in the intracellular level o f cAMP, 
resulting from activation o f adenylyl cyclase. As a second messenger, cAMP acts to 
modify the rates o f different enzyme-catalyzed reactions in specific tissues generating 
various physiological responses such as liberation o f glucose and fatty acids, muscle 
contraction and relaxation.
The other major signalling pathway activated by a GPCR is the phospholipase C 
(PLC)-mediated pathway. For instance, hormone binding to receptors coupled to Gq 
protein induces activation o f the p isoform o f PLC (Lee et al., 1994) by the general 
mechanism outlined in Figure 1.3. As a result, two second messengers, IP3 and DAG, 
are derived from this pathway through the hydrolysis o f  PI(4 ,5 )P2  by PLC, another 
important lipid signalling molecules involved in many cellular events. This activating 
PLCps may be via the a  or Py subunits.
1.2.2. Signalling through RTKs
The RTKs are a family o f more than 50 different transmembrane proteins. The 
ligands for RTKs are soluble or membrane-bound peptide/protein hormones including 
nerve growth factor (NGF), platelet-derived growth factor (PDGF), fibroblast growth
24
factor (FGF), epidermal growth factor (EGF), and insulin. Binding o f a ligand to this 
type o f receptor stimulates the receptor's intrinsic protein-tyrosine kinase activity, 
which subsequently stimulates a signal-transduction cascade leading to changes in 
cellular physiology and/or patterns o f gene expression (Figure 1.3).
Activation o f the RTK is initiated by ligand binding to the extracellular domain 
o f the receptor followed by the sequential processes o f receptor dimerization and 
autophosphorylation (transphosphorylation) o f tyrosine residues in its cytosolic 
domain (van der Geer et ol., 1994). The activated receptor also can phosphorylate 
other protein substrates.
Unlike GPCRs, which interact directly with an associated G protein, RTKs are 
linked indirectly to Ras via two proteins, GRB2 and Sos. Ras is an intracellular 
GTPase switch protein that acts downstream from most RTKs. Like Gsa, Ras cycles 
between an inactive GDP-bound form and active GTP-bound form. Ras cycling 
requires the assistance o f two proteins, GEF and GAP, whereas Gsa cycling does not. 
The SH2 domain in GRB2, an adapter protein, binds to specific phosphotyrosines in 
activated RTKs. The two SH3 domains in GRB2 then bind Sos, a guanine nucleotide 
exchange factor, thereby bringing Sos close to membrane-bound Ras-GDP and 
activating its exchange function. Binding o f Sos to inactive Ras causes a large 
conformational change that permits release o f GDP and binding o f  GTP.
All RTKs in mammalian cells appear to induce a kinase cascade that culminates 
in activation o f  MAP kinase pathway. This pathway consists o f Ras, Raf, Mek, MAP 
kinase and Rsk. This serine/threonine kinase, which can translocate into the nucleus, 
phosphorylates many different proteins including transcription factors that regulate
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expression o f important cell-cycle and differentiation-specific proteins (Moodie et al., 
1993).
Like GPCRs, RTKs can activate the PLC pathway. Indeed, one o f the first 
signalling pathways to be identified in RTK signalling involves PLC-y. Growth factors 
such as PDGF, EGF, FGF and NGF are known to stimulate turnover o f PI(4,5)P2 by 
activating PLC-yl in a wide variety o f cells (Rhee and Choi, 1992).
Another enzyme implicated in signalling by RTKs is the phosphoinositide 3- 
kinase (PI3K). PI3K catalyzes the addition o f phosphate to the 3’-position o f 
phosphatidylinositol (PI). The 3 ’-phosphorylated products o f this enzyme act as 
second messengers or affect membrane function. PI3K is composed o f regulatory 
(p85) and catalytic (pi 10) subunits, each o f which is a member o f a larger family o f 
homologous proteins. PI3K was the first signalling molecule to be shown to associate 
with RTKs through its two SH2 domains present in the p85 regulatory subunit 
(Coughlin et al., 1989). Mutation o f the p85 binding sites in the PDGF receptor 
impairs mitogenesis in response to PDGF in some cell types (Valius and Kazlauskas, 
1993). Studies with mutant receptors suggest that PI3K is also apparently required for 
PDGF-induced membrane ruffling and chemotaxis (Wennstrom et al., 1994).
1.2.3. GPCRs and RTKs can activate PLD pathway
Both GPCRs and RTKs have been implicated in the activation o f PLD whose 
regulation and functional significance will be thoroughly addressed below. PLD 
catalyses the breakdown o f a major membrane phospholipid, namely 
phosphatidylcholine (PC) into phosphatidic acid (PA) and a soluble head group, 
choline.
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GPCRs have been found to interact with and signal through the small GTP- 
binding proteins o f the Ras superfamily such as ARF and Rho proteins. Inhibitors o f 
ARF and RhoA prevent the activation o f PLD through a number o f GPCRs such as H I 
histamine, B2 bradykinin and M3 muscarinic receptors (Mitchell et al., 1998). In 
addition, solubilized M3 muscarinic receptor coimmunoprecipitates with ARF 1/3 or 
RhoA.
RTKs such as EGF and PDGF receptors were shown to induce PLD activation in 
certain cell types. This observation suggested that PLD activity could be modulated by 
tyrosine phosphorylation (Fisher et al., 1991; Ben and Liscovitch, 1989). Furthermore, 
priming by GM-CSF o f the neutrophil PLD response to chemoattractants such as the 
peptide fMLP, was tyrosine phosphorylation dependent (Bourgoin et al., 1991).
1.3. Biomembranes: lipid composition
As already mentioned earlier, enzymes such as PLC, PLD and PI3K play 
important roles in cellular metabolism including the degradation o f membrane 
phospholipids to generate crucial second messengers that participate in numerous 
signalling pathways.
A typical biomembrane is assembled from phosphoglycerides, sphingolipids, and 
steroids. All three classes o f lipids are amphipathic molecules (i.e., they have a 
hydrophilic and a hydrophobic part).
In phosphoglycerides, a principal class o f phospholipids synthesized in the 
endoplasmic reticulum (ER), fatty acyl side chains are esterified to two o f the three 
hydroxyl groups in glycerol, and the third hydroxyl group is esterified to phosphate. 
The phosphate group is also esterified to a hydroxyl group on another hydrophilic
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compound, such as choline in phosphatidylcholine (PC) (Figure 1.4). The other 
phosphoglycerides include phosphatidylserine (PS), phosphatidylethanolamine (PE) 
and phosphatidyl inositol (PI) (Figure 4).
Figure 1.4. Some common phosphoglycerides found in membranes. (Taken 
from Molecular Cell Biology, http://www.ncbi.nlm.nih.gov/books).
PC is usually the most abundant phospholipid in animal and plants, often 
amounting to almost 50% of the total, and as such it is obviously the key building 
block of membrane bilayers. In particular, it makes up a very high proportion o f the 
outer leaflet of the plasma membrane. As noted above, PC is susceptible to hydrolysis 
by phospholipases, enzymes that cleave various bonds in the hydrophilic ends of 
phospholipids (Figure 1.5).
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Figure 1.5. Specificity o f phospholipases. Each type 
of phospholipase cleaves one of the susceptible 
bonds shown in red. (Taken from Molecular Cell 
Biology, http://www.ncbi.nlm.nih.gov/books)
PI is an important lipid, both as a key membrane constituent and as a source of 
essential signalling molecules such as PIP2 and PIP3 which mediate lipid-protein 
interactions. They are especially effective in specific binding to PH domains of 
cellular proteins. PI is an acidic phospholipid that in essence consists of a phosphatidic 
acid backbone, linked via the phosphate group to inositol (Figure 1.4).
In summary, cell stimulation triggers an array of signalling events involving the 
activation of cell-surface receptors, intracellular protein and lipid molecules leading to 
cellular responses. The remaining of this introduction will focus on the mechanisms of 
regulation of PLD and its cellular functions.
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1.4. PLD pathway: a major signalling event
1.4.1. Origin
PLD was first purified from plants (Wang et al., 1994) and subsequently purified 
and cloned in a wide array o f species such as bacteria (Iwasaki et al., 1994), yeast 
(Rose et al., 1995, Waksman et al., 1996), and mammals (Hammond et al., 1995). 
Two mammalian PLD isoforms, PLD1 (Park et al., 1997; Hammond et al., 1995) and 
PLD2 (Lopez et al., 1998; Colley et al., 1997; Kodaki and Yamashita, 1997), have 
been identified in human, mouse and rat species.
PLD1 exists as two splice variants, namely PLD la  and PLD lb  which are found 
in various cell types and tissues o f all mammals (Katayama et al., 1998; Hammond et 
al., 1997; Park et al., 1997; Yoshimura et al., 1996). These two splice variants differ 
by the absence o f a 38-amino acid region in the C-terminus in PLD lb  (Katayama et 
al., 1998; Hammond et al., 1997). Both mammalian PLD la and PLD lb have very 
similar properties and, on the whole, can be regulated by the same set o f molecules 
(see below). However, it should be noted that there may be significant differences. For 
example, rat PL D lb was reported to be less sensitive to a member o f the Rho family 
GTPases namely RhoA than rat PLD la (Yoshimura et al., 1996).
Three splice variants for human PLD2 has also been cloned (Steed et al., 1998) 
although no functional differences among variants have been described.
1.4.2. Structure
Comparison o f  the amino acid sequences o f human, yeast, plant and bacterial 
PLD revealed the existence o f functional highly conserved regions such as two 
essential motifs (Freyberg et al., 2003; Exton et al., 2002; Frohman et al., 1999;
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Morris et al., 1996). Figures 1.6 and 1.7 show the sequence alignment and the 
functional domains o f the PLDs mentioned above. These two domains consist of 
conserved histidine (H), lysine (K), and aspartate (D) residues that are required for 
catalysis (Sung et al., 1997) and are referred to as HKD domains. In addition to the 
catalytic domains, PX (phox homology) domain and PH (pleckstrin homology) 
domain have also been identified in human and yeast PLDs. The PX and PH modules 
have been widely implicated in a variety o f protein-protein and protein-lipid 
interactions (Lemmon, 2003; Kanai et al., 2001; Ponting, 1996). However, these two 
domains are absent in the plant and bacterial PLDs. In particular, plant PLD differs 
from the other PLDs in that it has an N-terminal C2 domain, a structural element that 
usally mediates calcium and phospholipid-binding and which is found in a wide range 
o f signalling proteins (Ponting and Parker, 1996). Outside the conserved regions, the 
amino and carboxy terminal sequences o f PLD have been suggested to promote 
interaction with protein kinase C (PKC) (Sung et al., 1999a) and membrane 
association (Frohman et al., 1999) respectively. The mammalian PLDs also contain a 
PIP2  binding site and other conserved regions o f unknown function. Interestingly, 
human PLD1 (hPLDl) contains a loop sequence between the two HKD domains that 
is not present in human PLD2 (hPLD2). As illustrated in Figure 1.6 and Table 1.1 
analysis o f the amino acid sequences o f PLD1 and PLD2 indicates 50% sequence 
similarity while homology between the yeast, plant, bacterial and human PLD is 
considerably lower (Morris et al., 1996).
A molecular weight o f approximately 120 kDa has been found for the 
recombinant hPLDl confirming the predicted size o f 124 kDa (Hammond et al., 1995)
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hPLDl 1 MSLKNEPRVN TSALQKIAADMENiIENLDTRELHFEGEEVDYDVS-----------PSDPKIQEVYI PFSAIYNTQG--------------FKEPNIQTYLSGCPIKA
SP014 1 MYSRNENSLFRIHLEYGIDEDRLKWSIIRSYKDIKSLHHKLKIVAFQQLTISKLYSDNNRYHSLQLPHFPHYKEMVKERNVMEKKAENKPSSAASAEHTS
RcPLD 1 -------------------------------- MAQISLHGTLHVTIYEVDKLHSGGG------------------------------------------------------------------------------------------------------------------
SaPLD 1 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
hPLDl 84 QVLEVERFTSTTRVPSIN-----------LYTIELTHGEFKWQVKRKFKHFQEFH", LLKYKAFIRIPIPTLRRHTFRRQNVREEPREMPSLPRSSENMIREEQFL
SP014 101 ENNNNDNGSNITSLETLSSSEISEFNIDNVKMKHLQDLIDEPDDFSQPIHLRLERi_RLLNIALCLiRPHANRLFEFYELSPLGNLLSRESGFQGKQGYLV
RcPLD 2 6 -------------------------------------------------------------- PHFFRKLVENIEETVGFGKGVSKLYATIDLEKARVGRTRILENEQSNPRWYESFHVYCAHQASNVIFT
SaPLD 1 ----------------------------------------------------------------MTSDQRPARLPTHKGVLLAPHRLHRLIPVSVALTTTVCAALPSSTAYAADTPPTPHLDAIERS---------
hPLD l 178 GRRKQLED YLTKILKMPMYRNYHATTEFLDISQLSFIHDLGPKG-IEGMIMKRSGGHP.IPG— LNCCGQGRACYRWSKRWLIVKDSFLLYMKPDS
SP014 201 IP.STAKAQGWRVSHFGKHAFKDMIDRHTTKWFLVRNSYLTYVSDLSSTTPLDVFLIDWKFKVFFSGNKNNILDNENEINWIIHDPNLEINDELEEFGIEN
RcPLD 94 VKDD---------------------NPIGPTLIGPAYVPVEELLDGEEIDRWVEILDED-------------------------------------KNPVHSGSKIHVKLQYFEVTKT)----- RNWGQGI
SaPLD 6 3 --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- LRDTSPGL
hPLDl 270 GAIAFVLLVDKEFKIKVGKKETETKYGIRIDNLSRTLILKCNSYRH-ARWWGGAIEEFIQKHGTNFUC-DHRFGSYAAIQENALAKWYVNAKGYFEDVAN 
SP014 301 DANNILDKNGKSKTHQKKSNISSKLLLLTLENSERKLKIICKSESS-LKQWMSSIIKMSTS— TPWSK-PNRFGSFAPVRTNSFCKFLVDGRDYFWSLSE
RcPLD 161 RSSKYPGVPYTYFSQRQGCKVSLYQDAHIPDKFVPQIPLAGGNYYEPHRCWEDVFDAITNAKHLIYITGWSVYTEISLIRDSRRPKPGGDITLGELLKKK 
SaPLD 71 EGSVWQRTDGNRLDAPDG-------- DPAGWLLQTPGCWGDAGCKDRAGTRRLLDKMTRNIADARHTVDIS------------ SLAPFPNGGFEDAWDG------LKAWA
hPLDl 368 AMEEANEEIFITDWWLSPEIFLKRPWEGNRWRLDCILKRJCAQQGVRIFIMLYKEVELALGINSEYTKRTLMRLHPNIKVMRHPDHVSSTVYLWAHHEKL 
SP014 397 ALLMAKDVIYIHDWWLSPELYLRRPVKGNQGFRIDRMLKSCAEKGIKIFIVIYRNVGNIVGTDSLW7KHSMLNLHPNIHIIRSPNQWLQNTYFWAHHEKF
RcPLD 261 ASEGVRVLMLVWDDRTSVGLLKKDGLMATHDEETEHFFQNTDVH CVLCPRNPDDGGSFVQDLQISTMFTHHQKIVWDS---------------------AMPNGD
SaPLD 157 AGHSPRVRILVG AAPIYHLNWPSRYRDELIGKLGAAAGK-------------------------VTLNVASMTTSKTSLSWN----------------------------------------- HSKL
hPLD l 4 68 VIIDQSVAFVGGIDLAYGRWDDNEHRLTDVGSVKRVTSGPSLGSLPPAAMESMESLRLKDKNEPVQNLPIQKSIDDVDSKLKGIGKPRKFSKFSLYKQLH
SP014 497 W IDETFAF XGGTDLCYGRYDTFEHVLRDD----------------------------------------------AESLLDQN---------------------------------------------------------------------------
RcPLD 346 SQRRRIVSFVGGLDLCDGRYDSPFHSLFRT-----------------------------------------------------------------------------------------------------------------------------------------
SaPLD 219 LWDGKTAITGGINGWKDDYLDTAH---------------------------------------------------------------------------------------------------------------------------------------------------
hPLD l 568 RHHLHDADSISSIDSTSSYFNHYRSHHNLIHGLKPHFKLFHPSSESEQGLTRPHADTGS1RSLQTGVGELHGETRFWHGKDYCNFVFKDWVQLDKPFADF
SP014 535 -----------------------------------------------------------------------------------------------------------------------------------------------------FPGKDYSNARIADFHDLDKPFESM
RcPLD 376  ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------- LDSAHHDDFHQPN— FAGA
SaPLD 244 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
hPLD l 668 IDRYSTPRMPWHDIASAVHGKAARDVARHFIQRWNFTK---------- IMKSKYRSLSYPFLLPKSQTTAHELR-------------- YQVPGSVHANVQLLRSAADWSAG
SP014 559 YDRKVIPRMPWHDVQMMTLGEPARDLARHFVQRWNY-------------- LLRAKRPSRLTPLLTPPSDI ' EELKSLPM— FEILREKSTCETglLRSAGNWSLG
RcPLD 393 SIEKGGPREPWHDIHSRLBGPIAWDVLFNFEQRWRKQGGKDLLIQLRELEDVIIPHLLLCYPDDLRHGMSSCLDPIHVELHLVSLRHLKMRQRLGLYSGK 
SaPLD 24 4 ----------------PVSDVDMALSGEAAASAGKYLDTLWDWT----------------CRNASDPAKVWIATSKGASCMPSMEQ------------DEAGSAPAEPTGDVPVIAVGGLG
hPLDl 755 IKYHEESIHAAYVHVIENSRHYIYIEN--------------- Q FFIS— CADDKWFNKIGDAIAQRILKAHRENQKYRVYWIPLLPGFEGDISTGGGNALQAIMH
SP014 649 LKKTECSIQNAYLKLIEQSEHFIYIEN--------------- QFFITSTVWNGT 'LNKIGDALVDRIVKANQEKKPWKAFILIPLMPGFDSPVDTAEASSLRLIMQ
RcPLD 493 DNIIDRSIQMLISMPFEGQRILFILKISISLEVLFGWSPDGIKPEDINALHLIPKELSLKILSKIAAGERFTVYIWPMWP EGIPESASVQAILD
SaPLD 321 VGIKESDPSSGYHPDLPT---------------------------------------------- APDTKCTVGLHDKTNADRDYDTVN--------------------------------------------- PEENALRSLIA
hPLDl 845 FNYRTMCRGENSILGQLKAELGNQWIN-YISFCGLRTHAELEGN— LVTEL---------------------------------IYVHSKLLIADDNTVIIGSANINDRSMLGKRD
SP014 741 FQYQSISRGEHSTFSKLKKlH-IDPAQ-YIQFFSLRKWSt FAPNERLITEQ--------------  --------------LYVHAKILIADDRRCIIGSANINERSQLGNRD
RcPLD 588 WQKrTMEMMYKDIVQALKANGIIEDPRNyLTFFCLGNREVKKSGEYEPAeKPEPDT’ RAQEARRFMiy VHTKMMIVDDEYIIIGSANINQRSMDGARD 
SaPLD 374 SARSHVEISQQDLNATCPPl P------------------- RYDIRTYDTLAGK-------------------------------------------------------------LAAGVKVRlWSDPAfJRGAVGSGGY
hPLDl 925 SEMAVIVQDTETVPSVMDGKEYQAGRFARGLRLQCFRWlG-------------------------------------------------------------------------------------------------------------------
SP014 822 SEVAILIRDTDLIKTKMNGDDYYAGKFPWELRQRLMREHLGCDVDLVEFVEKKFERFEKFAAKNYEKLHTLSICEGDSGNNWSDREMIDSAMIELGYREIF
RcPLD 688 SEIAMGAYQPHHlSTRQPARGQIHg  FRMSLWYEHLG-------------------------------------------------------------------------------------------------------------------
SaPLD 433 SQIKSLDEISDTLRTRLVALTGDNEKASRALCGNLQLASFR-------------------------------------------------------------------------------------------------------------------
hPLDl 966 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
SP014 922 GCKFSPQWKSGHGNSVDDGSTQCGINEKEVGREDENVYEKFFNSVDYGKSSRKRTE ’YHNFASLGLTFNHRAGIENVGIRDHKVLSTDPRLRKNDEHKK
RcPLD 724 ------------------------------------------------ -------------- -------------------------------------------------- - ---------------------------------------------------------------------------------
SaPLD 474 ------------------------------------------------------------------------------------------       — - ---------------------- ---------------- ------
hPLD l 966 -------------------------------------------------------------------------------------------------------------------------------YLDDPSBD----------------------------------------------------
SP014 1022 EVDGYGPDCWKKESNKKFKADATEQLKEWALNSLASKVLDDKEMIKSEIPEGFSNYLPNEKDLEMYL,TnKTVTNRNKWSMLKRICYLQYLSHKLDERKTQ
RcPLD 724 --------------------------------------------------------------------------------------------------------------------------------------  --------------------------------------------------------
SaPLD 474 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
hPLD l 974 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
SP014 1122 RLKKIKDMRRHLSSSTESTRNGSNSLPLNEKSNEGESTNVDQDIEGDEYHRLHEDILKNQELDDGSLDDLLSQIIPKITNFNSGEIDDAKKEELLKLNFI
RcPLD 724 ------------------------------------------------------------ — -----------------------------------------------------------------------------------------------------------m----------------- —
SaPLD 474 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
hPLD l 974  IQDPVSDKFFKEVWVSTAARNATIYDKVFRCLPNDEVHNLIQLRDFINKPVLAKE-------------------------------------------------------------------------------------
SP014 1222 d py s f e d p l is s f s e g l w f t ia l r n t l l y k l v f h c q p d n a v q n w k e y g e f t e l e q e f q in q e k l id l e a e n in s t t t n w d k d r e k e k m r k a a e l r m k l s
RcPLD 724 --------------m l d e s f l n f e se e c v r k v n q m a e k y w d l y s s e t l e h d l p g h l l r y p ig v a s--------------------------------------------------------------------------------
SaPLD 474  s sd a a k w a d g k py a lh h k lv sv d d sa fy ig sk m ly pa w lq d fg y iv espa a a q ------------------------------------------------------------------------------------
hPLD l 1029 -----------------------DPIRAEEELKKIRGFLVQFPFYFLSEESLLP----- SVGTKLVPMEVWT
SP014 1322 GSLLYGFNQKVFDKHTAQRILERIHGHLVIFPTEWLAKEVESRNWIFNSD’' r s p m e iy n
RcPLD 775 ---------------------------------------------- EGDVTELPGTEFFPDTKARVLGAKSDYLPPDrrr-
SaPLD 527 --------------------------------------------------------QLKTELLDPEWKYSQQAAATPAGCPARQAG
Figure 1.6. Alignment o f  human, yeast, plant and bacterial amu,o acid sequences for PLD enzymes. Conserved amino acids 
(aa) are shown in red and similar residues are in blue. The abbreviations used are as follows: hPLDl, human PLD1, gi 
1125739; SP014, Saccharomyces cerevisiae PLD, gi 954831; RcPLD, Ricinus communis PLD, gi 626007; SaPLD, 
Streptomyces antibioticus PLD, gi 517155. Alignment was generated by ClustalW and the printing of the multiple alignment 
output was performed by Boxshade.
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Figure 1.7. Domain structure o f  human, yeast, plant and bacterial amino acid fo r  PLD enzymes. Regions o f conserved sequence are 
shown. The abbreviations used and protein accession numbers are as follows: PX, phox homology domain; PH, pleckstrin homology 
domain; PLDc, PLD catalytic site (motifs II and IV known as HKD); C2, calcium- and phospholipid-binding domain; hPLD l, human 
PLD1, AAB49031; hPLD2, human PLD2, NP 002654; Spol4, Saccharomyces cerevisiae PLD, AAA74938; RcPLD, Ricinus 
communis PLD, AAB04095; SaPLD, Streptomyces antibioticus PLD, BAA03913. The conserved protein domains were obtained by
Table 1.1.
Comparison o f  deduced amino acid sequences o f  PLDs from various species 
The percentage identity of the indicated PLD-deduced amino acid sequences is 
indicated above the diagonal, and the percentage similarity is below. The 
abbreviations are as follows: hPLDl, human PLD1; hPLD2, human PLD2; Spol4, 
Saccharomyces cerevisiae PLD; RcPLD, Ricinus communis PLD; SaPLD, 
Streptomyces antibioticus PLD. The asterisk (*) indicates that no significant identity 
and similarity was found. The percentage global amino acid sequence identity and 
similarity was calculated by pairwise BLAST using BLOSUM62 matrix.
hPLDl hPLD2 Spol4 RcPLD SaPLD
hPLDl - 50 41 25 *
hPLD2 63 - 34 25 *
Spol4 59 53 - 24 *
RcPLD 41 40 39 - *
SaPLD * * * * -
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while hPLD2 has a reported molecular weight o f 106 kDa based on the amino acid 
sequence (Kodaki and Yamashita, 1997).
1.4.3. Expression and localization
The expression and subcellular locations o f PLD 1 and PLD2 vary within tissues 
and between cell types. For instance, the brain (Brown et al., 1995) and the lung 
(Okamura and Yamashita, 1994) are the organs with the highest PLD activity. In 
human, PLD1 is highly expressed in the kidney and the lung. In rat, PLD lb is the 
major expressed form and is detected at high levels in the kidney, small intestine, 
colon and liver. PLD la is mostly expressed in the lung, heart and spleen (Liscovitch et 
al., 2000; Katayama et al., 1998). In human, high levels o f  PLD2 was found in the 
prostate, placenta and thymus, followed by heart, pancreas, kidney and lung 
(Liscovitch et al., 2000; Steed et al., 1998). In rodents, highest expression was 
detected in lung, followed by brain, heart and kidney (Liscovitch et al., 2000; Kodaki 
and Yamashita, 1997; Colley et al., 1997). Moreover, several types o f mammalian 
cells such as human myeloid HL-60 cells, rat fibroblast Rat-1 cells and mouse T- 
lymphocyte EL4 cells can express one, both, or neither PLD isoform respectively 
(Gibbs and Meier, 2000). Interestingly, previous studies showed that HL-60 cells 
express exclusively PLD1 (Marcil et al., 1997; Ohguchi et al., 1997; Saqib and 
Wakelam, 1997) although PLD2 expression was also found in granulocytic 
differentiation o f HL-60 cells (Nakashima et al., 1998). This particular type o f cell 
line has been much used by others to investigate the regulation o f PLD and is the 
major focus o f attention in this thesis.
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There is no general agreement about the exact localization o f PLD 1 and PLD2 in 
cells because o f differences in cell type and methodology (Exton, 2002; Cockcroft, 
2001). However, subcellular localization studies have demonstrated that the 
mammalian PLD1 is generally detected in the following regions: Golgi apparatus, ER, 
nucleus, endosomes, lysosomes, and plasma membranes (Freyberg et al., 2001; 
Liscovitch et al., 1999; Toda et al., 1999; Colley et al., 1997). There is also PLD 
protein present in more specialized vesicles such as histamine granules in mast cells 
(Brown et al., 1998), glut4-containing vesicles in adipocytes (Emoto et al., 2000) and 
also in the secretory granules in neutrophils (Morgan et al., 1997). There is no 
apparent difference in the localization o f the PLD1 splice variants (Toda et al., 1999). 
By contrast, the mammalian PLD2 is predominantly found in the plasma membrane 
(Colley et al., 1997) and, in some cases, membrane ruffles (Honda et al., 1999). 
However, overexpressed forms o f PLD2 has been shown to accumulate in the Golgi 
apparatus, endosomes, lysosomes, and secretory granules (Freyberg et al., 2001). 
Moreover, a PLD enzyme has been found in caveolae (Czamy et al., 1999), the well- 
defined cellular structures resembling membrane invaginations (Harder and Simons, 
1997). However, the molecular identity o f this caveolar PLD enzyme remains to be 
firmly established although studies tend to favor PLD2.
1.4.4. Functions of PLD activation
All PLD enzymes catalyze the hydrolysis o f the most abundant phospholipid in 
most cell membranes, PC, to generate PA and the polar head group, choline (Figure 
1.8). PLD activity towards other types o f phospholipid substrates such as PE and PG
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Figure 1.8. Regulation o f  PLD by multiple signalling pathways.
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has mainly been described in plants (Arisz et al., 2003; Pappan and Wang, 1999) and 
in bacteria (Okawa and Yamaguchi, 1975).
Interestingly, PLD can catalyze a transphosphatidylation reaction in which a 
primary alcohol is used instead o f water as a “non-physiological” substrate for PLD to 
produce phosphatidylalcohol (PAR) in place o f PA. This type o f reaction is often 
erroneously described as being unique to PLD despite being a relatively common 
feature o f several different enzymes. What is unique is the ability to form 
phosphatidylalcohols and this feature unequivocally reflects PLD activity, as opposed 
to any other phospholipase activity against PC. The transphosphatidylation reaction 
has been extensively used to analyze PLD activation in vivo and in vitro assays. The 
work described in this thesis took advantage o f another approach, which is to quantify 
the release o f choline in broken-cell and cell-free preparations.
In addition to its functions in lipid catabolism, PLD is mostly indirectly 
implicated in other important cellular processes. Indeed, in most mammalian cells, 
PLD is activated in response to a broad range o f agonists including hormones, 
neurotransmitters, growth factors, cytokines and related molecules involved in 
intercellular communication (Exton, 1997; Morris et al., 1997). Moreover, 
environmental stress conditions in plants such as drought (Frank et al., 2000), 
hyperosmotic stress (Meijer et al., 2002) and wounding (Ryu and Wang, 1996) have 
also been reported to trigger PLD activity.
The rest o f this chapter will only deal with the regulation o f PLD in mammalian 
cells. Thus, the fact that PLD responds to such a wide range o f stimuli that use cell- 
surface receptors implies that PLD participates in signal transduction mechanisms in
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cells. Evidence that PLD activation was required for exocytosis in primary neutrophils 
and mast cells in their related cell lines, HL-60 cells and RBL-mast cells, came from 
the observation that alcohols blocked exocytosis. A reconstitution system has been 
used to examine the requirement for ARF proteins, one o f the best known activators o f 
PLD, in PLD activation and exocytosis. In cytosol-depleted cells HL-60 cells, both 
reactions are refractory to stimulation and can be restored upon addition o f  ARF 
proteins (Fensome et al., 1996). ARF-reconstituted secretion is blocked by ethanol, 
further substantiating the dependence on PA derived from the PLD pathway (Way et 
al., 2000). Furthermore, PLD has also been found to play a role in controlling changes 
in the actin cytoskeleton. Stimulation o f actin stress fibre formation (Cross et al.,
1996) and membrane ruffling (Honda et al., 1999) are both dependent on PLD 
activity. Membrane ruffling is sensitive to 0.5% butanol while actin stress fibre 
formation is inhibited by expressing the catalytically inactive form o f PLD 1.
In addition to mediating the effects o f PLD, PA is now considered to be an 
intracellular second messenger signalling molecule which participates and regulates 
numerous cellular functions, including ligand-induced exocytosis, protein 
phosphorylation (Fang et al., 2001; Rizzo et al., 2000), respiratory burst (Erickson et 
al., 1999; McPhail et al., 1995), endocytosis (Shen et al., 2001), Golgi transport 
(Ktistakis et al., 1996), and modulation o f membrane traffic (Manifava et al., 2001; Bi 
et al., 1997). Many o f these processes are mediated by the binding o f PA in a highly 
selective and specific manner. Thus, it appears that PA might function in a manner 
similar to many other lipid-derived second messenger molecules (PIP2, PIP3, IP3,
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DAG, LPA) and may act by promoting the binding o f selected targets to specific 
regions o f the cell membrane.
The direct interaction o f PA with the cell proteins has been shown in a small 
group o f proteins. Thus, PA is required for agonist-dependent translocation of 
serine/threonine kinase Raf-1, an essential component o f the MAPK cascade, to 
intracellular membranes (Rizzo et al., 2000). Insulin stimulation o f HIRcB fibroblasts 
led to accumulation o f Ras, Raf-1, phosphorylated MEK, phosphorylated MAPK and 
PA on endosomal membranes. Mutations that disrupt Raf-PA interactions prevented 
recruitment o f  Raf-1 to membranes. This observation confirmed previous findings 
demonstrating that treatment with ethanol inhibited phorbol ester-induced 
translocation o f Raf-1 to membranes (Ghosh et al., 1996). Interestingly, the 
interactions o f  PA with Raf-1 have been mapped to a 35 amino acid domain within the 
CR3 region o f Raf-1 (Ghosh et al., 1996). In addition to the MAPK signalling 
pathway, PA may also regulate another signalling cascade involving the mammalian 
target o f rapamycin (mTOR) that governs cell growth and proliferation (Fang et al., 
2001). mTor is a protein kinase related to the PI 3 kinase superfamily. The binding o f 
PA to mTor was shown to implicate R2109 near the rapamycin-binding domain o f the 
protein.
The second messenger role for PA has also been demonstrated in neutrophils 
(Sergeant et al., 2001). These cell express a large number o f non-receptor protein 
tyrosine kinases which participate in many cellular functions induced by many 
signalling events following cell stimulation. PA has previously been shown to function 
as an intracellular regulator o f protein tyrosine phosphorylation activity since
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exogenously added or endogenously generated PA enhanced tyrosine phosphorylation 
in neutrophils and other cell types (Siddiqui and Yang, 1995). This suggests a possible 
activation o f either a protein tyrosine kinase or the inhibition o f a protein tyrosine 
phosphatase. Interestingly, Sergeant et al. (2001) observed that Fgr, a Src family 
enzyme, eluted exclusively with the peak o f PA-dependent protein tyrosine 
phosphorylating activity obtained from gel filtration chromatography o f leukocyte 
cytosol. Thus this observation suggests a possible direct interaction between PA and 
the protein tyrosine kinase activity in intact cells.
Other protein targets for PA have recently been identified including protein 
phosphatase-1 (PP-1) (Jones and Hannun, 2002), the protein tyrosine phosphatase 
SHP-1 (Frank et al., 1999), the cyclic AMP-specific phosphodiesterase PDE4A1 
(Baillie et al., 2002) and the p47 phox subunit o f the NADPH oxidase (Yaffe, 2002).
Finally, it has been suggested that PA also plays a part in the synthesis o f another 
type o f phospholipid namely PIP2  by activating lipid-metabolizing enzymes. 
(Cockcroft, 2001). This was based on the finding that PA could stimulate the activity 
o f type I PIP 5-kinase (Honda et al., 1999). However, all these cellular responses 
cannot be exclusively attributed to PLD since PA is also formed by the tandem action 
o f phosphoinositide-specific PLCs and DGKs. It is well-established that many 
receptors that activate PLD also trigger hydrolysis o f PIP2  by PLC, releasing inositol 
IP3 and DAG (Berridge, 1993). The latter is then rapidly phosphorylated to PA by 
DGK.
Overall, these numerous cellular events underline the complex regulation o f 
PLD and little is known about the upstream events leading from signal-perception at
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the cell surface to PLD activation within the cells. Over the years, strong evidence 
points to the recurrent role o f different types o f protein kinases and 
polyphosphoinositides, small GTP-binding proteins such as Rho, RalA and ARF 
proteins and their respective regulating proteins, in the control o f PLD activation in 
different in vitro and in vivo model systems. In addition to these various activators, 
protein inhibitors o f PLD have been identified (Han et al., 1996; Kim et al., 1996; 
Lukowski et al., 1996; Geny et al., 1995).
1.5. Regulation o f PLD by PKC
Studies o f the activation o f PLD by phorbol esters in various cell types 
implicated PKC in its regulation. Inhibitors o f PKC reduced agonist activation o f PLD 
activity, although the magnitude o f the inhibition was variable, depending on the 
agonist and cell type (Exton, 1997). Other approaches indicating the involvement of 
PKC included down-regulation o f the enzyme by prolonged treatment with phorbol 
ester, and overexpression or antisense deletion o f specific PKC isozymes (Exton,
1997). In addition, overexpression o f phosphoinositide PLC, which generates DAG 
and activates PKC, resulted in increased PLD activity (Lee et al., 1994).
Interestingly, the activation o f PLD by PKC was also observed in the absence o f 
ATP by a non-phosphorylating mechanism (Hammond et al., 1997). In addition, 
Synergistic interaction between PKC and other small G proteins (Rho, ARF) that 
activate PLD was observed (Hammond et al., 1997).
‘ Based on these observations, it is possible that agonists that activate PLC cause 
membrane translocation and activation o f conventional PKC which, in turn, activates
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PLD. The activation o f PLD probably occurs because o f direct interaction o f PKC 
with PLD rather than direct phosphorylation.
1.6. Regulation o f PLD by Rho family proteins
There is much evidence that RhoA, Racl and Cdc42Hs activate PLD1, but not 
PLD2 (Colley et al., 1997; Hammond et al., 1997). For example addition o f GTPyS- 
activated forms o f these proteins to recombinant PLD1 in vitro results in its activation. 
RhoA is the most efficacious, but Racl and Cdc42Hs cause significant activation.
The in vivo effects o f RhoA on PLD activity have been explored through the use 
o f  clostridial toxins (C3 exoenzyme and toxin B) (Schmidt et al., 1996) and also by 
transfection o f dominant negative and constitutively active forms o f RhoA and R acl. 
However, these agents do not distinguish between direct and indirect effects o f these 
small G proteins on PLD.
1.7. Regulation o f PLD by Ras family proteins
Ras does not directly activate PLD, but there is evidence that Ras mediates the 
activation o f PLD induced by v-Src in vivo (Jiang et al., 1995). Furthermore, RalA, a 
member o f the Ras subfamily, has been shown to interact directly with the ARF- 
responsive, PHVdependentPLDl (Luo et al., 1997).
1.8. Regulation o f  PLD by ARF family proteins
1.8.1. Role of ARFs
1.8.1.1. Origin
The ADP-ribosylation factors commonly termed ARFs are one o f the five 
subfamilies o f the RAS superfamily o f small (= 20 kDa) regulatory guanine 
nucleotide-binding proteins (Takai et al., 2001). In fact, the ARF family comprises the
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ARF, ARL, ARD and SAR proteins. The ARF proteins were originally discovered as 
cofactors required for the ADP-ribosylation o f Gsa  by cholera toxin (Kahn and 
Gilman, 1986; Kahn and Gilman, 1984).
1.8 .1.2. Different classes o f ARFs
The ARF proteins are highly conserved across mammalian species (Hosaka et 
al., 1996). So far six ARF members and their amino acid sequences (deduced from 
cDNA sequences) have been reported in mammals (Hosaka et al., 1996; Moss and 
Vaughan, 1995; Tsuchiya et al., 1991) and three members have been identified in 
yeasts (Lee et al., 1994). Figure 1.9 shows the amino acid sequence alignment for six 
mouse ARFs and bovine ARF1. Based on their amino acid sequence similarity, the 
mammalian ARFs are consequently classified into three groups (Table 1.2). ARF1, 
ARF2 and ARF3 form class I and are 96 ± 0.8% (n = 6 ) (mean ± S.E.M) identical to 
one another at the amino acid level. ARF4 and 5 form class II and are 90% 
homologous to one another sharing 80.3 ± 0.5% (n = 9) amino acid identity with class 
I ARFs. ARF6  forms class III and is the most distant member o f  the family as it shares 
68.3 ± 0.8% (n = 6 ) amino acid identity with class I and class II ARFs.
1.8.1.3. Structure and properties
As indicated above, the comparison o f the amino acid sequences o f ARF proteins 
from different species has shown that they are conserved in primary structure. Like all 
small G proteins, ARFs bind guanine nucleotides (GDP, GTP) and therefore adopt two 
different conformations: an inactive GDP-bound state and an active GTP-bound state 
(Figure 1.10). As illustrated in Figure 1.9 ARFs have consensus amino acid sequences 
that are believed to be involved in guanine nucleotide binding and hydrolysis (Moss
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Figure 1.9. Alignment o f  amino acid sequences fo r  mammalian ARFs. Identical 
residues are in red and similar residues are in blue. The consensus sequences for 
GDP/GTP-binding and GTPase activities are highlighted in green; G2, the site o f N- 
terminal myristoylation after co-translational removal o f methionine, is shaded in 
yellow. Switch 1 (residues 45-54) and Switch 2 (residues 70-80) are shown in boxes. 
The abbreviations used and GenBank protein accession numbers are as follows: 
mARF4, mouse ARF4, JC4948; mARF5, mouse ARF5, JC4949; m A RFl, mouse 
ARF1, JC4945; bA RFl, bovine ARF1, NP_788826; mARF3, mouse ARF3, JC4947; 
mARF2, mouse ARF2, JC4946; mARF6, mouse ARF6, JC4950. Alignment was 
generated by ClustalW and the printing o f the multiple alignment output was performed 
by Boxshade.
Table 1.2.
Comparison o f  deduced amino acid sequences o f  ARFs
The percentage identity of the indicated ARF-deduced amino acid sequences is 
indicated above the diagonal, and the percentage similarity is below. The 
abbreviations are as follows: bARFl, bovine ARF1; mARF2, mouse ARF2; mARF3, 
mouse ARF3; mARF4, mouse ARF4; mARF5, mouse ARF5; mARF6, mouse ARF6. 
The percentage global amino acid sequence identity and similarity was calculated by 
pairwise BLAST using BLOSUM62 matrix.
bARFl mARFl mARF2 mARF3 mARF4 mARF5 mARF6
bARFl - 100 95 96 82 81 70
mARFl 100 - 95 96 82 81 70
mARF2 96 96 - 94 80 80 69
mARF3 97 97 95 - 79 78 69
mARF4 88 88 85 86 - 90 65
mARF5 88 88 87 85 96 - 67
mARF6 85 85 84 83 81 81 -
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Figure 1.10. Cyclical activation/inactivation o f ARF proteins.
Myristicactive
Effector
Downstream signal
and Vaughan, 1995; Bourne et al., 1991). In addition to their guanine nucleotide 
binding property, ARFs have a critical N-terminus which is required for interaction 
with downstream effectors and therefore essential for ARF activities (Randazzo et al., 
1995; Kahn et al., 1992). Unlike the other small G proteins including Ras, 
Rho/Rac/Cdc42 and Rab, ARF proteins can be post-translationally modified at the N- 
terminal glycine residue (G2) with the 14-carbon saturated fatty acid myristate. This 
post-translational modification is catalysed by V-myristoyltransferase (Duronio et al., 
1990; Kahn et al., 1988). Myristoylation o f ARF proteins has been widely reported to 
be critical for at least three reasons. First, myristoylation increases the nucleotide 
exchange on ARFs (Franco et al., 1995). Second, myristoylation contributes to the 
recruitment o f ARFs to natural or artificial membrane phospholipids (Franco et al., 
1996). Third, myristoylation has been demonstrated to be essential for ARF 
interactions with regulator and effector proteins (Massenburg et al., 1994; Brown et 
al., 1993).
Single crystal X-ray diffraction analysis o f ARF1 (Goldberg, 1998; Greasley et 
al., 1995; Amor et al., 1994) and ARF6  (Pasqulato et al., 2001; Menetrey et al., 2000) 
in several forms have revealed important functional regions. Figure 1.11 shows the 
crystallographic structure o f ARF1 bound to GDP and GTP. Indeed, the overall 
structure o f the ARF molecule consists o f seven P-strands, six a-helices and twelve 
connecting loops arranged in the classical Ras fold. As noted, the feature that 
distinguishes ARFs from the other Ras family GTP-binding proteins is the N- 
terminus. This region is an extension o f 14 residues as shown for ARF1 (Greasley et 
al., 1995) and forms an a  helix that is tightly packed against the core domain o f ARF
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Figure 1.11. Crystallographic structure o f ARF 1 bound to GDP (bovine GDP-ARF1, PDB code: 1RRF) 
and GTP (mouse GTP-[A17]ARF1, PDB code: 103Y). In the ARF1-GTP bound form, the N-terminus a - 
helix has been deleted.
when it is bound to GDP. Upon GTP binding, this myristoylated N-terminal a  helix is 
thought to be mechanically displaced into the solvent and orient to interact with the 
membrane. Interestingly, sequence differences among ARFs mainly occur near the N- 
terminus since the alignment o f the mammalian ARFs shows that the N-terminus of 
ARF6  is shorter than that o f the other ARFs by four residues (Figure 1.9). This 
observation indicates a possible differential affinity interaction with downstream 
effector proteins. In addition to the N-terminal helix, two highly flexible regions 
defining, or close to, the acceptor site for the y-phosphate o f GTP have been identified. 
These two regions have been named switch 1, from residues 45-54, and switch 2, from 
residues 70-80 (Goldberg, 1998) in accord with the known structure-function 
relationships o f other members o f the Ras superfamily. Close to the binding site for 
guanine nucleotides lies a Mg2+ ion. This ligand also constitutes another significant 
feature in the ARF molecule and is thought to stabilize the binding o f GTP by the 
switch regions. Consequently, since these two switch regions undergo major 
rearrangements on GTP<-*GDP exchange they probably form, along with the N- 
terminus, the major sites for the interaction o f ARF proteins with their cellular 
regulators and effectors. Specifically, upon guanine nucleotide exchange, the switch 
regions are thought to restructure, inducing the movement o f one loop (between P2  
and p3 strands), which displaces the N-terminal helix from its buried position against 
the protein core (Figure 1.11). As a result, the N-terminus exposes its attached 
myristate tail which subsequently inserts into the membrane bilayer. Furthermore, as 
shown in Figure 1.9, the amino acid sequences for switch 1 and switch 2 regions are 
surprisingly almost identical among the ARF proteins suggesting that they may have
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the same conformation and that they may not be readily distinguishable by the various 
regulatory and effector proteins that interact with them. It is worth noting that 
sequence differences between the most distantly related ARF isofoms, ARF1 and 
ARF6 , occur outside the switch regions (Figure 1.9).
Thus minor differences found in the N-terminus region and the switch regions 
must presumably account for all o f the reported differences in the localization and 
function o f  ARF1 and ARF6 . It should be noted that since these two isoforms o f ARF 
are the most extensively studied, especially where side-by-side comparisons are 
attempted, there is a significant bias in the literature.
1.8.1.4. Localization and functions
In general, all ARF proteins, with the exception o f ARF6 , are predominantly 
cytosolic in their inactive, GDP-bound form. Upon GTP-binding, ARFs translocate 
from the cytosol to the membranes o f different cellular compartments. Indeed, ARF1 
and ARF3 are mainly localized in the Golgi and ER where they are involved in the 
GTP-dependent formation o f  the COPI-coated and clathrin-coated vesicles that act at 
distinct steps in intracellular membrane transport (Spang, 2002; Peters et al., 1995; 
Stamnes and Rothman, 1993). Among the class II ARFs, ARF5 also appears to be 
localized in the Golgi and the endoplasmic reticular Golgi intermediate compartment 
(ERGIC) but the function o f these proteins is unknown. However, ARF4 has been 
recently reported to regulate cellular PLD2 activity (Kim et al., 2003). Unlike the 
other two categories o f ARFs, ARF6  is permanently enriched in the plasma membrane 
where it plays a role in the exocytotic and endocytotic pathways and in controlling the
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actin cytoskeleton (Boshans et al., 2000; Radhakrishna and Donaldson, 1997; Peters et 
a l,  1995).
In addition to regulating processes related to vesicle formation and therefore 
intracellular membrane transport, ARFs have a catalytic role in that they activate 
phospholipid-metabolising enzymes such as phosphoinositide kinases and PLD. O f 
course these two effects may be related.
Indeed, it has been reported that ARFs, specifically ARF6 , are activators o f  
PI(4)P5K, a lipid-metabolising enzyme primarily responsible for the synthesis o f PIP2  
(Honda et al., 1999). Interestingly, the activation o f PI(4)P5K by ARFs strictly 
requires PA.
Activation o f PLD by ARFs was independently discovered by two groups who 
identified ARF1 and ARF3 as potent activators o f PLD, now known to be PLD1 
(Cockcroft et al., 1994; Brown et al., 1993). Massenburg et al. (1994) subsequently 
separated an ARF-stinulated PLD from an oleate-stimulated PLD after solubilization 
from brain membranes and showed that the ARF-dependent PLD could be activated 
by all three classes o f mammalian ARFs in vitro. The majority o f studies o f the 
regulation o f PLD by ARFs have been mostly performed in vitro and in a pseudo in 
vivo system involving the use o f permeabilized cells. These model systems revealed 
that myristoylation o f  all ARF subtypes greatly increased their potency and efficacy in 
activating PLD (Brown et al., 1995; Massenburg et a l,  1994; Brown et a l,  1993) and 
therefore clearly required the presence o f an intact N-terminus on ARFs (Zhang et a l, 
1995). Subsequently, ARF-dependent PLD activity has been detected in plasma 
membranes, nuclei, Golgi and cytosol (Exton, 1999).
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1.8.1.5. Regulation o f PLD through the ARF-dependent pathway is multi-factorial
There is abundant evidence that PLD can be independently activated by various
2+
signalling molecules including PKC, Rho-family G proteins, Ca ions, tyrosine 
kinases and polyphosphoinositides such as PIP2 and PIP3 (Exton, 1999; Houle and 
Bourgoin, 1999; Exton, 1997). As a result, the physiological regulation o f PLD by 
ARF in a cellular context probably requires the participation o f several o f these PLD 
stimulatory molecules. Indeed, experiments in vitro and in cells have clearly 
demonstrated that the activation o f PLD resulted from a synergistic o f  effects o f PKC, 
Rho proteins (RhoA, R acl, Cdc42) and other unidentified cytosolic factors with ARF. 
This observation is further complicated by the fact that the activity o f each o f these 
PLD regulatory molecules is in turn controlled by other partner proteins. One o f these 
molecules is PIP2  itself (whose presence in well-established in vitro PLD assays is an 
absolute requirement) as this phohsphoinositde greatly enhances ARF-stimulated PLD 
activity (Hammond et al., 1997; Brown et al., 1993). Its role in ARF-dependent PLD 
activation is thought to arise either through direct interaction with PLD or through the 
recruitment o f ARF-regulatory proteins such as ARF guanine nucleotide exchange 
factors (ARF-GEFs).
1.8.2. Role of the small GEFs in the activation of ARFs
ARFs are regulated by two types o f proteins: ARF guanine nucleotide exchange 
factors (GEFs) or guanine nucleotide exchange proteins (GEP) and ARF GTPase 
activating proteins (GAPs). The term guanine nucleotide exchange factors (GEFs) 
will be used from now on throughout this thesis. The ARF-GEFs promote a fast and 
effective activation o f ARFs through the replacement o f GDP with GTP. Hence the
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ARF-GEFs are key regulators of the biological functions o f ARF proteins including 
the activation o f PLD. By contrast, the ARF-GAPs activate the hydrolysis o f bound 
GTP to GDP (Jackson et al., 2000).
In general, the ARF-GEFs are members o f the Sec7 family proteins. This family 
can be subdivided in two major classes, the large (> 100 kDa) ARF-GEFs and the 
smaller (< 100 kDa) ARF-GEFs, on the basis o f sequence similarity, functional 
differences and sensitivity to a fungal metabolite BFA.
1.8.2.1. Two different classes o f ARF-GEFs
The identification o f ARF-GEFs was facilitated by the finding that BFA 
disrupted Golgi trafficking by inhibiting a Golgi-associated guanine nucleotide 
exchange activity for ARF1 (Donaldson et al., 1992; Helms and Rothman, 1992). The 
high-molecular-weight (> 100 kDa) ARF-GEFs were first isolated from yeast 
Saccharomyces cerevisiae. These include Sec7p (Morinaga et al., 1996), G ealp  and 
Gea2p (Peyroche et al., 1996). Homologs o f the yeast G eal/2 proteins have 
subsequently been identified in human (GBF1) and plant (GNOM/Emb30p) (Mansour 
et al. 1998; Shevell et al., 1994) while homologs o f yeast Sec7p comprise mammalian 
p200 (Mansour et al., 1999; Morinaga et al., 1997), BIG1 and BIG2 (Yamaji et al., 
2000). All these large ARF-GEFs, with the exception o f GBF1, are BFA-sensitive. 
However, they are all localized to the Golgi in mammalian cells without exception 
(Nie et al., 2003; Donaldson and Jackson, 2000; Jackson and Casanova, 2000).
Recently, a novel BFA-insensitive ARF-GEF termed ARF-GEPioo o f 
intermediate size (100 kDa) has been reported and this protein may define a new 
family o f ARF-GEFs (Someya et al., 2001).
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In contrast to these BFA-sensitive ARF-GEFs, another family o f mammalian 
small ARF-GEFs (<100 kDa) with BFA-insensitive catalytic activity has been 
identified. These include ARNO-1 (or cytohesin-2) (Chardin et al., 1996), cytohesin-1 
(or B2-1 or ARNO-2) (Kolanus et al., 1996), GRP-1 (or ARNO-3 or cytohesin-3) 
(Franco et al., 1998; Klarlund et al., 1997), cytohesin-4 (Ogasawara et al., 2000) and 
EFA 6  (Franco et al., 1999). In general, the preferred nomemclature employed for the 
small ARF-GEFs family is ARNO, cytohesin-1 and GRP-1 exactly as listed above. 
The amino acid sequences o f all ARF-GEFs contain a central Sec7 domain, a region o f 
roughly 2 0 0  amino acids responsible for guanine nucleotide-exchange activity 
(Jackson and Casanova, 2000; Chardin et al., 1996). Figure 1.12 shows the amino acid 
sequences o f ARNO, cytohesin-1 and GRP-1. Structurally, the Sec7 domain shows 
very similar arrangements o f 1 0  a-helices grouped in two sets o f five, which form a 
hydrophobic groove that is conserved in all ARF-GEFs (Cherfils et al., 1998). The 
sequences o f motifs 1 and 2 in the Sec7 domain, which are highly conserved among 
ARF-GEFs, contain all o f the major residues necessary for ARF interactions, as shown 
by the crystallization o f nucleotide-free ARF1 and a Sec7 domain GEF (Goldberg,
1998). Importantly, motif 1 contains a conserved and critical glutamic acid residue 
involved in catalysis o f guanine nucleotide exchange (Beraud-Dufour et al., 1998).
In addition to the catalytic Sec7 domain, the ARNO/cytohesin-1/GRP-1 family 
also possess an N-terminal coiled-coil domain o f approximately 40 amino acids, a 
region believed to be involved in homodimerization (Chardin et al., 1996), Golgi 
targeting (Lee and Pohajdak, 2000) and interactions with specific protein targets 
(Venkateswarlu, 2003; Klarlund et al., 2001). Furthermore, proteins in this sub-family
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cytohesin-1 1 -------------------MEEDDS---- YVP SDLTAEERQELENIRRRKQELLADIQRLKDEIAEVANEIENLGSTEERKNMQRNKQVAMG
GRP-1 1 MRGSHHHHHHGSACELGTDEDGGGEGGGVP EDLSLEEREELLDIRRRKKELIDDIERLKYEIAEVMTEIDNLTSVEESKTTQRNKQIAMG
ARNO 1 ----------------CELGTEDGV----- YEPPDLTPEERMELENIRRRKQELLVEIQRLREELSEAMSEVEGLEANEGSKTLQRNRKMAMG
cytohesin-1 70 RKKFNMDPKKGIQFLIENDLLKNTCEDIAQFLYKGEGLNKTAIGDYLGERDEFNIQVLHAFVELHEFTDLNLVQALRQFLWSFRLPGEAQ
GRP-1 91 RKKFNMDPKKGIQFLIENDLLQSSPEDVAQFLYKGEGLNKTVIGDYLGERDEFNIKVLQAFVELHEFADLNLVQALRQFLWSFRLPGEAQ
ARNO 73 RKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIGDYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQ
cytohesin-1 160 KIDRMMEAFAQRYCQCNNGVFQSTDTCYVLSFAIIMLNTSLHNPNVKDKPTVERFIAMNRGINDGGDLPEELLRNLYESIKNEPFKIPED
GRP-1 181 KIDRMMEAFASRYCLCNPGVFQSTDTCYVLS FAIIMLNTSLHNHNVRDKPTAERFIAMNRGINEGGDLPEELLRNLYESIKNEPFKIPED
ARNO 163 KIDRMMEAFAQRYCLCNPGVFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRNEPFKIPED
LA
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cytohesin-1 250 DGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVEDSKKPNCFELYIPDNKDQVIKAC 
GRP-1 271 DGNDLTHTFFNPDREGWLLKLGG-RVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVEDPRKPNCFELYNPSHKGQVIKAC
ARNO 253 DGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVDDPRKPNCFELYIPNNKGQLIKAC
cytohesin-1 340 KTEADGRWEGNHTVYRISAPTPEEKEEWIKCIKAAISRDPFYEMLAARKKKVSSTKRH---
GRP-1 360 KTEADGRWEGNHWYRISAPSPEEKEEWMKoIKASISRDPFYDMLATRKRRIANKK-----
ARNO 343 KTEADGRWEGNHMVYRISAPTQEEKDEWIKSIQAAVSVDPFYEMLAARKKRISVKKKQEQP
Figure 1.12. Alignment of amino acid sequences for mammalian full-length c 'tolrzsin-1, GRP-1 and ARNO. Identical residues are 
in red and similar residues are in blue. The essential glutamate residue (corresponding to Glu 156 o f ARNO) is highlighted in 
yellow. Details o f the constructs are as follows: human cytohesin-1, corresponding to GenBank code Q15438; human GRP-1 
corresponding to GenBank code N P 0 0 4 2 1 8  in pQE30; ARNO (from Geraint Thomas) corresponding to GenBank code 
NP 059431. Diglycine (GG) and triglycine (GGG) motifs are shown by asterisks. Alignment was generated by ClustalW and the 
printing o f the multiple alignment output was performed by Boxshade.
contain a C-terminal pleckstrin homology (PH) domain that mediates binding to 
polyphosphoinositides particularly PIP2  and PIP3 and seems to mediate the activity o f 
GEFs by recruiting them on the membrane surface where the nucleotide exchange 
reaction is thought to occur (Jackson and Casanova, 2000; Klarlund et al., 1998; 
Klarlund et al., 1997; Chardin et al., 1996). The PH domain is a protein module o f 
approximately 1 2 0  amino acids, which consists o f an orthogonal fold o f several p- 
sheets and a C-terminal a-helix (Rebecchi and Scarlatta, 1998). Analysis o f the amino 
acid sequences o f the PH domains among the ARNO/cytohesin-l/GRP-1 family 
indicate they are about 90% identical (Table 1.3). Notably, the large ARF-GEFs lack 
the PH domain and therefore must rely on other proteins to mediate membrane 
recruitment. In addition to the PH domain, the small ARF-GEFs contain a C-teminal 
polybasic sequence adjacent to the PH domain. This C-terminal polybasic domain is 
also important for membrane association (Macia et al., 2000; Nagel et al., 1998). 
Figure 1.13 shows the domain structure o f ARNO, GRP-1 and cytohesin-1, the 
activity o f which will be extensively investigated in this thesis.
Besides sharing these common domain structures, ARNO, cytohesin-1, and 
GRP-1 are closely related in size (45-50 kDa) and are more similar to each other (83. 
±  2.0% global sequence identity) (Table 1.4) than any o f them is to the more recently 
discovered cytohesin-4 (Ogasawara et al., 2000).
There is conflicting information on the subcellular localization o f the small ARF- 
GEFs. Indeed, while some groups have demonstrated the membrane association o f 
these proteins (Ashery et al., 1999; Frank et al., 1998), others have found that these 
proteins are cytosolic and only translocate to the plasma membrane following
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Table 1.3.
Comparison o f  deduced amino acid sequences o f small ARF-GEF PH domains 
The percentage identity of the indicated ARF-GEF-deduced amino acid sequences is 
indicated above the diagonal, and the percentage similarity is below. Comparison of 
the sequences o f the PH domains correspond to residues 208 to 324 of the full-length 
ARF-GEFs. The percentage global amino acid sequence identity and similarity was 
calculated by pairwise BLAST using BLOSUM62 matrix.
ARNO GRP-1 Cytohesin - 1
ARNO - 89 93
GRP-1 91 - 89
Cytohesin-1 93 91 -
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N-terminal coiled- 
coil domain
\
ARNO (404 aa) N
264 382
GRP-1 (404 aa)
Cytohesin-1 (398 aa)
Fngpire 1.13. Domain structure o f ARNO, GRP-1 and cytohesin-1. Regions of conserved 
sequence are shown. The abbreviations used and protein accession numbers are as follows: 
Sec7, Sec7 domain; PH, pleckstrin homology domain. Human cytohesin-1, corresponding to 
GenBank code Q 15438; human GRP-1 corresponding to GenBank code NP 004218 in 
pQE30; ARNO corresponding to GenBank code N P059431 (from Geraint Thomas). The 
conserved protein domains were obtained by submitting the PLD amino acid sequences to 
the SMART server. The C-terminal polybasic domain contains 33 amino acids past the 
conserved tryptophan (W). This domain binds to acidic phospholipids.
Polyphosphoinositide- 
ARF-binding site binding site
C-terminal 
polybasic domain
Table 1.4.
Comparison o f  deduced amino acid sequences o f  small ARF-GEFs 
The percentage identity of the indicated ARF-GEF-deduced amino acid sequences is 
indicated above the diagonal, and the percentage similarity is below. The abbreviations 
are as follows: human cytohesin-1, corresponding to GenBank code Q15438; human 
GRP-1 corresponding to GenBank code NP 004218 in pQE30; ARNO corresponding 
to GenBank code NP 059431 (from Geraint Thomas). The percentage global amino 
acid sequence identity and similarity was calculated by pairwise BLAST using 
BLOSUM62 matrix.
ARNO GRP-1 Cytohesin- 1
ARNO - 80 83
GRP-1 90 - 87
Cytohesin-1 92 92 -
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stimulation o f cells with growth factors (Li et al., 2003; Venkateswarlu et al., 1999; 
Venkateswarlu et al., 1998). Furthermore, reports have indicated that the 
overexpression o f ectopic ARNO (Monier et al., 1998) and GRP-1 (Franco et al., 
1998) caused fragmentation o f  the Golgi, suggesting that their function is in the Golgi. 
This is supported by the observation that all three small ARF-GEFs act on ARF1, 
which has historically been localized to the Golgi compartment in addition to the 
cystosol (Peters et al., 1995).
1.8.2.2. Model for the GDP/GTP exchange reaction
The current proposed model for the guanine nucleotide exchange reaction 
catalyzed by the ARF-GEFs involves several stages in strict sequence (Jackson and 
Casanova, 2000; Cherfils and Chardin, 1999; Peyroche et al., 1999). First, GEF 
recognizes the GDP-bound ARF protein and forms a low affinity complex with GDP- 
ARF. This then leads to the dissociation o f GDP from the initial complex (ARF-GDP- 
GEF) which becomes a transient high affinity GEF-ARF complex. It is likely that the 
apo-ARF is held in a state very similar to that o f the final GTP-form. GTP 
subsequently occupies the empty guanine-binding site and “locks” the GEF-induced 
conformational change. The GTP-ARF then rapidly dissociates from the GEF.
Interestingly, this model o f guanine nucleotide has provided an explanation for 
the molecular mechanism o f the inhibitory effects o f BFA originally observed on 
some o f the ARF-activating GEFs. Biochemical studies have shown that BFA binds 
the transient complex formed between ARF-GDP and the Sec7 domain, resulting in an 
abortive ARF-GDP-BFA-Sec7 domain complex (Chardin and McCormick, 1999; 
Peyroche et al., 1999).
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The sequence o f events leading to the activation o f ARFs by GEFs is still a 
matter o f debate. It is not clear whether the interaction o f ARF and ARF-GEF occurs 
in the cytosol prior to their translocation to the membrane surface or on the membrane 
following their independent membrane association via the myristoylated N-terminus 
o f ARF and the coiled-coil and PH domains o f ARF-GEF. Alternatively, it is possible 
that ARF-GEF first localizes to the membrane via interaction with 
polyphosphoinositides and membrane-bound adaptor proteins in response to cell 
stimulation and then facilitates the recruitment o f ARF. Based on these considerations, 
it is reasonable to assume that the membrane binding o f both ARF and its exchange 
factor is the prerequisite for protein-protein interactions on the grounds that membrane 
binding reduces the dimensionality o f protein diffusion from three to two dimensions. 
Random collisions, the major factor influencing kinetic on-rates, are o f course more 
frequent because o f this reduction.
1.8.2.3. Differential GEF specificities for ARF isoforms.
The majority o f large ARF-GEFs including Gealp/Gea2p (Peyroche and 
Jackson, 2001; Peyroche et al., 1996), Gnom/Emb30 (Steinmann et al., 1999), Sec7p 
(Chavrier and Goud, 1999; Sata et al., 1998), p200 (Mansour et al., 1999), and 
BIG1/BIG2 (Togawa et al., 1999) have been shown to act mostly on class I ARF 
proteins (Morinaga et al., 1999; Togawa et al., 1999; Morinaga et al., 1996). This is 
probably because class I ARFs have been the most studied o f mammalian ARFs for 
the past 20 years. In addition, Sec7p, GBF1, BIG1/BIG2 and p200 have been reported 
to exhibit specificity towards class II and class III ARFs (Claude et al., 1999; 
Morinaga et al., 1999; Togawa et al., 1999; Sata et al., 1998).
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However, a current contention exists over the substrate specificity o f the small 
ARF-GEFs towards the three classes o f ARFs. Indeed, ARNO (Beraud-Dufour and 
Robineau, 2001; Macia et al., 2001; Franco et al., 1998; Paris et al., 1997; Chardin et 
al., 1996), GRP-1 (Klarlund and Czech, 2001; Franco et al., 1998; Klarlund et al., 
1998), cytohesin-1 (Knorr et al., 2000; Ogasawara et al., 2000; Moss and Vaughan, 
1999; Betz et al., 1998; Franco et al., 1998; Pacheco-Rodriguez et al., 1998; Meacci et 
al., 1997), and cytohesin-4 (Ogasawara et al., 2000) have generally been shown to 
stimulate guanine nucleotide exchange on class I ARFs in vitro. In addition, structural 
studies mostly used ARNO and ARF1 to demonstrate GEF activity (Beraud-Dufour et 
al., 1998; Mossessova et al., 1998). However, other groups managed to demonstrate 
that the ARNO/cytohesin-1/GRP-1 proteins also have distinct specificities with 
respect to other ARF isoforms. Depending on assay conditions, ARNO has been 
reported to act on ARF6  in vivo (Santy and Casanova, 2001; Santy et al., 2001; 
Caumont et al., 2000; Frank et al., 1998b) and in vitro (Santy et al., 1999; Frank et al., 
1998a), whereas GRP-1 also functions on class II (Klarlund et al., 1998) and class III 
(Langille et al., 1999) ARFs. Cytohesin-1 also stimulates guanine nucleotide exchange 
on ARF5 (Ogasawara et al., 2000) and ARF6  (Knorr et al., 2000; Ogasawara et al., 
2000) while cytohesin-4 can activate ARF5 but not ARF6  (Ogasawara et al., 2000). 
The recently identifed EFA 6  apparently promotes efficient guanine nucleotide 
exchange exclusively on ARF6  (Chavrier and Franco, 2001; Macia et al., 2001; 
Franco et al., 1999).
Interestingly, the Sec7 domain has been suggested to be responsible for the 
specificity o f small ARF-GEFs for class I ARF proteins under certain conditions. For
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instance, the isolated ARNO Sec7 domain was shown to only be active on ARF1, but 
not on ARF6  (Franco et al., 1998). On the other hand, it is possible that the observed 
promiscuity in vitro o f all the ARF-GEFs in general and o f the small ARF-GEFs in 
particular is due to the highly conserved nature o f the Sec7 domain. Table 1.5 
summarizes reported distinct substrate specificities o f all ARF-GEFs with respect to 
different ARF isoforms.
Furthermore, polyphosphoinositides have been shown to play a role in 
determining the specificity o f the small GEFs for ARFs. As indicated earlier, it has 
been shown that cytohesin - 1  was able to effectively catalyze guanine nucleotide 
exchange on ARF1 and ARF6  in vitro (Knorr et al., 2000). Interestingly, the addition 
o f PIP3 strongly suppressed this exchange activity on ARF6  while enhancing it on 
ARF1. Thus, it appears that cytohesin-1 is capable o f discriminating between ARF1 
and ARF6  in vitro when the small ARF-GEF binds PIP3 indicating a possible 
functional role for this phosphoinositide in the regulation o f the recruitment o f ARF1 
in vivo. However, there may be other functional events in the cell in which the small 
ARF-GEFs display selectivity for ARF6 .
1.8.2.4. GEF binding partners: regulation by polyphosphoinositides and novel proteins
As already indicated, the binding o f the GEFs via their PH domain to 
polyphosphoinositides such as PIP2 and PIP3 is crucial for their functions as this 
protein-phospholipid interaction dramatically enhances the rate o f ARF nucleotide 
exchange by concentrating the GEFs on the bilayer membrane where the ARFs also 
localize through their myristoylated N-terminal a-helix. PIP2 was the first 
polyphosphoinositide found to be involved in the recruitment o f ARNO and therefore
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Table 1.5.
Substrate specificities o f  all ARF-GEFs fo r the three classes o f  ARF isoforms and their subcellular localization and activity towards BFA
.» ARF specificity Activity is BFA Localization
' ARF1 ARF2 ARF3 ARF4 ARF5 ARF6 V
Large ARF-GEF family
Geal/2p V V sensitive Golgi
GBF1 V V vvv resistant Golgi
Gnom/Emb30 V sensitive ND
Sec7p V V V V sensitive Golgi
p200 < V V sensitive Golgi
BIG1/BIG2 V < V V sensitive Golgi
Intermediate ARF-GEF family
ARF-GEP100 V V vvv resistant Cell periphery
Small ARF-GEF family
ARNO-1 (or cytohesin-2) vvv V V resistant PM/Golgi
GRP-1 (or ARNO-3 or cytohesin-3) V resistant PM/Golgi
cytohesin-1 (orB 2-l or ARNO-2) vvv < V V resistant PM/Golgi
cytohesin-4 V V resistant ND
EFA6 vvv resistant PM
VW: preferred substrate in vitro. References are included in the text. PM, plasma membrane; ND, not determined.
the activation o f ARF nucleotide exchange in vitro (Chardin et al., 1996). Following 
this discovery, several groups have shown a preference by ARNO (Venkateswarlu et 
al., 1998), GRP-1 (Klarlund et al., 1998) and cytohesin-1 (Nagel et al., 1998) PH 
domains for PIP3 over PIP2  in vitro. This reported specificity o f the GEFs for PIP3 was 
supported by the fact that the transient recruitment o f ARNO (Venkateswarlu et al., 
1998), GRP-1 (Langille et al., 1999; Venkateswarlu et al., 1998) and cytohesin-1 
(Nagel et al., 1998) to the plasma membrane was a response to agonists that activate 
the Class I PI-3-kinases, the source o f PIP3 . This recruitment was in each case 
inhibited by PI 3-kinase inhibitors wortmannin and LY294002. In addition to 
biochemical studies, structural studies also favor the view that there is a stronger 
binding-affinity amongst ARF-GEF PH domains for PIP3 over PIP2  (Ferguson et al., 
2000; Lietzke et al., 2000). However, since data presented in this thesis address this 
current view the rationale for this differential affinity will be considered in more detail 
elsewhere.
In addition to the important role o f polyphosphoinositides in the regulation o f  the 
activity o f the small ARF-GEFs, recent reports identified novel interacting proteins, 
such as IPCEF1 (Venkateswarlu, 2003), Cbyr (Tang et al., 2002), CASP (Mansour et 
al., 2002), GRSP1 (Klarlund et al., 2001a), GRASP also known as tamalin (Kitano et 
al., 2002; Nevrivy et al., 2000), and Muncl3-1 (Neeb et al., 1999). These target 
proteins are believed to have the same role as the polyphosphoinositides in the GEF 
function i.e. recruitment o f the GEFs to membranes. Contrary to the situation with 
polyphosphoinositides, they interact with the coiled-coil domain o f  the small ARF- 
GEFs indicating a different aspect o f protein targeting. The functional relevance o f
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these interactions have not been fully examined although Cbyr has been shown to 
enhance cytohesin-1 activity in vitro (Tang et al., 2002). More interesting still is the 
model o f the small GEF-ARF interaction on the Golgi membrane proposed by Lee and 
Pohajdak (2000). In this model, the ARF-GEF uses its coiled-coil N-terminus to bind 
a membrane-bound adaptor protein. The authors o f this work suggested that the 
coiled-coil N-terminus is in fact necessary and sufficient to target the small ARF- 
GEFs to the Golgi membrane, therefore making the PH domain functionally 
redundant. Alternatively, it is also likely that the coiled-coil-domain-dependent 
membrane targeting mechanism via direct association with an adaptor protein 
enhances or stabilizes the membrane interaction o f the ARF-GEF with 
polyphosphoinositides through the PH domain. As a result, it is conceivable that this 
double interaction supports a favorable orientation o f the ARF-GEF that would allow 
its Sec7 domain to activate more efficiently the GDP/GTP exchange on membrane 
associated ARF than in cases of single interaction.
Thus, in summary, the positive coordinated regulation o f PLD by ARFs and their 
small exchange factors is likely to rely on their multiple interactions with PLD- 
controlling proteins (e.g. G-proteins, protein kinases) and polyphosphoinositides (PIP2  
and PIP3 ).
1.8.3. Evidence for a coordinated regulation of PLD by ARF and its GEFs
Although the activation o f PLD by ARFs is well-established in most in vitro 
systems, very little is known about the exact molecular mechanisms coupling the cell 
surface receptors to the ARF-dependent activation o f PLD. Over the past few years, 
studies in intact and permeabilized cells have implicated ARF as a mediator o f
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receptor-stimulated PLD activity in response to agonists including FMLP, phorbol 
esters and growth factors in a number o f cell lines (human neutrophils and neutrophil- 
related HL-60 cells, rat fibroblast cells, human embryonic kidney cells) (Li et al., 
2003; Shome et al., 1998; Shome et al., 1997; Fensome et al., 1996; Rumenapp et al., 
1995). A role for ARF in receptor-regulated PLD activity relies on the following 
findings: 1) BFA inhibited PDGF-, insulin- and PMA-induced PLD activation; 2) 
addition o f  recombinant ARF restores agonist-dependent PLD activation to 
permeabilized, cytosol-depleted cells; 3) dominant-negative ARF mutants (ARF1, 
ARF6 ) inhibited PLD stimulation by PDGF or PMA; 4) growth factor-promoted 
activation o f ARF and recruitment to cellular membranes. Obviously, the observation 
that growth factors such as insulin and PDGF induced the activation o f ARF, and its 
subsequent binding to cell membranes, suggests the involvement o f ARF-GEFs in the 
signalling pathway controlling the activation o f PLD. More recently, a study by Li et 
al. (2003) has implicated ARNO as a mediator o f the activation o f ARF1 and PLD by 
insulin in rat fibroblast cells in which both human insulin receptors and ARNO were 
overexpressed. In this study, insulin was found to promote the translocation o f ARNO 
to cell membranes confirming earlier observations o f insulin-dependent translocation 
o f ARNO (Venkateswarlu et al., 1998) and GRP-1 (Langille et al., 1999) to the 
plasma membrane o f  murine 3T3 LI adipocytes and Chinese hamster ovary (CHO-T), 
respectively. In addition, the translocation o f cytohesin-1 from the cytosol to the 
plasma membrane in response to growth factor stimulation has also been demonstrated 
in PC 12 cells (Venkateswarlu et al., 1999). The translocation o f ARNO, GRP-1 and 
cytohesin - 1  mentioned in those reports was blocked by wortmannin, suggesting the
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participation o f the PI 3-kinase pathway for the small ARF-GEFs recruitment to the 
plasma membrane o f the studied cells. Interestingly, Li et al. (2003) showed that the 
recruitment o f ARNO on to the plasma membrane was accompanied by activation and 
subcellular translocation o f ARF1. Thus, these two events correlated well with the 
previously observed insulin-stimulated PLD activity in intact cells (Shome et al., 
1997). These findings suggest an appealing model o f a coordinated regulation o f PLD 
by ARF and its exchange factor(s) involving the timely activation o f the PI 3-kinase 
pathway in response to stimulation by insulin receptors (Li et al., 2003; Rizzo and 
Romero, 2002).
However, such a mechanism might be restricted to the rat fibroblast cells and the 
particular type o f agonist used i.e. insulin. Therefore, the stimulation o f different types 
o f cell-surface receptors might trigger various signalling mechanisms in different cell 
types. It is difficult to confidently extrapolate a particular model o f the mechanism o f 
PLD activation from a single type o f cell.
In order to clarify the role o f the small ARF-GEFs in the ARF-regulated PLD 
activity, the main approach adopted in the work described in this thesis uses a cell 
permeabilization technique in which HL-60 cells, the selected cell line, are depleted of 
ARFs and other cytosolic components. The experiments proceed through the 
subsequent reconstitution o f PLD activity by the reintroduction o f  recombinant ARFs 
and small ARF-GEFs in the presence o f GTP. This system bypasses receptor- 
stimulation step and therefore allows the characterization the individual signalling 
components thought to participate in PLD regulation.
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O f note, HL-60 cells have proven to be an exceptionally useful model system for 
the analysis o f various aspects o f the regulation o f PLD for several reasons. First, they 
are o f human origin and can be used, with certain limitations, as a model system for 
neutrophils and monocytes. Furthermore, HL-60 cells possess several membrane 
receptors, many o f them G-protein coupled, such as FMLP receptors, PAF receptors, 
histamine H] and H2 -receptors, adenosine receptors (Gessi et al., 2002) and purinergic 
receptors (Adrian et al., 2000). Interestingly, the ARF-activated PLD isoform that is 
predominantly expressed in HL-60 cells is PLD1 (Colley et al., 1997). Moreover, 
previous reports indicate that BFA does not influence the stimulation o f  PLD activity 
by FMLP in HL-60 cells (Fensome et al., 1998; Bourgoin et al., 1995) or by ARF in 
Golgi-enriched membranes o f HL-60 cells (Guillemain and Exton, 1997), suggesting 
both the presence and function o f BFA-insensitive ARF-GEFs in human granulocytes. 
Specifically, cytohesin-1 has been identifed in human neutrophils and HL-60 cells 
(Garceau et al., 2001). This supports a key role for cytohesin-1 and potentially its 
counterparts, ARNO and GRP-1, in agonist regulation o f PLD in HL-60 cells.
Since cultured cell lines are often derived from patients suffering from cancer, 
and cancer cells have been shown to upregulate the PLD proteins, caution must be 
exercised when evaluating data from cell lines because they may not represent the 
situation in primary cells. This observation is important, because the majority of 
studies haveutilised cultured cell lines for the analysis o f PLD localization.
1.8.4. Role of the GAPs in the inactivation of ARFs
GAPs stimulate ARF-bound GTP hydrolysis and return ARF to the inactive 
GDP-bound state. Many new ARF GAP proteins have been identified and have been
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categorized into three groups: A rf GAP1 type, Git type and AZAP type (Nie et al., 
2003). These new ARF GAPs are multidomain proteins that were identified as binding 
partners o f signal transduction molecules. All these proteins share a common GAP 
domain o f 70 amino acids which include a zinc finger motif that is essential for GAP 
activity (Donaldson and Jackson, 2000). In addition to the zinc finger, all ARF GAPs 
have a conserved arginine within the GAP domain. Mutation o f this arginine to lysine 
results in a 100,000-fold decrease in GTPase activity for ASAP1 (Randazzo et al., 
2000) indicating that this arginine is essential for GAP activity.
Since ARF1 is involved in the formation o f coatamer from Golgi vesicles, the 
disassembly o f coatomer requires that the small GTP-ARF1 hydrolyzes its bound GTP 
by the action o f a GAP. In vitro, the binding o f the ARF1 GAP to lipid vesicles and its 
activity on membrane-bound ARF 1-GTP are increased by diacylglycerols with 
monounsaturated acyl chains, such as those arising in vivo as secondary products from 
the hydrolysis o f PC by ARF-activated PLD. Thus, the PLD pathway may provide a 
feedback mechanism that promotes GTP hydrolysis on ARF1 and the consequent 
uncoating o f vesicles (Antonny et al., 1997).
It has been suggested that the ARF GAPs do more than turn off ARF. They 
provide the link between the ARF GTPase cycle and various signal transduction 
events in the cell. For instance, ASAP1 has been shown to coordinate cell signaling, 
the actin cytoskeleton, and the ARF nucleotide cycle. Overexpression o f ASAP1 in 
cells results in a loss o f focal adhesions and an inhibition o f cell spreading and PDGF- 
induced ruffling. ASAP1 can work in vitro as a GAP on ARF1, ARF5, and ARF 6 , 
albeit more effectively on ARF1 and ARF5. These observations, together with the
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recent indication that ARF6  affects cortical actin by activation o f a 
polyphosphoinositide 4-phosphate 5-kinase (Honda et a l, 1999), support a role for 
ARFs and ASAP1 in growth factor-stimulated reorganization o f the actin 
cytoskeleton.
1.9. Principal aims o f  thesis
The major purpose o f this thesis is to bring more insight into the complex 
regulation o f PLD1 with respect to its numerous regulators. This thesis focuses on 
specific aspects o f PLD 1 regulation by taking advantage o f the use and comparison of 
the cell-free and the permeabilized-cell model systems
The first aim o f this study is to establish a direct comparison between the effects 
o f ARF1 and ARF6  on PLD1 activity in an attempt to rigorously establish if  there is 
any selectivity for particular ARF iso forms in PLD1 activation.
The second aim will focus on the role o f the small ARF-GEFs in regulating the 
activation o f ARF proteins and their specific interactions with polyphosphoinositides 
in vitro. In particular, experiments will determine whether the reported specificity o f 
certain small ARF-GEFs towards PIP3 is in fact a function o f the specific interaction 
between the PH domains o f these ARF-GEFs with this polyphosphoinositide. This is 
important since other agents like GEF-interacting proteins might also contribute to any 
effective discrimination o f the ARF-GEFs for PIP3 and PIP2.
The third aim will be the study the effects o f coupling the ARFs and their 
exchange factors and the consequences for PLD activity both in vitro and 
permeabilized HL-60 cells. In addition, polyphosphoinositides will be tested for their 
effects in this tripartite system.
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Chapter two
Materials and Methods
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2.1. Materials
2.1.1. Reagents
Culture medium RPMI-1640 and Medium 199 were purchased from Sigma. 
Supplements to these media are fetal calf serum obtained from Imperial Laboratories, 
penicillin (5000 units/mL) and streptomycin (5000 pg/mL) obtained from Invitrogen.
Culture medium IPL-41 for insect cells and supplements such as fungizone liquid 
(250 pg/mL), yeastolate ultrafiltrate (200 g/L) were purchased from Invitrogen. Other 
supplements to this medium are tryptose phosphate broth solution (29.5 g tryptose 
phosphate broth/L in deionised water) from Sigma and fetal calf serum.
Radiochemicals such as [methyl- H] choline chloride (79 Ci/mmol) and 
l , 2 -didecanoyl-.s?7-glycero-3 -phospho[ HJcholine (85 Ci/mmol) were purchased from 
Amersham Pharmacia Biosciences; [3 5 S]GTPyS (1250 Ci/mmol) was from NEN.
All other reagents including fatty acid-free bovine serum albumin, amberlite 
CG-50 (weakly acidic cation exchanger), ammonium sulfate, benzamidine, 
bromophenol blue, EGTA, HEPES, kanamycin, L -a  dimyristoyl (C l 4)
phosphatidylcholine, myristic acid, nalidixic acid, PE (from egg yolk), PIPES, PMSF, 
potassium chloride, sodium chloride, SDS, sodium phosphate, SLO, suramin, 
TEMED, Tris, and Triton X-100 were from Sigma. Ampicillin, ATP (disodium salt), 
GTP (lithium salt) and GTPyS were purchased from Roche. Calcium chloride solution, 
chloroform, EDTA (disodium salt), glycerol, glycine, hydrochloric acid, imidazole, 
IPTG, lysozyme, magnesium chloride, methanol, PBS, reduced glutathione, sodium 
azide, sodium hydroxyde were from BDH Laboratory supplies. APS, 40% 
Acrylamide/Bis solution and Supported Nitrocellulose membrane (0.2 pM) were from
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Bio-Rad. Coomassie Brillant blue R250 was from Fluka, glutathione sepharose 4B 
from Amersham Biosciences, DTT from Alexis Biochemicals, hybond-C extra­
membranes from Amersham Pharmacia Biotech, Ni-NTA from Qiagen, VectaSpin 
Micro 10 pM Polypropylene Mesh filters from Fisher, Ultima Gold scintillation liquid 
from Packard BioScience, tissue culture flasks from Helena BioSciences. Synthetic 
lipids such as l,2-dibromostearoyl-sn-glycero-3-phosphocholine (PC) and dipalmitoyl 
phosphatidyl-L-serine (PS) and brain L-a-PIP 2  were obtained from Avanti Polar 
Lipids. The indicated phosphoinositides used in the liposome-binding assay and the 
protein-lipid overlay assay were purchased from CellSignals, Inc (Ohio, USA).
2.1.2. Preparation of 100 mM stock MgATP
A stock o f 100 mM MgATP was prepared as follows: 1.815 g o f di-sodium ATP 
was added to 15 mL o f distilled water and stirred until the ATP was dissolved. Then 
3 mL o f 1 M MgCl2  was added under constant stirring followed by the addition o f  
6  mL o f 1 M Tris (pH > 10) to buffer the 2 mols/mol o f protons accompanying the 
ATP. The pH o f the solution was checked and adjusted to pH 7.0 with HC1. The 
volume was made up to 30 mL taking at least one wash from the beaker. The pH was 
checked a second time and readjusted to pH 7.0 if  necessary. Aliquots o f the solution 
were stored at -20°C.
2.1.3. Preparation of Ca2+ buffers
Two stock solutions were prepared. Firstly, EGTA solution: 100 mM EGTA, 
20 mM Na+-PIPES pH 6 .8 , 73 mM MgCl2. Secondly, Ca/EGTA solution: 100 mM 
Ca2+-EGTA 20 mM Na+-PIPES pH 6 .8 , 67 mM MgCl2. Various ratios o f these two 
solutions were mixed to give 100 mM stock solutions o f calcium buffers. For example,
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9 +pCa7 stock buffer is prepared by mixing EGTA solution and Ca -EGTA solution in 
the ratio 7.008:0.992 and pCa5 in ratio 0.496:7.504 respectively. Each solution gives 
about 2 mM free MgCh final concentration when the buffer is diluted to 3 mM final 
EGTA concentration in the experiments described below.
2.1.4. Preparation of myristic acid and BSA
Myristic acid bound to BSA was prepared as follows: 1 g o f BSA and 126 mg o f 
myristic acid were dissolved in 25 mL o f water in each o f  two separate tubes. The 
solution o f myristic acid was warmed in a microwave as myristic acid is relatively 
insoluble in water at room temperature. The myristic acid solution was then mixed up 
with the BSA solution in a single tube (50 mL total volume). The newly prepared 
solution was kept in a water bath at 42°C prior to use.
2.1.5. Preparation of nalidixic acid
Nalidixic acid (25 mg/mL) was prepared as follows: 125 mg o f nalidixic acid 
was added to 5 mL o f water. A few microlitres o f sodium hydroxyde were added to 
clarify the solution. The solution o f nalidixic acid was prepared immediately before 
use.
2.1.6. Preparation of 6X SDS sample buffer
6 X SDS sample buffer (0.376 M Tris, pH 6 .8 , 12% SDS, 60% (w/v) glycerol, 
0.6 M DTT, 0.06% (w/v) bromophenol blue) was prepared as follows: 9.4 mL o f  1 M 
Tris, pH 6 . 8  were diluted into 15.6 mL o f water in a beaker. Then 15 g o f glycerol 
(liquid), 3 g o f SDS (solid), 15 mg o f bromophenol blue and 2.3 g o f DTT (solid) were 
added to the Tris buffer. The solids were allowed to dissolve. Another extra 15 g o f
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glycerol was finally added when the solution was all dissolved. Aliquots o f  6 X SDS 
sample buffer were stored at -20°C.
2.1.7. Sources of cell lines and viruses
HL-60 human promyelocytic leukemic cell line was purchased from the 
European Collection o f Animal Cell Culture (UK).
Sf9 (Spodoptera frugiperda) insect cells were a kind gift from Dr Claudia 
Wiedemann. The recombinant baculovirus encoding for the hPLD lb was kindly 
provided by Prof. Michael J.O. Wakelam (Birmingham University, UK).
2.2. Methods
2.2.1. Cell culture and radiochemical labelling
2.2.1.1. Promyelocytic HL-60 cells
HL-60 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) 
heat-inactivated fetal calf serum, penicillin (50 units/mL) and streptomycin 
(50 pg/mL). Cells were grown to a density o f approximately 1 x 106  cells/mL in a 
humidified atmosphere containing 5% CO2 at 37°C.
For experiments, cells were cultured in Medium 199 supplemented with 10% 
(v/v) dialyzed heat-inactivated fetal calf serum, penicillin (50 units/mL) and 
streptomycin (50 pg/mL) and grown in the presence o f [methyl- 3 H]Choline 
(1 pCi/mL) for 48 hours.
2.2.1.2. Sf9 cells
The Sf9 cells were grown in monolayers at 27°C in tissue culture flasks, using 
IPL-40 insect medium supplemented with 10% (v/v) fetal calf serum, 1% (v/v) 
amphotericin B (Fungizone), 8 % (v/v) tryptose phosphate broth solution and 2% (v/v)
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yeastolate ultrafiltrate. For the production of recombinant hPLDlb, the cells were 
grown in a monolayer up to 5 x 107 cells per 175 cm2 culture flask in 20 mL IPL-40 
insect medium with supplements except for fungizone. An inoculum of the 
recombinant baculovirus encoding hPLDlb was added to the cell culture at a 
multiplicity of infection of around 100 pfii/cell.
For recombinant virus amplification, new insect cells were infected with the 
recombinant baculovirus and were incubated for 7 days at 27°C in IPL-40 insect 
medium containing all of the mentioned supplements. The cells were dislodged from 
the surface by gentle scraping and then centrifuged at 1000 x g  for 10 min at 4°C and 
the resulting supernatant containing the new stock of virus was passed through 
0.22 (iM Millex filter (Millipore) and kept at 4°C in the dark for short-term storage.
2.2.2. Construction of the ARF expression plasmid pMon 5840-ARF1 (His)6 and 
5840-ARF6 (His)6
DNA coding for ARF proteins was amplified by PCR from authentic samples 
using forward and reverse primers that coded for the termini of the sequence and any 
desired extensions. These extensions comprised 5’ sequence for an Nco-1 restriction 
site and 3’ sequence containing codons for six consecutive histidine residues followed 
by a Hind III restriction site. For example, the following primers were used for bovine 
ARF1:
N-terminus: (sense strand):
5'-TATATACC•ATG•GGG•AAT•ATC•TTT•GCA•AAC•CTC-3'
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C-terminus: (antisense strand):
5'-ATTATTAAGCTTCA•GTG•ATG•ATG•ATG•ATG•ATG•TTT•CTG•GTT• 
CCG•GAG•CTG•ATT•GGA•CAG-3'
Restriction sites are underlined, ARF1 sequence and reverse compliment ARF1 
sequence are shown in red, the stop codon is in bold and the 6 xHis coding sequence is 
in blue. Related primers, but with sequence corresponding to fragments o f ARF1 or 
ARF6 , were designed along similar lines with all restriction sites and other features as 
for the ARF1 primers. PCR products were digested with N col and Hind III, purified 
and ligated into a sample o f plasmid pMon5840 (see below) which had been 
previously cut with the same two restriction enzymes. After transformation into E.coli 
XL1 Blue cells and selection by ampicillin resistance, plasmid DNA was isolated from 
positive clones and the insert sequenced to exclude any mutations. Plasmids were then 
transformed into E.coli BL21-DE3 pLysS cells with or with out co-transformation 
with expression plasmid pBB131 coding for the yeast A-myristoyltransferase 1 
(NMT1 and see below) and selected by ampicillin or ampicillin plus kanamycin 
resistance respectively. Positive or double positive clones were expanded and stored as 
frozen glycerol stocks until required.
2.2.3. pBB131 (yeast NMT1) plasmid
The expression plasmids pMon5840 and pBB131 were a kind gift o f Dr J.I. 
Gordon (Washington University Medical School, Missouri, USA).
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2.2.4. Expression o f proteins in E. coli and subsequent purification of 6 xHis- 
tagged recom binant ARFs fusion proteins
Recombinant non-myristoylated and myristoylated ARF1, ARF6  and [A17]ARF1 
(ARF1 with amino acids 1-17 deleted) were prepared as described previously 
(Randazzo et al., 1995) with a few modifications.
The preparation o f [A17JARF1 (His) 6  did not require the co-translational 
addition o f myristic acid as it is an ARF1 mutant in which the N-myristoylation site is 
deleted.
For the expression and purification o f ARF proteins the BL21 (DE3) E. coli 
bacteria transformed with either pMon5840-ARFl (His) 6  or pMon5840-ARF6 (His) 6  
each with or without pBB131 (yeast NMT1) plasmids were used. NMT catalyses the 
in vivo transfer o f a myristate group to a glycine residue at position 2 o f  the ARF 
protein. Bacteria lack this type o f transferase activity, hence its coexpression with the 
different plasmids coding for ARF proteins if  myristoylation is required. A 6 xHis tag 
was inserted into the sequence for ARF1, ARF6  and [A17JARF1 at the C-terminus as 
described above. Since the pMon5840 plasmids carry ampicillin resistance and 
pBB131 carries kanamycin resistance all cultures o f the double or singly transformed 
bacteria can be selected at all points by combinations o f these antibiotics e.g. 
ampicillin (100 pg/mL) and kanamycin (50 pg/mL).
An initial culture o f transformed cells were grown in 5 mL o f LB (Invitrogen) 
overnight at 37°C in presence o f the appropriate antibiotic. Cells from the overnight 
culture were expanded in two conical flasks containing 200 mL o f LB, once again 
containing antibiotics, and allowed to grow overnight at 37°C. The next day the cells
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were expanded in four 1-litre flasks o f LB for 1 hour. A freshly prepared solution 
containing myristic acid (2.52 mg/mL) and BSA (0.02 g/mL) was then added to the 
growing cells (12.5 mL in each flask) for an extra hour. The temperature was then 
reduced to 26°C to optimize the yield o f myristoylated proteins as previously shown 
by Franco et a l (1995). Cells were left for a further hour to cool down to the new 
temperature. Where required the expression o f NMT was then induced with 1 mM 
IPTG. Nalidixic acid (25 mg/mL) was added to the cells (at the same time as the IPTG 
if  required) to induce ARP protein expression (1.25 mL o f  the freshly prepared 
nalidixic acid stock solution was added to each flask). After 3 hours o f protein 
expression, further myristic acid and BSA were added and the culture was then 
allowed to grow overnight at 26°C. The cells were harvested by centrifugation at 
4420 x g  for 10 min at 4°C using a JA-10 fixed angle rotor in a J2-21 Centrifuge 
(Beckman). The cell pellet from a 4-litre culture was then resuspended in a total 
volume o f 80 mL o f lysis buffer 1 (50 mM Tris, pH 8.0, 25% (w/v) sucrose, 0.02% 
(w/v) NaN 3 , 1 mg/mL lysozyme) and incubated with gentle stirring for 30 min at room 
temperature. The cells were lysed by the addition o f 32 mL o f lysis buffer 2 (50 mM 
Tris, pH 8.0, 100 mM MgCl2, 0.2% (w/v) Triton X-100, 0.02% (w/v) NaN3). In 
addition, 1 mM DTT and PMSF were added to the suspension which was then 
incubated for 30 min at 4°C with stirring. The cells were subsequently homogenized 
by using a Citenco homogenizer (type KQTS7). The homogenate was clarified by 
ultracentrifugation at 100,000 x g  for 60 min at 4°C using a Type 35 Beckman rotor in 
a Sorvall Ultracentrifuge (OTD 65B model). ARF proteins were then purified from the 
supernatant through two steps. Firstly, the supernatant obtained after
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ultracentrifugation was pumped through a 25 mL bed volume column o f Ni-NTA fast- 
flow beads with a Minipuls II pump (Gibson) at about 2 mL/min. The column was 
previously equilibrated with the following cycle: 100 mL o f Nickel column buffer 
containing 20 mM NaLLPO^ 20 mM Tris, 300 mM NaCl, 0.2% (w/v) NaN 3 , pH 6.0, 
followed by 100 mL o f  the same buffer supplemented with 0.5 M imidazole and then 
followed by 50 mL o f a mixture (5:2 ratio) o f lysis buffers 1 and 2 respectively. The 
Ni-NTA column was then connected to an FPLC system which was set at a flow rate 
o f 2.5 mL/min. After a washing step, the protein was eluted with a continuous gradient 
o f 0 to 0.5 M imidazole in the Nickel column buffer. This particular column 
chromatography step was performed at room temperature or at 4°C with identical 
results. Fractions o f 5 mL were collected. In a second chromatographic step, 
myristoylated ARFs were resolved from the underivitised forms by hydrophobic 
interaction chromatography on phenyl superose if  required. The pooled samples from 
the Ni-NTA column were mixed with solid ammonium sulphate to a final 
concentration o f 1 M. In the cold, the pH was adjusted to 7.6 and the sample clarified 
by centrifugation and passage through a 0.45 pM filter. The HR10/10 phenyl Superose 
column was equilibrated in a cold Tris buffer (20 mM Tris, pH 7.6 and 0.02% (w/v) 
NaN 3 ) containing 1 M (N H ^S C ^. After passage o f the sample through the column the 
bed was washed with one volume o f buffer containing 1.7 M (NFL^SOzi. The column 
was then developed with a decreasing linear ammonium sulphate gradient in the same 
Tris buffer and 8 mL fractions were collected. All flow rates were 0.5 mL/minute or 
less. Protein elution was monitored by absorbance at 280 nm. Protein-containing 
fractions were dialysed against several changes o f Tris buffer (100:1 volume ratios as
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above) in the cold and then concentrated as described for other samples and stored 
frozen in small aliquots. Alternatively, the myristoylated protein could be collected by 
differential ammonium sulphate precipitation. Peak fractions from the Ni-NTA 
chromatography step containing the ARF protein mixture were pooled and dialyzed 
against 1.7 M (NFL^SC^, pH 7.6 overnight at 4°C. The resultant precipitate 
containing myristoylated ARF proteins was collected by centrifugation at 27000 x  g  
using a JA-20 fixed angle rotor (Beckman) for 15 min at 4°C. The pellet containing 
the protein sample was dissolved in 20 mM Tris, pH 7.6 and subsequently dialyzed 
three times against the same buffer at a volume about 100 times the volume o f the 
protein sample to remove the highly concentrated salt (see “Protein dialysis” section 
and following sections for more details on protein analyses).
We could not detect biochemical difference between forms o f myristoylated 
ARFs prepared by either o f these two methods.
The extent o f myristoylation o f the protein preparations was assessed by reverse 
phase HPLC as myristolated forms o f the proteins show a characteristic increase in 
retention time.
2.2.5. Construction of the recombinant plasmids pQE30 containing the coding 
sequences for full-length ARNO, GRP-1 and cytohesin-1
A sample o f the pQE30 expression plasmid with an insert coding for human 
cytohesin-1 was the generous gift o f Dr. Joel Moss, NHLBI, Bethesda, Maryland, 
USA. cDNAs coding for other ARF-GEF proteins were amplified by PCR using 
forward and reverse primers that coded for the termini o f the sequence and any desired 
extensions. Authentic DNA coding for GRP-1 was from Dr. J. Klarlund, University o f
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Massachusetts Medical Center, Massachusetts, USA. DNA coding for ARNO was 
obtained by direct PCR from a mouse foetal brain cDNA library kindly provided by 
Professor C. Carpenter, Harvard Medical School, Boston, USA. In both cases the 
extensions comprised 5 ’ sequence for a Kpnl restriction site and 3’ sequence for a 
Hind III restriction site. For example, the following primers were used for mouse 
GRP-1:
N-terminus (sense strand):
5'-ATTGGTACC•GAC•GAA•GGC•GGT•GGC•GGT•GAG•GGC•GGC•- 3 '  
C-terminus: (antisense strand):
5'-TAAAAGCTT•CTA*TTT•CTT•ATT•GGC•AAT•CCT•CCT•TTT-3' 
Restriction sites are underlined, GRP-1 sequence and reverse compliment GRP-1 
sequence are shown in red and the stop codon is in bold Subsequent cloning into 
pQE30 then gives DNA coding for an N-terminal 6xHis extension to the ARF-GEF 
translation products. Related primers, but with complimentary and reverse 
complimentary sequence corresponding to ARNO-1, were designed along similar lines 
with all restriction sites and other features as for the GRP-1 primers. PCR products 
were digested with Kpnl and Hind III, purified and ligated into a sample o f plasmid 
pQE30 (see below) which had been previously cut with the same two restriction 
enzymes. After transformation into E.coli XL1 Blue cells and selection by ampicillin 
resistance, plasmid DNA was isolated from positive clones and the insert sequenced to 
exclude any mutations. Plasmids were then transformed into E.coli M15[pREP4] cells 
and again selected by ampicillin resistance. Colonies o f positive clones were expanded 
in suspension culture and samples frozen as glycerol stocks until required.
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2.2.5.1. Recombinant full-length ARNO-1 (His) 6, GRP-1 (His) 6 and cytohesin-1 (His) 6 
E. coli strain M15[pREP4] harboring the recombinant pQE30 plasmids
containing in frame coding sequences for full-length ARNO, GRP-1 and cytohesin-1 
were used for 6xHis-tagged recombinant protein expression. Consequently, the protein 
products could be purified by Ni-NTA chromatography using exactly the same 
procedure as described above for the purification o f ARF proteins.
2.2.5.2. Recombinant ARNO, GRP-1 and cytohesin-1 GST-Cys-tagged PH domains 
The ARF-GEF PH domains were kindly provided by Gerald Hammond (Cancer
Research UK, London). Briefly, the recombinant pGEX-4T3 plasmids containing the 
coding sequences for PH domains o f ARNO (residue 235 to the C-terminus), GRP-1 
(residue 240 to the C-terminus) and cytohesin-1 (residue 236 to the C-terminus) were 
transformed individually into the E.coli strain TG I. By this cloning procedure a 
GST-Cys fusion tag was inserted into each protein at the N-terminus o f the mentioned 
PH domains. This allowed expression and purification o f the PH domains by standard 
methods for GST-tagged fusion proteins. Briefly, after cell lysis and 
ultracentrifugation, the GST-PH domain proteins present in the supernatant were 
incubated with glutathione sepharose 4B beads and rotated at 4°C overnight. After 
washing away unbound proteins the fusion proteins were then eluted with 10 mM 
reduced glutathione in 50 mM Tris-HCl, pH 8.0.
2.2.6. Expression of GST-hPLDlb in sf9 insect cells and its subsequent 
purification
A baculovirus-based expression system was used to obtain recombinant N- 
terminus-GST-tagged hPLDlb. Sf9 insect cells infected with the baculovirus encoding
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the hPLD lb were harvested after 48 hours o f infection. The cells were centrifuged for 
10 min at 1000 x g  at 4°C and were washed in cold PBS. The cells were then 
resuspended in ice-cold lysis buffer (20 mM Tris, 1 mM EGTA, 1 mM MgCb, 
0.1 mM DTT, 0.1 mM PMSF, 0.1 mM benzamidine, pH 7.5) and disrupted by brief 
sonication. The resultant suspension was centrifuged at 1500 x g  for 10 min at 4°C 
and the supernatant recovered. The supernatant was then centrifuged at 16000 x  g  for 
30 min at 4°C to pellet the cellular debris. The clarified supernatant from this second 
centrifugation was mixed with 1 mL o f packed glutathione sepharose 4B beads and 
rotated at 4°C overnight. The beads were subsequently washed 3 times with 10 mL 
lysis buffer and the newly purified GST-hPLDlb captured on beads was stored at 4°C 
(without elution) in the same buffer. On average, the activity o f the PLD lb used in 
separate incubation in each experiment (20 pL PLD 50% slurry beads) was 
7 fmol/min PC-hydrolyzed.
2.2.7. General protein handling and quality control procedures: protein dialysis, 
protein concentration, protein quantification, protein storage, protein 
electrophoresis, protein staining and destaining, gel drying and western blotting
2.2.7.1. Protein dialysis to remove imidazole and ammonium sulphate
After the elution step at the end o f the purification process, the protein sample to 
be dialyzed was transferred into a soaked dialysis tubing 12 kDa molecular weight 
cut-off (Sigma) which was then carefully clamped and placed into a 5 L container 
filled with 20 mM Tris, pH 7.6 at a volume about 100 times the volume o f the protein 
sample. The container was then placed in a cold room set at 4°C. To facilitate the 
removal o f high salts, a spin bar was placed in the bottom o f the container. The protein
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sample was dialyzed for 24 hours with gentle stirring. Changes o f buffer were 
performed 2 more times giving a one million-fold theoretical salt dilution.
2.2.7.2. Protein concentration
After dialysis, the purified protein was transferred to a properly preassembled 
50 mL capacity Amicon concentrator (Millipore) containing a 10,000 MW-cut off 
Amicon ultrafiltration membrane (YM10 Millipore). The ultrafiltration membrane was
placed in the bottom o f the concentrator with its glossy side up. A nitrogen gas head at
2 2 an operating pressure read between 20 psi (1.4 kg/cm ) and 30 psi (2.1 kg/cm ) was
applied to the concentrator during stirring.
Subsequently, a further concentration o f protein sample was also performed
using 10 kDa MW-cut o ff Microsep microconcentrators (Pall, Gelman Laboratory) in
order to get a smaller volume o f protein sample (< 0.5 mL). A maximum o f 3.5 mL of
protein sample was transferred into the sample reservoir o f the microconcentrator
which was then centrifuged at 3000 x g  using a JA-20 fixed angle rotor (Beckman) for
30 min at 4°C.
2.2.7.3. Protein quantification
The concentrated protein sample (except for hPLDlb which was isolated on 
glutathione sepharose beads) was quantified by using a dye-binding assay based on the 
method o f Bradford (Bio-Rad or Pierce kit). The amount o f protein in the sample was 
measured according to the manufacturer’s instructions. The protein samples were read 
using an Ultrospec II spectrophotometer (LKB Biochrom) with reference to a BSA 
standard curve. Usually, final unmyristoylated and myristoylated ARF concentrations 
ranged from 2.5 mg/mL to 3 mg/mL. Concentrations between 5 mg/mL to 12 mg/mL
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were usually obtained for the GEF recombinant proteins ARNO, cytohesin-1 and 
GRP-1.
2.2.7.4. Protein storage
All recombinant proteins were dated and stored at -20°C  for short-term storage 
and -80°C  for long-term storage.
2.2.7.5. Protein electrophoresis
Protein samples were first separated by SDS-PAGE. The following protocol was 
used to analyze the ARF and GEF recombinant proteins purified as described above. 
A 1 mm thick, 12.5% SDS-PAGE separating gel was made with a discontinuous 
stacking gel (< 5%). The separating or lower gel was made first by mixing 10 mL o f 
separating gel buffer (1.5 M Tris, pH 8.8 with HC1, 0.4% (w/v) SDS) with 17.5 mL o f 
water, 12.5 mL o f 40% acrylamide/bis solution, 400 pi o f 20% (w/v) APS and 30 pL 
TEMED. The separating gel was then poured between the slabs o f the preassembled 
SE 600 vertical slab gel unit (Hoefer) in the dual gel casting stand to a level about 
4 cm from the top o f the gel. A few microlitres o f water-saturated isobutanol were 
added on top o f the separating gel to eliminate any air bubbles and prevent oxygen 
diffusion. While polymerization o f the separating gel was taking place, the stacking or 
upper gel was prepared by mixing 5 mL o f stacking buffer (0.5 M Tris, pH 6.8 with 
HC1, 0.4% (w/v) SDS), 12.7 mL water, 2 mL o f 40% acrylamide/bis acrylamide 
solution, 100 pL o f  20% (w/v) APS and 10 pL TEMED. After polymerization o f the 
separating gel, the small excess o f alcohol was poured off and the surface o f  the 
polymerized separating gel before it was washed 3 times with distilled water. The 
stacking gel was then poured in on top o f the separating gel. A 1 mm thick, 20-well
comb was subsequently inserted, taking care not to trap any air bubbles below the 
teeth o f the comb. The gel was allowed to sit for at least 30 min. After polymerization, 
the comb was gently removed from the stacking gel and the newly formed wells were 
filled with tank buffer (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3).
The protein samples were diluted in a total volume of 50 pL to get approximately 
5 pg o f protein per tube to which 10 pL o f 6X SDS sample buffer were added. The 
samples were heated to about 80°C for 5 min and then loaded in the wells.
The SE 600 vertical slab gel unit was then connected to an Electrophoresis Power 
supply (Model 3000 Xi, Bio-Rad) and the gel run for 14 hours at 9 mA constant 
current per gel.
2.2.7.6. Protein staining and destaining
A portion or all o f the SDS-PAGE gel was placed in a staining solution (0.025% 
Coomassie Brillant blue R 250 (Fluka), 40% (v/v) methanol, 7% (v/v) acetic acid) for 
periods between approximately 3 hours and overnight under gentle shaking.
In order to reveal the separated protein bands, the staining solution was replaced 
by a destaining solution (40% (v/v) methanol, 7% (v/v) acetic acid). Changes o f the 
destaining solution were performed several times until the gel background became 
clear. Finally the destained gel was washed in water.
In some cases, the staining and destaining steps could be accelerated by repeated 
heating o f the staining and destaining solutions using a standard microwave.
The destained gel was either stored in water at 4°C or dried under vacuum.
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2.2.7.7. Gel drying
Vacuum drying was applied to the destained gel. The gel was placed on a piece 
o f wet filter paper (Whatmann number 1) which was then laid onto the plate o f a gel 
dryer (Model 583, Bio-Rad). The top o f the gel was covered with a piece o f  Saran 
plastic wrap. The silicon dryer cover flap was then lowered onto the gel, the vaccum 
turned on to seal the flap. The gel was usually dried at 70°C for 1 hour and 30 min.
2.2.7.8. Western blotting
Western blotting was performed for the recombinant ARF proteins using the 
following protocol: one portion o f  the SDS-PAGE gel containing resolved protein 
bands following electrophoresis was cut off and washed 2 times in transfer buffer 
(25 mM Tris, 192 mM glycine, 20% (v/v) MeOH) for 15 min each time. A similarly 
equilibrated semi-dry transfer system was applied for the protein gel in a Multiphor II 
Electrophoresis System (Pharmacia Biotech). For each gel, one sheet o f 0.2 pM  pore 
nitrocellulose filter membrane (Bio-Rad) and 12 sheets filter paper (Whatman) were 
cut the same size as the gel and soaked in transfer buffer. Prior to protein transfer, a 
transfer sandwich was assembled on the anode plate in the following order: 6 sheets o f 
filter paper, nitrocellulose membrane, SDS-PAGE gel, 6 sheets o f filter paper. The 
Multiphor II Electrophoresis System was connected to a power supply (2303 
Multidrive XL, LKB Bromma). The protein sample was transferred to the 
nitrocellulose membrane for 1 hour using 0.8 mA/cm2 current density. After protein 
transfer, the nitrocellulose membrane was incubated in blocking solution containing 
5% (w/v) skimmed milk powder in 100 mL TBS Tween buffer (100 mM Tris/HCl, 
0.9% NaCl, w/v 0.1% (w/v) Tween-20) for 1 hour at room temperature on a lab shaker
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(gently rocking). After blocking, the membrane was washed 3 times in 100 mL TBS 
Tween for 10 min each time. ARF protein was then detected by incubating the 
membrane with a mouse monoclonal 1D9 antibody (Alexis) used at 1: 2000 dilution in 
TBS-Tween buffer for 1 hour at room temperature. After 3 buffer washes in TBS 
Tween, the membrane was subsequently incubated with secondary antibody goat anti 
mouse HRP (horseradish peroxidase) conjugate (Bio-Rad) at 1:3000 dilution in 
100 mL TBS Tween containing 5% (w/v) skimmed milk powder and 1% goat serum 
for 1 h at room temperature. The membrane was then washed 3 times in TBS Tween 
for 10 min each time and subsequently incubated with 10 mL o f an HRP substrate 
solution made up o f one volume o f Stable Peroxide Solution and one volume o f 
Luminol/Enhancer Solution (West Pico Chemiluminescent susbtrate, Pierce) for 
10 min at room temperature. Following the incubation time with chemiluminescent 
reagents, the membrane was laid flat between sheets o f clear plastic and developed by 
short exposure in the FujiFilm Intelligent Dark Box. Images were captured and stored 
electronically.
2.2.8. PLD assay in SLO-permeabilised HL-60 cells
Because the major goal o f this research is to understand the intracellular 
mechanisms that lead to the activation o f PLD, it has been necessary to gain access to 
the interior o f the cell. To achieve this HL-60 cells were permeabilized with the pore- 
forming-toxin SLO. SLO is a cytolytic protein secreted by the bacterial genus 
Streptococcus (Bhakdi et al., 1985). This toxin specifically binds to cholesterol in the 
plasma membrane and forms arc- and ring-shaped oligomers that penetrate the apolar 
domains o f the plasma membrane. The ring-shaped structures once embedded in the
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plasma membrane o f the cells form transmembrane channels o f between 25 and 30 nm 
in diameter. At the concentrations used in this study SLO generally preserves the 
architectural integrity o f the cells. Thus the formation o f these pores results in the loss 
o f cytosolic components (except for those that have strong interactions with 
membranes or the cytoskeleton) and enables the introduction into the cells o f specific 
recombinant proteins, nucleotides, and other low molecular weight agents that 
influence the activity o f PLD.
Different types o f assays have been reported for the determination o f PLD 
activity. In our laboratory, we use a headgroup-release assay which measures the 
formation o f [methyl- H]choline from [methyl- H]choline-labeled PC. At the end o f  
the radiolabelling period, the cells were centrifuged and washed in the assay buffer 
(137 mM NaCl, 2.7 mM KC1, 20 mM PIPES, 1 mg/mL BSA, 0.02% NaN3, pH 6.8). 
The resuspended cells were then treated with SLO (0.4 IU/mL final concentration) and 
EGTA (0.2 mM). EGTA was included in the buffer to chelate any free calcium 
released during permeabilisation. The cells were permeabilised for 10 min at 37°C. 
Proteins such as ARF proteins were shown to leak out o f the cells within 5-10 min 
(Fensome et al., 1996). At the end o f the permeabilisation step, the permeabilised cells 
were sedimented by centrifugation at 2000 x  g  for 5 min to remove the cytosolic 
components that had leaked out during permeabilisation. The permeable HL-60 cells 
were then resuspended in buffer containing 3 mM MgATP and 3 mM Ca2+/EGTA 
buffer (pCa5). Reaction mixtures (50 pL final volume) comprising 20 pL o f 
permeabilised cells and permuted combinations o f recombinant ARFs, GEFs, Arfaptin 
proteins, with or without the non-hydrolyzable GTP-analogue GTPyS in 30 pL were
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carried out for 20 min at 37°C. All mixtures were made on ice and the reactions 
started by transferring the test tubes to a 37°C water bath. The incubation was 
terminated by addition o f 500 pL methanol/chloroform (1:1, v/v). Phases were 
separated by addition o f 250 pL water followed by vigorous mixing and 
centrifugation. [ HJCholine was recovered from the upper aqueous phase by cation- 
exchange chromatography as follows: 400 pL o f the upper aqueous phase o f each 
reaction was loaded into the cation-exchange resin (Amberlite CG-50) columns. The 
columns were rinsed with water to elute the phosphorylated choline metabolites.
<5
[ H]Choline was then eluted directly into scintillation vials with 1 mL o f elution buffer 
(50 mM glycine in 500 m M NaCl, pH 3.0), mixed with 5 mL Ultima Gold scintillation 
cocktail and quantified by liquid scintillation analysis.
2.2.9. Activity of G ST -hPL D lb  on glutathione sepharose beads quantified in vitro 
The recombinant human PLD lb  activity was assayed by measuring the free 
choline released upon phosphatidylcholine hydrolysis. Immediately before each 
experiment substrate was prepared from a mixture o f PE, PIP2 , and didecanoyl 
(including some radiolabelled material) PC in the molar ratio 10:0.3:1, with a final
concentration o f PC at 8.6 pM exactly as described by Vinggaard et al. (1996).
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[ H]Choline-labelled didecanoyl PC was added to give approximately 200000 d.p.m. 
per 10 pL o f substrate. The lipid mixture was “dried down” to a glass under a stream 
o f N 2  and resuspended in the substrate buffer. The substrate and the assay buffers were 
made up in 50 mM Na/Hepes (pH 7.5), 3 mM EGTA, 80 mM KC1 and 1 mM DTT, 
with the addition o f 0.5 mM MgCl2  and 2 mM CaCb in the assay buffer. Vesicle 
formation was carried out by a combination o f  hard vortexing and sonication (3 x  20
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sec on a medium setting). Assays were then carried out by mixing combinations o f the 
following reaction components on ice: 20 pL GST-hPLDlb on glutathione sepharose 
beads (50% slurry approximately), 10 pL substrate, 30 pL combinations o f ARFs, 
GEFs, Arfaptins, Cg polyphosphoinositide lipids, nucleotides in a final volume o f 60 
pL. The exact concentrations are indicated in the legends o f the corresponding figures 
presented in subsequent chapters. The reaction mixtures were transferred to a 37°C 
water bath and incubated for 1 hour.
2.2.10. Nucleotide binding assay
The assay is based on the stimulation o f [35S]GTPyS binding to ARP proteins, the 
exchange reaction being either spontaneous or catalyzed by a GEF. The assay was 
performed as follows: a recombinant ARF protein was diluted to a final concentration 
o f 1 pM  in an exchange buffer containing 50 mM Hepes, pH 7.5, 1 mM MgCh, 
100 mM KC1, 1 mM DTT, 12 |xM [35S]GTPyS and 1 mM phospholipid vesicles in 
50 pL volume o f reaction. Where present GEFs were at a final concentration o f 1 pM. 
Phospholipids vesicles used in the exchange assays were prepared as follows: 
solutions o f L -a  dimyristoyl (Cl 4) PC in chloroform and PIP2  in 
chloroform:methanol:H20 (1:1:1, v/v) were mixed in the required proportion (50:1, 
molar concentration). The mixture was dried under nitrogen and resuspended in 
exchange buffer. The suspension was vortexed thoroughly and sonicated until the 
solution clarified.
Reaction mixtures were incubated at 37°C for between 5 and 10 min depending 
on the type o f recombinant ARF proteins used. All o f the exchange reactions are linear 
over this period. The reactions were stopped by transferring the samples to an ice
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water bath followed by the addition o f 150 pL ice-cold Triton X-100 solution (w/v
'i f
1.67%). The ARF proteins along with any bound [ S]GTPyS were recovered by 
immediately mixing the reactions with nickle-coated agarose beads for 10 min at 4°C 
to recover the polyhistidine-tagged ARFs. Specifically, 50 pL beads (20% slurry in 
exchange buffer) were added to the reaction mixture and placed on a rotary mixer. 
Samples o f beads were collected by brief centrifugation on 10 pM pore size 
Polypropylene Mesh filters and the beads washed extensively in washing buffer 
(20 mM NaH2H3P 0 4, 20 mM Tris, 300 mM NaCl, 0.02% w/v NaN3, pH 6.0) to 
remove unbound [35S]GTPyS. ARFs were then specifically eluted from the nickel 
beads, with 60 pL elution buffer (20 mM NaH2H3P 0 4, 20 mM Tris, 300 mM NaCl, 
0.02% w/v NaN3, 0.5 M imidazole, pH 6.0) and the amount o f eluted [35S]GTPyS 
estimated by scintillation counting. It was established in preliminary experiments there 
is little or no further detectable exchange of GTPyS onto ARFs under the reaction stop 
conditions, even in the presence o f GEFs. Hence the assay faithfully reports only the 
exchange catalysed in the initial incubation before quenching.
2.2.11. Protein-liposome-binding assay
Mixtures o f PC and PS (4:1 molar ratio) with and without the indicated 
phosphoinositides (3 Mol% o f total lipids) in methanol ichloroform (1:1 v/v) 
containing 0.4% (w/v) 1 M HC1 were dried under N2. The lipid mixtures were 
resuspended in a buffer containing 10 mM Tris-HCl, pH 7.5, and 75 mM NaCl at a 
total lipid concentration o f 25 mM. The lipid mixtures were maintained at 65°C and 
regularly vortexed. After 1 hour o f rehydration, the mixtures were alternately frozen in 
dry-ice and thawed five times by transferring to the heat block for 5 min each time.
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Unilamellar liposomes were then formed by multiple passages (> 30) through a Mini- 
Extruder (Avanti Polar Lipids) equipped with a 0.1 pm pore polycarbonate membrane 
(Whatman). Purified GST-Cys-PH domains (10 pM total protein) and full-length 
6xHis-tagged ARF guanine nucleotide exchange factors (5 pM total protein) were 
incubated with liposomes (2 mM total lipid) for 1 hour at room temperature in buffer 
containing 50 mM Tris-HCl, pH 8.3, 75 mM NaCl, ImM EDTA, 2 mM DTT in a total 
volume o f 100 pL. The liposomes were pelleted by ultracentrifugation at 25000 x g  
for 1 hour at 25°C. The amount o f  protein that remained in the supernatant was 
quantified using a dye-binding assay based on the method o f Bradford (Bio-Rad) and 
compared with that o f a control reaction that contained proteins without lipids.
2.2.12. Protein-lipid overlay assay
A protein-lipid overlay assay was performed using either full-length 
6xHis-tagged GEFs and their respective isolated GST-Cys-tagged PH domains. Lipid 
solution (1 pL) containing between 6.25 and 200 pmoles o f phosphoinositides 
dissolved in chloroform:methanol:water (1:2:0.8, v/v) was spotted onto Hybond-C 
extra-membranes and dried at room temperature for 1 hour. The membrane was 
blocked in 3% (w/v) fat-free BSA in TNE (50 mM Tris (pH 7.5), 150 mM NaCl, 
1 mM EDTA) that contained 0.1% Tween-20 at 4 °C overnight. Membranes were 
incubated at room temperature with the same solution containing 1 pg/mL o f the 
indicated GEF proteins for 1 hour, washed five times in TNE containing 0.1% (v/v) 
Tween-20, and then incubated for 1 hour with a mouse monoclonal anti-penta-his 
antibody used at 1:1000 (Qiagen) or with an anti-GST antibody (1:1000 dilution). 
After washing, the membranes were incubated with goat anti-mouse HRP-conjugated
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antiserum at 1:2500 (Pierce) or with HRP-conjugated goat anti-rabbit antibody 
(Boehringer Mannheim; 1:2500 dilution) for 1 hour at room temperature. The 
membranes were washed four times at room temperature in TNE containing 0.1% 
(v/v) Tween 20, once with Tris-buffered saline (20 mM Tris (pH 7.5), 150 mM NaCl), 
and signals were detected by enhanced chemiluminescence (NEN Life Science 
Products).
2.2.13. Expression of data
All results presented are from individual experiments repeated at least three times 
with similar results. Within each o f these individual experiments all individual 
measurements were made as duplicates or occasionally triplicates. Data and statistical 
analysis were performed by SigmaPlot 8.0 and Excel softwares. Data are shown as 
mean ± SEM unless otherwise stated. Statistical significance o f the values was 
evaluated by Student’s /-test. Oftentimes it is necessary to describe the significance o f 
statistical relationships between various different measurements within one 
experiment. Under these circumstances precise P values are described in the 
accompanying text while code letters indicate significance in the diagrams.
In Chapter 3, EC 5 0  and Vmax values in some experiments were determined by 
non-linear regression curve fitting o f concentration-response data fitted to the equation
L
f(x) = (m + M -m )/(l + (x/ECso) ), where m and M are the minimal and maximal 
responses, respectively, x is the ARF protein concentration, and h is the Hill slope 
(SigmaPlot 8.0).
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The analyses o f the amino acid sequences o f the proteins o f  interest described in 
this thesis were conducted as described in the legends o f the corresponding figures and 
tables.
Further analysis was performed to determine the extent o f sequence identity 
between representative members o f a particular protein.
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Chapter three
ARF isoform specificity of PLD studied in 
permeabilized HL-60 cells and a cell-free system
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3.1. Introduction
As indicated in Chapter one, six mammalian ARF family members have been 
identified and they have been classified into three categories based on their size and 
sequence similarity homology. ARF1, ARF2, and ARF3 form class I, ARF4 and 
ARF5 constitute class II, and ARF6 represents class III (Moss and Vaughan, 1995). 
Unlike other GTP-binding proteins, ARFs are myristoylated on an N-terminal glycine 
in a cotranslational event catalyzed by V-myristoyltransferase (NMT) (Kahn et al., 
1988). This lipid modification plays a critical part in ARF function including the 
activation o f  PLD. All classes o f ARFs have been shown to activate PLD. However, it 
remains a point o f contention as to whether there is any difference in their potency. 
Early studies showed little difference (Brown et al., 1995; Massenburg et al., 1994) 
but some later work showed significant difference (Jones et al., 1999; Sung et al., 
1999). In an attempt to redress the comparative lack o f side-by-side studies o f ARF 
isoforms in PLD activation, the principal aim o f this chapter is to decide if  ARF1 and 
ARF6 have distinct or similar effects on PLD activity. Using a bacterial expression 
system based on the yeast myristoyl-CoA: protein NMT coexpression system o f 
Duronio et al. (1990), recombinant fully and partially myristoylated ARF1 and ARF6, 
non-myristoylated ARF1 and ARF6 and deletion mutant human [A17]ARF1 were 
synthesized in E. coli, purified to homogeneity and characterised in order to give a set 
o f comparable reagents to investigate their specific role in the activation o f PLD. 
Well-established cell permeabifization and a new cell-free system were used to carry 
out these studies.
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3.2. Results
3.2.1. Purification o f  ARF proteins
ARF proteins purified from bacteria were subjected to two consecutive 
purification steps. ARF proteins obtained from cell lysis were first loaded on Ni-NTA 
column and eluted with a linear gradient o f imidazole (Figure 3.1). A single symmetric 
peak for each ARF isoform was obtained and the corresponding fractions under this 
peak were pooled and loaded on a phenyl Superose column in a second 
chromatographic step in which myristoylated ARFs were resolved from the 
underivitised forms by hydrophobic interaction chromatography. Example o f a 
chromatogram of phenyl Superose fractionation step in ARF1 purification is shown in 
Figure 3.2. The peaks o f myristoylated ARF1 and nonmyristoylated ARF1 are 
indicated.
The extent o f myristoylation o f the protein preparations was determined by 
reverse phase HPLC. The myristolated forms o f the proteins showed a characteristic 
increase in retention time confirming earlier HPLC analyses o f purified recombinant 
ARF proteins (Randazzo and Kahn, 1995). The profile o f myristoylated and non­
myristoylated ARF1 and ARF6 is shown in Figures 3.3 and 3.4.
SDS-PAGE analysis indicated a 21 kDa band corresponding to the expected 
molecular weight o f ARF1 (Figure 3.5, upper panel). In addition, Western blot 
analysis confirmed the identity o f the ARF protein as the antibody 1D9 reacted 
strongly with ARF1 (Figure 3.5, lower panel). O f note, the mobility o f myristoylated 
ARF1 on SDS-PAGE was greater than that o f  non- myristoylated ARF1. This result 
confirms an earlier observation by Franco et al. (1995).
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Figure 3.1. Elution o f ARF proteins from  Ni-NTA column. The supernatant obtained after cell lysis was applied to 
a 25 mL bed volume column o f Ni-NTA, which had previously been equilibrated in 100 mL o f Nickel column 
buffer (20 mM NaH2P 0 4, 20 mM Tris, 300 mM NaCl, 0.2% NaN3 (w/v), pH 6.0) followed by 100 mL o f the same 
buffer supplemented with 0.5 M imidazole and then followed by 50 mL o f a mixture (5:2 ratio) o f lysis buffers 1 
and 2 respectively (see Materials and Methods section for more details). Proteins were eluted with a linear gradient 
o f 0 to 0.5 M imidazole in the Nickel column buffer. Fractions o f 5 mL are collected. Protein elution was 
monitored by absorbance at 280 nm.
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Figure 3.2. Elution o f myristoylated ARF1 from phenyl-Superose. 
Fractions pooled from the Ni-NTA column were concentrated and 
made to 1 M with solid ammonium sulphate and applied to the 
phenyl-Superose column equilibrated with buffer containing 1 M 
ammonium sulphate. Proteins were eluted with a descending 
ammonium sulphate gradient and 8 mL fractions were collected. 
Protein elution was monitored by absorbance at 280 nm. The peaks 
o f nonmyristoylated (peak 1) nd myristoylated (peak 2) are 
indicated.
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Figure 3.3. Analysis by HPLC o f purified bovine ARF1. Bovine ARF1 was coexpressed with NMT and purified as 
described in Materials and Methods section. (A) The two peaks correspond to nonmyristoylated ARF1 (RT *  23 min) and 
myristoylated ARF1 (RT »  34 min). (B) The two peaks correspond to myristoylated ARF1 (RT »  28 min) and 100% 
myristoylated ARF1 (RT ~ 41 min). The two separate experiments illustrate two points. Firstly that the absolute retention 
times can vary from experiment to experiment. Secondly a sample o f  myristoylated ARF 1 without resolution on phenyl 
Superose shows two peaks o f protein in chromatogram (A) while the peaks can be seen to have been resolved in the two 
separate, but overlaid, chromatograms in (B).
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Figure 3.4. Analysis by HPLC o f  purified mouse ARF6. Mouse ARF6 was coexpressed with NMT and purified as described 
in Materials and Methods section. (A) The second peak corresponds to nonmyristoylated ARF6 (RT »  15 min). (B) The 
second peak corresponds to myristoylated ARF6 (RT « 26 min).
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Figure 3.5. SDS-PAGE and Western blot at alyses o f  purified 
.ny\ .s toy la ted ARF I. (Upper panel) SDS-PAGE analysis o f 
fractions o f myristoylated ARF1 following the hydrophobic 
interaction chromatographic step. The proteins were visualized 
with Coomassie blue dye. {Lower panel) Following transfer to 
nitrocellulose, blots were probed with an ARF-specific antibody 
(monoclonal antibody 1D9). Western blotting procedures are as 
described in Materials and Methods section.
3.2.2. ARF myristoylation enhances the activation o f  PLD in permeabilized HL-60 
cells
In the following experiments the fraction o f the total ARF1 protein derivatised 
with myristate was varied; either 0%, 35% or 100%. The percentage myristoylation o f 
ARF6  was either 0% or > 90%. The 35% partial myristoylation o f ARF1 is useful as 
this is the usual upper bound o f derivatisation that seems to be achieved in prokaryotic 
expression systems by other investigators, although on the whole the average is 
probably between 1 0  to 2 0 %.
Figures 3.6 and 3.7 show the comparison o f partially myristoylated ARF1 
(mARFl) and non-myristoylated ARF1 (ARF1) and partially myristoylated ARF6  
(mARF6 ) and non-myristoylated ARF6  (ARF6 ) in their respective activation o f PLD 
in permeabilized HL-60 cells. As illustrated in Figure 3.6, little PLD activity was 
generated by the 35% myristoylated ARF1 alone. However, the addition o f GTPyS 
greatly enhanced the 35%-myristoylated-ARFl-stimulated PLD activity. Its effect was 
concentration-dependent and was characterized by an EC 5 0  value o f 1.13 ± 0.54 pM 
and a predicted Vmax o f 2.71 ± 0.39% o f total choline-labelled lipids hydrolyzed (PLD 
activity). By contrast, the non-myristoylated ARF1 showed very little effect on PLD 
activity and the addition o f GTPyS barely improved its effect. An estimate o f the 
activated non-myristoylated ARF1 in terms o f potency was determined by noting that 
one has to titrate in about 30 times more o f the non-myristoylated ARF1 to equal the 
PLD response elicited by for instance 0.20 pM 35% myristoylated ARF1 as indicated 
in Figure 3.6.
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Figure 3.6. Effects o f  partially and
unmyristoylated ARF1 proteins on PLD activity in 
permeabilized HL-60 cells. After 10 min 
permeabilization with SLO (0.4 IU/mL) at 37°C, 
[3H]choline-labelled and cytosol-depleted HL-60 
cells were centrifuged and resuspended in buffer 
containing 3 mM MgATP and 3 mM Ca2+/EGTA 
(pCa5). The cells were then incubated for 2C min 
at 37°C with the indicated concentrations of 
recombinant partially and unmyristoylated ARF1 
proteins in the presence or absence of 10 pM 
GTPyS. Reactions were stopped by transferring 
cells to ice and by adding methanol/chloroform 
(1:1, v/v). Phases were partitioned by addition of 
water. Release of [3H]choline was measured as 
described in the Materials and Methods section. 
The result represent one experiment conducted in 
duplicate. Inset: the data of the concentration- 
response relation for 35% myristoylated ARF1 
plus GTPyS were fitted by nonlinear regression to 
a rectangular hyperbola with the use of SigmaPlot 
8.0 software. The degree of curve fitting was 
indicated by the coefficient of correlation (R), 
which has the highest value of 1, when 100% 
fitting would be established. The concentration 
that gives 50% of maximum PLD respDnse (EC5 0) 
to 35% myristoylated ARF1 plus GTPyS was 1.13 
± 0.54 pM and the Vmax was 2.71 ± 0.39 % total 
lipids hydrolyzed (PLD activity).
  mARFl (35% myr)
mARFl (35% myr) + GTPyS
 ARF1 (0% myr)
— ARF1 (0% myr) + GTPyS
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The requirement for myristoylation was also observed in experiments using the 
90% myristoylated ARF6 and non-myristoylated ARF6. The results shown in 
Figure 3.7 firstly show that both myristoylated ARF6 and non-myristoylated ARF6 
could activate PLD activity without the requirement for a guanine nucleotide in a 
concentration-dependent fashion. The myristoylated form displayed a significantly 
higher potency than its non-myristoylated counterpart at concentrations > 100 nM (P < 
0.05, n = 3) except at 0.9 pM ARF6 where the myristoylated and non-myristoylated 
proteins did not show any significant difference in activating PLD (P = 0.07, n = 3). 
The subsequent addition o f GTPyS to myristoylated ARF6 increased PLD activity. 
This increase in PLD response to myristoylated ARF6 plus GTPyS was significant at 
concentrations ranging from 0 to 0.3 pM myristoylated ARF6 (P < 0.05, n = 3). 
However, the observed enhancement o f PLD activity was mostly due to the presence 
o f GTPyS rather than the protein. Similar effects on PLD were observed for the non- 
myristoylated GTPyS-activated ARF6. Not too surprisingly, the myristoylated GTPyS- 
activated ARF6 was significantly more efficient in activating PLD than its non- 
myristoylated GTPyS-activated counterpart at concentrations between 0.03 pM and 
0.09 pM  ARF (P < 0.05, n = 3). At concentrations above 0.09 pM ARF6, no 
significant difference between the stimulatory effects on PLD activity elicited by the 
GTPyS-activated myristoylated and non-myristoylated ARF6 proteins was detected (P 
> 0.05, n = 3). In addition, the PLD response induced by the 90% myristoylated ARF6 
in the presence o f GTPyS reached a plateau at concentrations > 100 nM and 
significantly decreased at 10 pM myristoylated ARF6 when compared with the PLD 
response to 0.09 pM myristoylated ARF6 (P = 0.03, n = 3). This decrease in PLD
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Figure 3.7. Effects o f  partially and unmyristoylated ARF6 
proteins on PLt> activity in permeabilized HL-60 cells. After 
10 min permeabilization with streptolysin O (0.4 IU/mL) at 
37°C, [3H]choline-labelled and cytosol-depleted HL-60 cells 
were centrifuged and resuspended in buffer containing 3 mM 
MgATP and 3 mM  Ca2+/EGTA (pCa5). The cells were then 
incubated for 20 min at 37°C with the indicated 
concentrations o f recombinant partially and unmyristoylated 
ARF6 proteins in the presence or absence o f 10 pM GTPyS. 
Reactions were stopped by transferring cells to ice and by 
adding methanol/chloroform (1:1, v/v). Phases were 
partitioned by addition o f water. Release o f  [3H]choline was 
measured as described in the Materials and Methods section. 
Data shown are mean ± S.E.M. o f  duplicate samples from 3 
experiments. The significance o f data was evaluated using 
Student’s t.
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activity might be due to the activation o f inhibitory pathways by high concentrations 
o f myristoylated GTPyS-activated ARF6. Alternatively, direct inhibition o f  PLD 
activity may as well occur.
Taken together, the results described so far confirmed previous studies on the 
critical role o f myristoylation in the ARF-dependent PLD activity (Massenburg et al., 
1994; Brown et al., 1993).
3.2.3. Comparison o f  the stimulation o f  PLD activity by myristoylated ARF1 and 
ARF6 in permeabilised HL-60 cells and cell-free experiments
After examination of the literature on ARF1 and ARF6 effects on PLD activity, it 
emerges that this thesis is the first to present a direct comparison between the effects 
o f properly characterised, myristoylated ARF1 and ARF6 on PLD activity in both cell- 
based and cell-free systems.
In the permeabilized HL-60 cell model system, 35% myristoylated ARF1 and 
90% myristoylated ARF6, the highest percentage o f myristoylation available at the 
time o f the assays for each o f these proteins, were tested alongside each other. The 
results are illustrated in Figure 3.8. The activity o f PLD was equally stimulated by 
35% myristoylated ARF1 and 90% myristoylated ARF6 in a concentration-dependent 
way at concentrations ranging from 0 to 0.9 pM ARF proteins in the presence and in 
the absence o f GTPyS. However, both ARF isoforms strongly relied on the presence 
o f GTPyS for optimal PLD activation. The basal activity o f PLD was signficantly 
augmented by such concentrations o f 35% myristoylated ARF1 alone as 0.3 pM  (P = 
0.03, n = 4), 0.9 pM (P = 0.01, n = 4), 2.9 pM (P = 0.01, n = 4) and 9 pM (P = 0.002, 
n = 4). The addition o f GTPyS to 35% myristoylated ARF1 signficantly further
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Figure 3.8. Activation o f  PLD by myristoylated ARF1 and 
ARF6 in permeabilized HL-60 cells. After 10 min 
permeabilization with SLO (0.4 IU/mL) at 37°C, 
[3H]choline-labelled and cytosol-depleted HL-60 cells were 
centrifuged and resuspended in buffer containing 3 mM 
MgATP and 3 mM Ca2+/EGTA (pCa5). The cells were 
then incubated for 20 min at 37°C with increasing 
concentrations of recombinant ARF1 and ARF 6 in the 
presence or absence of 10 pM GTPyS. Reactions were 
stopped by transferring cells to ice and by adding 
methanol/chloroform (1:1, v/v). Phases were partitioned by 
addition o f water. Release of [3H]choline was measured as 
described in the Materials and Methods section Data shown 
are mean ± S.E.M. of duplicate samples from 4 
experiments. The significance of data was evaluated using 
Student’s t. Inset: the data of the concentration-response 
relation for 35% myristoylated ARF1 plus GTPyS were 
fitted by nonlinear regression to a rectangular hyperbola 
with the use of SigmaPlot 8.0 software. The degree of 
curve fitting was indicated by the coefficient of correlation 
(R), which has the highest value of 1, when 100% fitting 
would be established. The concentration that gives 50% of 
maximum PLD response (EC50) to 35% myristoylated 
ARF1 plus GTPyS was 1.56 ± 0.20 pM and the Vmax was 
1.27 ± 0.05% total lipids hydrolyzed (PLD activity).
112
potentiated its activation o f PLD over the whole range o f  selected concentrations (P < 
0.05, n = 4). Fitting a rectangular hyperbola concentration-response curve to the data 
obtained for 35% myristoylated ARF1 plus GTPyS gave an EC 5 0  value o f 1.56 ± 
0.20 pM and a Vmax value o f 1.27 ± 0.05% total choline lipids hydrolyzed (PLD 
activity). Similar to the effects o f 35% myristoylated ARF1 alone, the basal PLD 
activity was significantly increased by such concentrations o f 90% myristoylated 
ARF6  alone as 0.08 pM (P = 0.02, n = 4), 0.3 pM (P = 0.01, n = 4), 0.9 pM (P = 0.02, 
n = 4), 2.9 pM (P = 0.04, n = 4) and 9 pM (P = 0.02, n = 4). Although the activation o f 
PLD mediated by 35% myristoylated ARF1 seemed to be slightly better than 90% 
myristoylated ARF6  at 9 pM ARF proteins in the absence o f GTPyS, this difference 
was however not significant (P = 0.19, n = 4). Adding GTPyS to 90% myristoylated 
ARF6  significantly improved its stimulatory effects on PLD activity at concentrations 
ranging from 0 to 2.9 pM ARF proteins (P < 0.05, n = 4). However, as previously 
observed in Figure 3.7 this increase in PLD activity mediated by myristoylated ARF6  
was principally due to the effects o f GTPyS. Notably, 90% myristoylated ARF6  plus 
GTPyS apparently reduced PLD activity at 9 pM ARF protein but this decrease was 
not significant in comparison to the PLD response induced by 2.9 pM  90% 
myristoylated ARF6  plus GTPyS (P = 0.10, n = 4). Interestingly, this apparent 
inhibitory effect on PLD activity induced by high concentrations o f myristoylated 
GTPyS-activated ARF6  was previously observed in Figure 3.7.
Thus, the effects o f both myristoylated ARF1 and ARF6 on PLD activity in the 
presence o f  GTPyS were not significantly different at concentrations o f ARF up to 
2.9 pM (P > 0.05, n = 4). However, at the highest concentration o f ARF proteins used,
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that is 9 pM, myristoylated ARF1 was significantly and unequivocably more efficient 
in activating PLD than myristoylated ARF6 (P = 0.02, n = 4). In summary, at high 
concentrations 35% myristoylated ARF1 achieved a stronger activation o f PLD than 
90% derivitised ARF6 in the presence o f GTPyS. This prompts two plausible working 
hypotheses. Firstly, ARF1 at very high percentage myristoylation may prove to be an 
even stronger activator compared to ARF6 in HL-60 cells. Alternatively, higher 
myristoylation may reveal an inhibitory component to ARF1 action at high protein 
concentrations. These two hypotheses are tested below and the results reported later in 
this chapter.
In order to determine whether such an apparent discrepancy between ARF1 and 
ARF6 potency can also be seen in vitro, two fully myristoylated ARF1 and ARF6 
were employed to activate a recombinant human PLD lb  isoform expressed in sf9 
cells, partially purified and immobilised on beads. The use o f  PLD lb isoform in the 
cell-free system described in this thesis was prompted by in vitro studies which 
previously demonstrated that only PLD1 isoforms including PLD la  and PLD lb were 
ARF-dependent (Powner et al., 2002; Hodgkin et al., 1999; Hammond et al., 1997). 
Besides, PLD1 isoforms are thought to be the forms o f PLD activated by ARF1 in 
permeabilized HL-60 cells (Gibbs and Meier, 2000; Marcil et al., 1997; Ohguchi et 
al., 1997; Saqib and Wakelam, 1997). As illustrated in Figure 3.9, myristoylated 
ARF1 and ARF6 had no effect on recombinant PLD lb activity in the absence o f  
GTPyS. However, the addition o f GTPyS significantly enhanced the stimulatory 
effects on PLD lb exerted by myristoylated ARF1 and to some extent by ARF6 in 
comparison with the PLD basal activity (P < 0.05, n = 4). Similar to their effects in
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Figure 3.9. In vitro activation o f  recombinant human 
PLDlb by myristoylated ARF1 and ARF6. Sf9 cells were 
infected with recombinant baculovirus for the expression of 
hPLDlb which was recovered on glutathione sepharose 
beads. A sample of the hPLDlb on beads (20 pi) was 
incubated with the indicated proteins concentrations at 
37°C for 60 min in the presence of PC substrate (8.6 pM 
final concentration) and [3H]Choline-labelled PC (200000 
dpm per 10 pi substrate), with or without 10 pM GTPyS. 
Reactions were stopped by transferring cells to ice and by 
adding methanol/chloroform (1:1, v/v). Phases were 
partitioned by addition of water. Release of [3H]choline 
was measured as described in the Materials and Methods 
section. Data shown are mean ± S.E.M. of duplicate 
samples from 4 experiments. The significance of data was 
evaluated using Student’s t. Note: 100% PLD activation is 
equivalent to 4.45 ± 2 22% PC hydrolyzed. Inset: the data 
of the concentration-response relation for myristoylated 
ARF1 plus GTPyS were fitted by nonlinear regression to a 
rectangular hyperbola with the use o f SigmaPlot 8.0 
software. The degree of curve fitting was indicated by the 
coefficient of correlation (R), which has the highest value 
of 1, when 100% fitting would be established. The 
concentration that gives 50% of maximum PLD response 
(EC50) to myristoylated ARF1 plus GTPyS was 0.22 ± 
0.06 pM and the Vmax was 99.12 ± 5.01% PLD activation.
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permeabilized cells, both myristoylated, GTPyS-activated ARF1 and ARF6  did not 
show any significant difference in their ability to activate recombinant PLD lb at 
concentrations ranging from 0.02 pM to 0.6 pM ARF protein (P > 0.05, n = 4). The 
activation o f PLD lb by myristoylated, GTPyS-activated ARF1 was clearly 
concentration-dependent and was characterized by an EC5 0  o f 0.22 ± 0.06 pM and a 
Vmax o f 99.12 ±5 .01%  PLD activation. By contrast, and also similar to the effect o f 
myristoylated ARF6  already observed in the permeabilized cell system shown in 
Figure 3.8, the activation o f recombinant PLD lb by myristoylated ARF6  showed a 
biphasic trend since at concentrations above 1 pM ARF6  plus GTPyS became 
inhibitory. Indeed, 18.3 pM myristoylated, GTPyS-activated ARF6  significantly 
reduced the maximal PLD lb activation obtained at 0.6 pM by a factor o f two (P = 
0.04, n = 4).
Thus, the comparison between ARF1 and ARF6  in the two described model 
systems established parallels to some extent but above all clearly underlined critical 
differences between these two proteins in their regulation o f PLD activity.
3.2.4. Activation o f  PLD requires the N-terminus o f  ARF but the deletion o f  the amino- 
terminal 17 residues from ARF does not affect the ability o f  ARF to bind guanine 
nucleotides with high affinity
Comparison between the 35% myristoylated ARF1, and a mutant form o f ARF1, 
the [A17]ARF1, in which both the myristoylation site and an N-terminal a-helix with 
a key function are deleted by mutagenesis, is shown in Figure 3.10. [A17JARF1 
completely failed to activate PLD both at high concentration and in the presence o f 
GTPyS compared with 35% myristoylated ARF1. Clearly these results demonstrate
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Figure 3.10. Activation o f  PLD by myristoylated ARF1 but 
not by [A17JARF1 (ARF1 with amino acids 1-17 deleted) in 
permeabilized HL-60 cells. After 10 min permeabilization 
with SLO (0.4 IU/mL) at 37°C, [3H]choiine-labelled and 
cytosol-depleted HL-60 cells were centrifuged and 
resuspended in buffer containing 3 mM MgATP and 3 mM 
Ca2+/EGTA (pCa5). The cells were then incubated for 20 
min at 37°C with increasing concentrations o f recombinant 
ARF1 and [A17]ARF1 in the presence or absence o f 10 pM 
GTPyS. Reactions were stopped by transferring cells to ice 
and by adding methanol/chloroform (1:1, v/v). Phases were 
partitioned by addition of water. Release of [3H]choline was 
then measured as described in the Materials and Methods 
section Data shown are mean ± S.E.M. of duplicate samples 
from 4 experiments. The significance of data was evaluated 
using Student’s t. Inset: the data of the concentration- 
response relation for 35% myristoylated ARF1 plus GTPyS 
were fitted by nonlinear regression to a rectangular 
hyperbola with the use of SigmaPlot 8.0 software. The 
degree of curve fitting was indicated by the coefficient of 
correlation (R), which has the highest value of 1, when 
100% fitting would be established. The concentration that 
gives 50% of maximum PLD response (ECso) to 35% 
myristoylated ARF1 plus GTPyS was 1.56 ± 0.20 pM and 
the Vmax was 1.27 ± 0.05% total lipids hydrolyzed (PLD 
activity).
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that the activation o f PLD in permeabilised HL-60 cells absolutely requires the N- 
terminus o f ARF. This observation is in agreement with previous studies (Jones et al., 
1999; Zhang et al., 1995).
However, the deletion o f the N-terminus o f ARF1 did not abolish its ability to 
bind guanine nucleotide, the binding o f which is known to be catalysed by small GEFs 
such as ARNO, GRP-1 and cytohesin-1 (Jackson and Casanova, 2000). As shown in 
Figure 3.11, the deletion mutant was found to be capable o f spontaneously binding 
[ S]GTPyS. The spontaneous guanine nucleotide binding was significantly increased 
by ARNO (P = 0.02, n = 3), GRP-1 (P = 0.05, n = 3) and cytohesin-1 (P = 0.03, n = 3). 
These GEFs were equally efficient in increasing the binding o f [35S]GTPyS to 
[A17JARF1 as their exchange activities were not significantly different (P > 0.05, n = 
3). Indeed, the guanine nucleotide exchange on [A17]ARF1 mediated by ARNO was 
not significantly different from that mediated by GRP-1 (P = 0.10, n = 3) and 
cytohesin-1 (P = 0.75, n = 3). Similarly, there was no significant difference between 
the exchange activity displayed by GRP-1 and cytohesin-1 (P = 0.11, n = 3).
In summary, these results suggest that the failure o f [A17JARF1 to activate PLD 
is not due to an inability to bind GTPyS and subsequently undergo structural 
transitions in switch regions associated with this change.
3.2.5. .Increasing the extent o f  myristoylation on ARF1 significantly enhanced its 
stimulatory effects on PLD activity
Figure 3.12 presents the concentration-response curves for the myristoylated 
forms o f  ARF1 in the absence and in the presence o f GTPyS and their effects on PLD 
activity in permeabilized HL-60 cells. In the case o f 35% myristoylated ARF1, the use
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Figure 3.11. GTPyS binding to [A17JARF1 is increased by GEFs. 
Specific binding of [35S]GTPyS to [A17JARF1 (1 pM) was determined 
after 1 min incubation at 37°C in exchange buffer containing 50 mM 
Hepes, pH 7.5, 1 mM MgCk, 100 mM KC1, 1 mM DTT, 12 pM 
[35S]GTPyS and 1 mM phospholipid vesicles in 50 pi volume of reaction 
where the present GEFs were at a fine." concentration of 1 pM. Data are 
means ± S.E.M., n= 3 experiments. A s;'risks indicate significantly 
different from the control (P < 0.05).
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of the protein in the absence o f GTPyS significantly increased the basal PLD activity 
at such concentrations as 3 pM (P < 0.01, n = 4) and 9.5 pM  (P < 0.03, n = 4). 
Interestingly, increasing the degree o f myristoylation to 100% substantially increased 
the potency o f  the protein (left shift, Figure 3.12). This is indeed supported by the fact 
that as little as 300 nM 100% myristoylated ARF1 alone significantly enhanced the 
basal PLD activity (P < 0.01, n = 4). Moreover, PLD activity elicited by 100% 
myristoylated ARF1 alone was significantly higher than that produced by 35% 
myristoylated ARF1 alone at concentrations > 100 nM ARF (P < 0.05, n = 4). Kinetic 
parameters were obtained by fitting a rectangular hyperbola concentration-response 
curve to the data for the effects o f 100% myristoylated ARF1 in the absence o f  
GTPyS. As a result, an EC 5 0  value o f 0.42 ± 0.04 pM and a Vmax value o f 0.42 ± 
0 .0 1 % total choline lipids hydrolyzed confirmed the efficiency o f 1 0 0 % myristoylated 
ARF1 in stimulating PLD activity which was achieved in the absence o f GTPyS.
Interestingly, the addition o f GTPyS to both 35% and 100% myristoylated ARF1 
resulted again in the shift o f  the potency o f the proteins to the left but also increased 
the catalytic activity o f PLD to a greater extent. Parameters obtained by the fitting 
procedure for 100% myristoylated ARF1 (in the absence o f GTPyS: EC50 = 0.42 ± 
0.04 pM and Vmax = 0.42 ± 0.01% total choline lipids hydrolyzed; in the presence o f 
GTPyS: EC50 = 0.05 ± 0.01 pM and Vmax = 0.53 ± 0.02% total choline lipids 
hydrolyzed;) revealed the potentiating effect o f GTPyS. As seen, GTPyS decreased the 
EC50 by a factor o f 8  and increased the Vmax by a factor o f 1 . Strikingly, these data 
show that GTPyS increases the sensitivity o f PLD to ARF.
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Figure 3.12. Effects o f  fully and partially myristoylated ARF1 proteins on PLD activity in permeabilized HL-60 cells. PLD activity was 
determined under standard assay conditions as described in Materials and Methods section. Data shown are mean ± S.E.M. o f duplicate 
samples from 4 experiments. The significance of data was evaluated using Student’s t. Inset, right, the data of the concentration-response 
relation for the mentioned proteins were fitted by nonlinear regression to a rectangular hyperbola with the use o f SigmaPlot 8.0 software. 
The degree of curve fitting was indicated by the coefficient of correlation (R), which has the highest value of 1, when 100% fitting would 
be established. The E C 5 0  of 100% myristoylated ARF1,100%  myristoylated ARF1 plus GTPyS, and 3 5% myristoylated ARF1 plus GTPyS 
were 0.42 ± 0.04 pM, 0.05 ± 0.01 pM and 0.24 ± 0.04 pM, respectively. The corresponding Vmax values were 0.42 ± 0.01% total lipids 
hydrolyzed (PLD activity), 0.53 ± 0.02% total lipids hydrolyzed (PLD activity), and 0.53 ± 0.02% total lipids hydrolyzed (PLD activity), 
respectively.
More intriguingly still is the combined effects o f GTPyS and myristoylation. 
Indeed, the 100% myristoylated GTPyS-activated ARF1 was again a more potent 
activator o f PLD than its 35% myristoylated, GTPyS-activated counterpart. This is 
corroborated by the difference between the EC50 (0.05 pM) o f 100% myristoylated 
GTPyS-activated ARF1 and the EC50 (0.24 pM) o f 35% myristoylated GTPyS- 
activated ARF1. Thus increasing the percentage o f myristoylation on ARF decreased 
its EC50 by a factor o f 5. This result indicates an enhancement o f ARF potency as a 
result o f a better degree o f myristoylation and the complementary effect o f GTPyS. 
Interestingly, both 100% myristoylated GTPyS-activated ARF1 and 35% 
myristoylated GTPyS-activated ARF1 shared the same Vmax (0.53 ± 0.02% total lipids 
hydrolyzed). This result again clearly suggests that the maximal PLD activation 
strongly depends on the combined action of myristoylation and GTPyS. Therefore, a 
legitimate question arises about the extent of the role o f GTP and myristoylation in the 
ARF-mediated activation o f PLD.
Closer analysis o f the data shown in Figure 1.12 revealed that myristoylation in 
reality accounts for most o f the change in affinity o f ARF1 for PLD. Indeed, the 
average value found for the basal PLD activity was about 0.1% total choline lipids 
hydrolyzed. As already mentioned above, the Vmax value achievable with 100% 
myristoylated ARF1 in the absence and in the presence o f GTPyS were 0.42 ±0.01%  
and 0.53 ± 0.02% total choline lipids hydrolyzed, respectively. In view o f these 
results, it emerges that myristoylation contributes to 75% of the overall potency of 
ARF1 in PLD activation, while the apparent effect o f  GTPyS constitutes an additional 
25% o f the total PLD activation. This important observation prompts another critical
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question about the mechanism(s) by which GTPyS contributes to the optimal 
activation o f PLD by ARF1. It is possible that GTPyS effectively enhances the 
catalytic activity o f PLD by increasing the sensitivity o f ARF to PLD. For example, 
GTPyS may activate other G-proteins such the Rho family small GTP-binding proteins 
and the membrane-associated heterotrimeric G proteins. These GTPyS-activated 
G-proteins, or their downstream effectors, would thereby synergize with ARF to bring 
about a full, maximal activation o f PLD.
The observed increased activation o f PLD by a fully myristoylated ARF1 could 
be due to a better nucleotide exchange on ARF1. This aspect o f the ARF activity will 
be thoroughly considered in the next chapter.
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3.3. Discussion
The fully and partially myristoylated and non-myristoylated recombinant ARFs 
were assayed for reconstitution o f GTPyS-stimulated PLD activity in permeabilized 
HL-60 cells and in cell-free assays. The activation of PLD by ARF1 proteins in both 
model systems is concentration-dependent but also relies on the presence o f guanine 
nucleotides (GTPyS in this work) for a full and optimal activation o f  the enzyme. The 
myristoylated forms o f ARF proteins were found to be greatly more effective than its 
non-myristoylated counterpart in activating PLD confirming earlier findings (Tsai et 
al., 1998; Brown et al., 1995; Massenburg et al., 1994; Brown et al., 1993). The 
diminished potency o f the non-myristoylated ARF proteins may be attributed to a 
lower affinity for cellular proteins, possibly the PLD enzyme or decreased nucleotide 
exchange efficiency. Therefore, one unifying hypothesis is that the non-myristoylated 
ARF proteins display a reduced membrane association since both interaction with 
PLD and exchange factors require interaction with membranes. This is a conventional 
interpretation: myristoylation is thought to greatly enhance the membrane association 
o f the activated ARF since membrane targeting is conventionally thought to be a 
necessary step in the sequence o f events leading to a full and effective activation o f 
PLD and other ARF effectors such as vesicle coat proteins (Donaldson et al., 1992) 
and adaptors (Ooi et al., 1998; Stamnes and Rothman, 1993). The fact that ARF 
interacts with the vesicle coat proteins suggests that myristoylation must be involved 
in ARF-mediating events such as intra-Golgi (Palmer et al, 1993; Taylor et al., 1992) 
or endoplasmic reticulum to Golgi transport (Balch et al., 1992) and in endosome- 
endosome fusion (Lenhard et al., 1992).
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Interestingly, the data presented in this chapter highlight for the first time the 
crucial fact that fully myristoylated ARF proteins or high concentrations o f partially 
myristoylated ARF proteins can significantly achieve a potent activation o f PLD 
without the requirement for guanine nucleotide. This interesting finding allows 
interpretation and reconciliation o f  the observation made by Powner et a l  (2002). In a 
study investigating the in vivo regulation o f PLD lb  by Rho, ARF and PKC family 
proteins in antigen-stimulated RBL-2H3 cells, the authors demonstrated that these 
regulatory proteins bound directly and independently to PLD lb  by using surface 
plasmon resonance (SPR) techniques. These results were further strengthened by co­
localization studies that clearly showed that in antigen-stimulated RBL-2H3 
co-transfected with PLD lb  and its regulators, PLD lb  co-localized with R acl, ARF6 
and PK C a predominantly within actin-rich structures. Interestingly, they claimed that 
some o f  their unpublished data showed that the interaction between ARF proteins and 
PLD lb  was surprisingly independent o f the guanine nucleotide binding also detected 
by SPR. However, the same authors had previously found that in vitro activation o f 
PLD lb  was dependent on the guanine nucleotide binding (Hodgkin et al., 1999). PLD 
activation is the result o f a direct physical interaction between ARF and PLD as shown 
by in vitro PLD assay results described in this chapter and elsewhere (Powner et al., 
2002; Hammond et al., 1997). It is possible that the high concentrations o f ARF used 
in the broken HL-60 cells bring about sufficient transfer of protein to the intracellular 
membrane where PLD is localized and where the majority o f PLD activity has been 
detected (Hodgkin et al., 1999) purely by mass action. This would increase the 
probability o f  the two proteins colliding and provide a purely mass-action-based
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model o f  PLD activation. Therefore it is tempting to speculate that on the whole the 
activation o f PLD could be triggered by a collision-governed mechanism. This 
mechanism would be independent o f the presence o f guanine nucleotide and therefore 
independent o f the rearrangements o f ARF switch 1 and 2 regions induced upon 
nucleotide exchange. Since the highly concentrated ARF proteins are fully 
myristoylated, they could also bind the intracellular membrane via the myristoyl chain 
therefore susbtantiating the activation o f PLD through the collision mechanism.
However, the observed ARF-stimulated PLD activity in the absence o f  added 
exogenous GTPyS might also be attributed the endogenous pool o f GTP that would 
activate recombinant ARF. This ARF activation could be mediated by residual ARF- 
GEFs that did not leak out during the permeabilization process. Large ARF-GEFs 
might be involved in guanine nucleotide exchange since their relative big size (> 100 
kDa) might slow their exit from the permeabilized cells. Alternatively, an endogenous 
mechanism such as the NDPK might convert endognous GDP into GTP in the 
presence o f ATP.
More importantly still is the critical observation that myristoylation accounts for 
some 75% o f the whole stimulatory effects o f ARF on PLD activity. As a result, the 
remaining 25% of the total effects are attributed to the addition o f GTPyS. The 
guanine nucleotide binding brings about a rapid and full activation o f PLD by either 
increasing the sensitivity o f ARF to PLD or activating multiple cytosolic factors. It is 
possible that these factors interact with PLD and affect stimulation by ARF. For 
instance, the stimulatory effects o f the Rho family o f GTPases proteins have been 
reported by several groups (Powner et al., 2002; Hodgkin et al., 1999; Singer et ah ,
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1996; Singer et al., 1995). In particular, RhoA has been shown to synergize with ARF 
to stimulate PLD in HL-60 cell membranes (Siddiqi et al., 1995).
Conventionally GTP binding is thought to induce the translocation o f the ARF1 
protein to the membrane by stabilizing a very hydrophobic conformer with an 
exposed, myristoylated N-terminal a-helix and therefore enhance the efficiency o f 
PLD activation (Shome et al., 1997; Houle et al., 1995). Thus I propose that the main 
function o f GTP in PLD activation is in translocation o f ARF to membranes and the 
facilitation o f protein-protein interactions by collision alone, rather than the induction 
o f higher binding affinities between ARF and PLD.
The results described in this thesis also put emphasis on the presence o f the 
amino terminus o f ARFs. The N-terminus is critical for the interaction o f ARF with at 
least one downstream effector because a deletion o f this site rendered the protein 
unable to stimulate PLD, demonstrating that an essential interaction site on ARF, for 
subsequent activation o f PLD, is localized to the amino terminus. This is in accord 
with earlier observations (Jones et al., 1999; Zhang et al., 1995). However, the failure 
o f the recombinant deletion mutant [A17]ARF1 to activate PLD cannot be ascribed to 
failed GTPyS binding since guanine nucleotide binding assays revealed that the 
mutant retained this property to bind GTPyS with high affinity confirming similar 
observations by Jones et al. (1999) and Kahn et al. (1992). This spontaneous guanine 
nucleotide binding was significantly enhanced by specific GEFs such as ARNO, 
GRP-1 and cytohesin-1. Interestingly, the GEFs showed equal potency in catalyzing 
nucleotide exchange on [A17]ARF1. It is also true that the [A17]ARF1 interacts with 
Sec7 domain-containing ARF-GEFs present in the permeabilized cells. This result
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indicates that the amino terminal a-helix o f ARF1 is not essential in the interaction 
between the ARF and GEF proteins and therefore is not involved in the guanine 
nucleotide binding property o f ARF (this point will be developped in the following 
chapter). Overall, the amino terminus o f ARF is essential for ARF activity because it 
is an important component in coupling ARF to PLD in addition to any function 
mediated by switch regions in ARFs. Furthermore, the amino terminus also mediates 
the binding o f ARF to cellular membrane phospholipids (Antonny et al., 1997) and 
presumably inositol lipids through the presence o f hydrophobic residues and the 
myri state.
Finally, this chapter firmly establishes the direct comparison o f  the effects o f 
ARF1 and ARF6 on PLD activity in permeabilized HL-60 cells and in vitro assays. 
The data clearly reveal that HL-60 PLD1 and recombinant PLD lb  activities are 
equally regulated at low concentrations but differentially regulated at high ARF 
concentrations. This discrepancy was detectable at concentrations o f ARF higher than 
1 pM where ARF1 showed a significantly stronger PLD stimulation effect than ARF6 
in both assays. Furthermore, ARF6 significantly reduced the activity o f PLD at 9 pM 
in both model systems. Such a variance in PLD regulation by ARF1 and ARF6 is not 
attributed to a different degree o f myristoylation because the 100% myristoylated 
ARF1 was still a more efficacious PLD activator than nearly 100% myristoylated 
ARF6 in vitro. Besides, the fact that 35% myristoylated ARF1 induced a better PLD 
activity than 90% myristoylated ARF6 in HL-60 cells is a reasonable proof that ARF1 
is the preferred activator o f PLD under the experimental conditions described in this 
thesis. Since this observation was made with two distinctly different assay systems it
128
seems very likely indeed that ARF1 is also the preferred activator in vivo. These 
results seem to be in agreement to some extent with some studies (Jones et al., 1999; 
Sung et al., 1999) but also contrast with others (Brown et al., 1995; Massenburg et a l, 
1994). Indeed, Sung et al. showed that 1 pM myristoylated ARF1 was a significantly 
better activator o f PLD1 (derived from PLD 1-COS-7 transfected cells) than 1 pM 
myristoylated ARF6 in vitro. This observation agrees with the data o f this chapter on 
the differential activation o f PLD by ARF1 and ARF6 but this discrepancy was only 
detected at concentrations above 1 pM ARF proteins. Using non-myristoylated ARF 
proteins, Jones et al. (1999) demonstrated that ARF6 was a poor activator o f  the 
baculovirus-expressed recombinant hPLDl compared with ARF1. This difference in 
the stimulation o f PLD activity by ARF1 and ARF6 was detectable at 10 pM ARF but 
was also detectable at concentrations as high as 50 pM ARF. However, given the 
importance o f the role o f N-myristoylation in PLD activation it is not clear what value 
can be placed on this last set o f data. By contrast, Massenburg et al. 's  group showed 
that mammalian recombinant ARF1, ARF5 and ARF6 activated one o f the two PLD 
isoforms extractable from rat brain membranes (in a PIP2 -dependent manner) with 
little difference in their potency. The maximal concentration levels o f their ARF 
preparations were 3 pM for ARF1 and ARF5 and only 0.3 pM for ARF6. However, 
the authors did not show a direct comparison in their report. Brown et al. (1995) 
further suggested that the effect o f a myristoylated ARF6 on preparations o f PLD 
activity derived from HL-60 cells did not differ from that o f the myristoylated ARF1 
they had previously successfully characterized in an in vitro PLD assay (Brown et al., 
1993). The first obvious difference between the data reported in this thesis and those
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reported by Sung et a l  (1999), Brown et a l  (1995) and Massenburg et a l (1994) lies 
in the fact that the extent o f myristoylation o f the recombinant ARF proteins described 
in this thesis was accurately experimentally determined. In the previous studies the 
authors had not been able to discriminate the myristoylated and the non-myristoylated 
forms o f ARFs. Therefore they could not establish what fraction o f the ARF proteins 
used in their in vitro PLD assays were in fact myristoylated, or if  they were, then to 
what extent. However, the degree o f myristoylation o f ARF1 (and probably also 
ARF6) as demonstrated in this thesis does not seem to affect their observed distinct 
effects on PLD. Nevertheless, the use o f a fully myristoylated ARF protein gives a 
better assessment o f the potential difference in the ability o f the various ARF proteins 
to activate PLD in both permeabilized cells and in a cell-free system. Alternatively, 
one possible explanation for the apparent discrepancies between the data described in 
this chapter and those reported by other investigators might be the distinct sensitivity 
displayed by the PLD isoform (s) as a result o f different purification procedures. Sung 
et a l  (1999) transfected COS-7 cells with a PLD1 construct and subsequently lysed 
them for the assay o f  PLD activity in vitro. Brown et a l (1995) and Massenburg et a l 
(1994) extracted solubilized membrane PLD from porcine brain and rat brain 
respectively using differential centrifugation and detergents. In fact, Massenburg’s 
group separated two solubilized membrane PLD forms that were subsequently isolated 
by HPLC and the fractions assayed for PLD activity. One form exclusively relied on 
sodium oleate for activity and the other was dramatically activated by ARFs, GTPyS 
and PIP2 . Under these experimental conditions, the identity o f  ARF-dependent PLD 
was not clearly established. As a result, it is conceivable, though probably unlikely,
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that the ARF-dependent PLD activity detected could have been attributed to PLD2 
since PLD2 is also known to be responsive to class II ARFs (Kim et al., 2003) and 
also PIP2  (Colley et al., 1997). By contrast, the PLD lb  isoform characterized in this 
thesis was expressed in sf9 cells, purified and isolated in glutathione sepharose beads. 
This provided large amounts o f recombinant PLD lb  from an expression system 
capable o f performing many processing events such as postranslational modifications. 
The enzyme was shown to be fully functional since it was readily stimulated by ARFs 
and PIP2  and other PLD-activating proteins such as PK C a (data not shown).
On the whole, the data reported in this chapter make a strong case for ARF1 as 
the preferred activator o f PLD over ARF6 at high ARF concentrations. This view is 
readily supported by the same outcome obtained in two model systems. Importantly, it 
reconciles to some extent the apparent conflicting data published by Jones et al. 
(1999) and Sung et al. (1999) on one hand and those reported by Brown et al. (1995) 
and Massenburg et a l  (1994) on the other. This is because at low concentrations both 
ARFs are activators but at high concentrations a specificity emerges.
Several reasons may explain the fact that ARF1 is the preferred activator o f PLD 
over ARF6. Firstly, ARF1 and ARF6 have distinct subcellular distributions in many 
cell types. Indeed, ARF1 is thought to be predominantly cytosolic (Kahn et al., 1988) 
and associates with the Golgi (Palmer et al., 1993; Donaldson et al., 1992) upon GTP 
loading, whereas ARF6 is often localized to the plasma membrane (Caumont et al., 
1998; Cavenagh et al., 1996; Peters et al., 1995) and endosomes (Peters et al., 1995). 
Secondly, human ARF1 and human ARF6 are different in sequence, being only 66% 
identical at the amino acid level (Tsuchiya et al., 1991). The crystal structures o f
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ARF1 and ARF6 have been determined in several forms (Menetrey et al., 2001; 
Menetrey et al., 2000; Goldberg, 1998; Greaslet et al., 1995; Amor et al., 1994). 
Menetrey et al. (2000) showed that ARF1 and ARF6 have different conformations in 
their GDP-bound form. This finding indicates that these two proteins might have 
distinct guanine nucleotide binding properties. Interestingly, the data described in the 
next chapter showed that the rate o f binding o f guanine nucleotide catalysed by the 
small GEFs was higher on ARF1 than on ARF6 therefore suggesting a more specific 
molecular interaction between the ARF1 and the GEFs. As a result, this observation 
reinforces the view that PLD is preferentially regulated by ARF1 and this regulation is 
function o f its guanine nucleotide binding activity mediated by the small GEFs. This 
point will be considered in more details in the next chapter.
Taken together, the data described in this chapter clearly highlight myristoylation 
as a critical feature in the activation o f  PLD, one of the several ARF functions. 
Therefore optimal data in biochemical assays using recombinant ARF proteins are 
highly dependent on the generation o f fully-myristoylated ARF proteins and failure to 
achieve this may devalue the relevance o f any data obtained. The N-terminus o f ARF 
is an essential interacting site for PLD. Finally, the comparison o f the effects o f ARF1 
and ARF6 on PLD activity strongly points to a role for ARF1 and not ARF6 as the 
factor that regulates PLD1 in permeabilized cell and cell-free model systems and 
therefore probably also in vivo. However, this apparent discrepancy between ARF1 
and ARF6 in the regulation PLD activity in intact cells has not been established yet.
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Chapter four
Specificity of small ARF-GEFs for both ARFs and
polyphosphoinositides
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4.1. In troduction
Stimulation by agonists, hormones, growth factors and neurotransmitters 
promotes the activation o f one or more regulators o f PLD in most cell types (Carpio 
and Dziak, 1998; Shome et al., 1997; Garcia et al., 1992; Billah et al., 1989; 
Liscovitch et al., 1989). In the case o f the ARF family proteins, activation results from 
the exchange o f GDP for GTP on ARFs. This exchange reaction can occur 
spontaneously but it is greatly accelerated specific GEFs. The small GEFs involved in 
the regulation o f the ARF proteins include all ARNO/GRP- 1/cytohesin-l members 
(Donaldson and Jackson, 2000; Jackson and Casanova, 2000). These GEFs possess a 
specific phosphoinositide-binding site commonly known as the pleckstrin homology 
(PH) domain. Therefore, these low molecular weight GEFs were shown to be 
specifically regulated by polyphosphoinositides (Klarlund et al., 2000; Klarlund et al., 
1998; Klarlund et al., 1997; Chardin et al., 1996), some of which are involved in the 
regulation o f PLD (Hammond et al., 1997; Brown et al., 1993).
This chapter will focus on the role o f GEFs in activating ARF proteins and their 
specific interactions with polyphosphoinositides. These polyphosphoinositides were 
previously shown to be implicated in an array o f cellular functions by coordinating the 
transient recruitment o f their target proteins to the site o f activation o f downstream 
specific effector proteins.
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4.2. Results
4.2.1. Purification o f  small ARF-GEFs proteins
Procedure for the purification o f the small ARF-GEFs, ARNO, GRP-1 and 
cytohesin-1 is described in the Materials and Methods section. His-tagged ARNO, 
GRP-1 and cytohesin-1 proteins obtained after cell lysis were subjected to 
chromatography on Ni-NTA column and subsequently eluted with a linear gradient o f 
0 to 0.5 M imidazole. Samples o f proteins in the collected active fractions were 
separated by SDS-PAGE and subsequently stained with Coomassie blue (Figure 4.1). 
Bands were detected around 47 kDa.
4.2.2. Novel guanine nucleotide binding assay
During the course o f my investigation into the regulation o f ARF activity by the 
small ARF-GEFs, I have developed a novel guanine nucleotide binding assay. This 
assay readily demonstrates the stimulation o f [35S]GTPyS binding to ARF proteins, the 
exchange reaction can occur either spontaneously or greatly accelerated in the 
presence o f the GEFs (see below). Because the nucleotide exchange assay is based on 
the binding o f His-tagged proteins to Ni-NTA agarose beads, it is necessary to 
estimate the quantity o f ARF proteins that is recovered on beads following a period o f 
exposure to the beads. Figure 4.2. shows that an average of 20 to 25% o f ARF proteins 
were recovered on beads under the experimental conditions described in this thesis. 
This estimate allows calculation o f the fraction o f ARF protein present that undergoes 
exchange.
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ARNO
Cytohesin-1
47 kDa
Figure 4.1. Purification o f small ARF-GEF proteins. The 
supe natant obtained after cell lysis was applied to a 25 mL 
bed volume column o f Ni-NTA, which had previously been 
equilibrated in 100 mL o f Nickel column buffer (20 mM 
NaH2P 0 4, 20 mM Tris, 300 mM NaCl, 0.2% NaN3 (w/v), pH 
6.0) followed by 100 mL o f the same buffer supplemented 
with 0.5 M imidazole and then followed by 50 mL o f a 
mixture (5:2 ratio) o f lysis buffers 1 and 2 respectively (see 
Materials and Methods section for more details). Proteins were 
eluted with a linear gradient o f 0 to 0.5 M imidazole in the 
Nickel column buffer. Fractions o f 5 mL were collected. 
Protein elution was monitored by absorbance at 280 nm. 
Samples o f the corresponding eluted fractions were analyzed 
by SDS-PAGE and Coomassie blue staining.
ARF1
100 |ig/mL 0 5 10 15 20 25
21 kDa
% recovery 0 1.8 15.1 15.9 23.6 19.4
Figure 4.2. Recovery o f  myristoylated ARF1 
on Ni-NTA beads. Different concentrations 
o f myristoylated ARF1 were exposed to 25% 
slurry beads for 30 min. ARF1 proteins were 
eluted off the beads with imidazole and 
analyzed by SDS-PAGE (upper panel) and 
Western blot (lower panel) as described in 
Materials and Methods section. 1 pM ARF in 
a GTPyS binding experiment represents 
approximately 21 pg/mL.
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4.2.3. Myristoylation is necessary but not essential in enhancing the guanine 
nucleotide exchange on ARF proteins
ARNO, GRP-1 and cytohesin-1 were first examined for their guanine nucleotide 
exchange activity on [A17]ARF1 (ARF1 with the N-terminal 17 amino acid residues 
deleted), 35% myristoylated ARF1 and 90% myristoylated ARF6. The in vitro assay 
to monitor the exchange activity o f the GEFs on ARFs is based on the binding o f 
radio-labeled guanine nucleotides in the presence o f artificial lipid vesicles 
supplemented with PIP2  in near physiological conditions o f salt and pH. The lipid 
vesicles were included in these assays because previously ARF and GEF proteins have 
been shown to interact with membrane lipids through their myristoylated N-terminus 
and the PH domain respectively (Beraud-Dufour et al., 1999; Antonny et al., 1997). 
PIP2  was also added to the phospholipid vesicles as this phosphoinositide was reported 
to enhance the nucleotide exchange activity o f the GE|:s (Paris et al., 1997; Chardin et 
al., 1996). The three recombinant ARFs were tested simultaneously as shown in 
Figure 4.3. For both ARF1 and ARF6 there was a spontaneous GTPyS binding but the 
extent was much greater for 90% myristoylated ARF6 than for 35% myristoylated 
ARF1 (P = 0.02, n = 3). However, the rate o f spontaneous binding to ARF1 was 
apparently increased by the deletion o f the N-terminal <x-helix ([A17JARF1) although 
this increase was not significant (P = 0.07, n = 3). The rate o f guanine nucleotide 
exchange on [A17JARF1, 35% myristoylated ARF1 and 90% myristoylated ARF6 
was then significantly augmented in the presence o f all three GEFs tested (P < 0.05, n 
= 3). Indeed, the GEFs effectively enhanced the spontaneous loading o f  GTPyS 3 to 4 
times on [A17JARF1, 8 times on 35% myristoylated ARF1 and 3 times on 90%
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Figure 4.3. GEF specificity binding o f ARNO, GRP-1 and cytohesin-1 fo r  ARF 
proteins. Specific binding of [35S]GTPyS to [A17]ARF1 (1 pM), 35% 
myristoylated mARFl (1 pM) and 90% myristoylated mARF6 (1 pM) was 
determined after 1 min incubation at 37°C in exchange buffer containing 
50 mM Hepes, pH 7.5, 1 mM MgCl2, 100 mM KC1, 1 mM DTT, 12 pM 
[35S]GTPyS and 1 mM phospholipid vesicles in 50 pi volume of reaction 
where the present GEFs were at a final concentration of 1 pM. Data are means 
± S.E.M., n= 3 experiments. Asterisks indicate significantly different from the 
control (P < 0.05).
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myristoylated ARF6. These results suggest that the GEFs seem to be relatively more 
active on ARF1 than on ARF6 and [A17]ARF1.
The effect o f increasing the extent o f myristoylation was investigated next. The 
guanine nucleotide exchange reaction catalysed by all three tested members o f the 
family o f ARNO-like proteins was effective on myristoylated and non-myristoylated 
forms o f ARF1 and ARF6 in the presence of phospholipid vesicles supplemented with 
2% PIP2 . As illustrated in Figure 4.4(A), the binding o f [35S]GTPyS to 35% 
myristoylated ARF1 and its non-myristoylated counterpart was equally and 
significantly increased by the GEFs (P < 0.05, n = 3) except for cytohesin-1 whose 
apparent exchange activity on the non-myristoylated ARF1 was not significantly 
different from the spontaneous binding o f  [35S]GTPyS to non-myristoylated ARF1 (P 
= 0.17, n = 3). The guanine nucleotide exchange catalyzed by ARNO and GRP-1 on 
35% myristoylated ARF1 was signicantly greater than on the non-myristoylated ARF1 
(P = 0.02, n = 3). However, the guanine nucleotide exchange mediated by cytohesin-1 
was not significantly different on these two forms o f ARF (P = 0.27, n = 3). In 
addition, the comparison of the 100% and 35% myristoylated ARF1 proteins further 
demonstrated that increasing the percentage o f myristoylation on ARF protein also 
significantly enhanced the nucleotide exchange rate on ARF (P < 0.05, n = 3). Indeed, 
Figure 4.4(B) showed that the exchange reaction on the 100% myristoylated ARF1 
was 4 to 6 times greater than on the 35% myristoylated ARF1 (P < 0.05, n = 3). 
Likewise, the exchange reaction on the 90% myristoylated ARF6 was about two-fold 
more effective than on the non-myristoylated ARF6 (Figure 4.4(C) ). In addition, 
ARF1 and ARF6 were comparable in their ability to support guanine nucleotide
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Figure 4.4. GTPy. binding to recom inant ARF 
proteins cataly ed by GEFs is increased by 
myristoylation. Specific binding of [35S]GTPyS to 
ARF proteins (1 pM) was determined after 5-10 min 
incubation at 37°C in exchange buffer containing 
50 mM Hepes, pH 7.5, 1 mM MgCh, 100 mM KC1, 
1 mM DTT, 12 nM [35S]GTPyS and 1 mM 
phospholipid vesicles spplemented with 2% PIP2 in 
50 pi volume of reaction where the present GEFs were 
at a final concentration of 1 pM. Data are means ± 
S.E.M., n= 3 experiments. Data are means ± S.E.M., 
n= 3 experiments. Asterisks indicate significantly 
different from the control (P < 0.05).
exchange activity. Although 90% myristoylated ARF6  was used at the time o f the 
experiments, it is safe to assume that a further 1 0 % increase in myristoylation would 
render 100% myristoylated ARF6  as efficient as..100% myristoylated ARF1 in its 
ability to bind [3 5 S]GTP-yS.
All the tested small ARF-GEFs were efficient in catalysing the guanine 
nucleotide exchange reaction on the studied ARF proteins although cytohesin-1 
seemed to catalyse a weaker nucleotide exchange on the 35% myristoylated ARF1. 
However, this observation was not always consistent as preliminary data showed that 
other preparations o f  cytohesin-1 were as efficient as ARNO and GRP-1 in their 
capacity to stimulate the nucleotide exchange on ARF1 and ARF6 .
4.2.4. The isolated PH domains and fu ll length ARF-GEFs interact specifically with 
polyphosphoinositides
The binding o f the studied small ARF-GEFs to polyphosphoinositides were 
independently and quantitatively demonstrated by using a liposome-binding assay. In 
this assay, the recombinant ARNO, GRP-1 and cytohesin-1 proteins were separately 
mixed with large unilamellar liposomes produced by the extrusion technique. The 
liposomes contain the indicated phosphoinositides and the GEFs were shown to bind 
following ultracentrifugation o f the protein-lipid mixtures. As shown in Figure 4.5, 
each o f  the PH domains bound specifically to PI(3 ,4 )P2 , PI(4 ,5 )P2 , and PIP3 . The PH 
domains o f ARNO and GRP-1 showed between 25% and 45% binding to these 
particular phosphoinositides, whereas about 45% o f the PH domain o f cytohesin-1 
bound to the mentioned phosphoinositide-containing vesicles at a total lipid 
concentration o f  2 mM, corresponding to 60 pM phosphoinositides. The extent o f
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Figure 4.5. Phosp'oinositide binding specificity o f  the GFFs 
PH domains. Binding of the isolated PH domains of ARNO 
(panel A), GRP-1 (panel B ) and cytohesin-1 (panel C) to 
liposomes made of neutral phospholipids PC and PS (4:1 
mol; / ratio) supplemented with 3% of total lipids of various 
phosphoinositides as indicated. The exposure of the PH 
domains of the GEFs to the liposomes were performed at 
room temperature for 1 hour. The liposomes were pelleted 
by ultracentrifugation at 25,000 x g  for 1 hour at 25°C. The 
amount of protein that remained in the supernatant was 
quantified using a dye-binding assay based on the method of 
Bradford and compared with that of a control reaction that 
contained proteins without lipids. Error bars represent the 
standard error of the mean (SEM) for three independent 
experiments (n = 3). The significance of data was evaluated 
using Student’s t test.
binding o f the PH domains o f ARNO and cytohesin-1 to PI(3 ,4 )P2 , PI(4 ,5 )P2 , and PIP3 
was not significantly different from each other (P > 0.05, n = 3). The PH domain o f 
GRP-1 preferentially bound PI(3 ,4 )P2  over PI(4 ,5 )P2  (P = 0.04, n = 3) but its binding 
affinity towards PIP3 was not significantly different from that shown towards 
PI(3 ,4 )P2  (P = 0.10, n = 3) (Figure 4.5 (B)). Very weak binding was observed with the 
other phosphoinositides namely PI(3)P, PI(4)P arid PI(5)P. Interestingly, the isolated 
PH domains also bound PI(3 ,5 )P2 . The binding affinity towards this phosphoinositide 
was about two to three times smaller than that observed for PI(3 ,4 )P2 , PI(4 ,5 )P2 , and 
PIP3 . The PH domains o f GRP-1 and cytohesin-1 especially showed a significantly 
stronger binding towards PI(3 ,5 )P2  than that o f ARNO (P < 0.05, n = 3) (Figure 4.5 
(A), (B) and (C)).
Likewise, the full-length small ARF-GEFs also displayed a strong binding 
affinity for PI(3 ,4 )P2 , PI(4 ,5 )P2 , and PIP3 . As illustrated in Figure 4.6, the full-length 
ARNO and cytohesin-1 showed similar binding potency towards PI(3 ,4 )P2 , PI(4 ,5 )P2 , 
and PIP3 whereas the full-length GRP-1 bound signficantly better to PI(3 ,4 )P2  than to 
PI(4 ,5 )P2  (P = 0.01, n = 3). Very little or no binding was observed when the full-length 
GEFs were incubated with PI(3)P, PI(4)P and PI(5)P although ARNO showed a 
significantly higher percentage binding to these phosphoinositides than GRP-1 and 
cytohesin-1 (P > 0.05, n = 3). Most interestingly, the observed binding o f the GRP-1 
and cytohesin-1 PH domains to PI(3 ,5 )P2  was completely abolished by using 
full-length GEF proteins. The percentage o f  proteins bound to PI(3 ,5 )P2  decreased 20- 
fold and 5-fold when the full-length GRP-1 and cytohesin-1 were respectively exposed
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Figure 4.6. Phosphcmositide binding specificity o f  the 
full-length GEFs. Binding of the full length ARNO (panel 
A, GRP-1 (panel B), and cytohesin-1 (panel C) to 
liposomes made of neutral phospholipids PC and PS (4:1 
molar ratio) supplemented with 3% of total lipids of 
various phosphoinositides as indicated. The exposure of 
the GEFs to the liposomes were performed at room 
temperature for 1 hour. The liposomes were pelleted by 
ultracentrifugation at 25,000 x g  for 1 hour at 25°C. The 
amount of protein that remained in the supernatant was 
quantified using a dye-binding assay based on the method 
of Bradford and compared with that of a control reaction 
that contained proteins without lipids. Error bars represent 
the standard error of the mean (SEM) for three 
independent experiments (n = 4). The significance o f data 
was evaluated using Student’s / test.
to liposomes containing PI(3,5)P2. By contrast, the full-length ARNO showed the 
same binding affinity for PI(3,5)P2 as its isolated PH domain.
The high affinity specific binding o f the PH domains and full-length ARNO, 
GRP-1 and cytohesin-1 for PI(3 ,4 )P2 , PI(4 ,5 )P2 , and PIP3 observed in the liposome 
binding assay were further qualitatively confirmed by similar results obtained using 
the protein-lipid overlay or dot-blot assay. As shown in Figures 4.7, 4.8 and 4.9, the 
PH domains and full-length GEFs displayed a clear specificity for PI(3 ,4 )P2 , PI(4 ,5 )P2  
and PIP3 as shown by high-intensity binding signals. However, the binding o f the full- 
length ARNO and the cytohesin-1 PH domain to PIP3 was not clearly detected 
(Figures 4.7 and 4.9). This observation along with the fact that neither the isolated PH 
domains nor the full-length GEFs showed binding specificity towards PI(3 ,5 )P2  in this 
type o f assay indicate a possible removal o f the phosphoinositides applied to the 
Hybond-C extra-membranes during the blocking and the washing steps. Alternatively, 
the binding interactions on vesicle surfaces may be different from those with 
polyphosphoinositides dispersed on nitrocellulose.
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Figure 4.7. Phosphoinositides-binding properties 
o f the full-length ARNO and its isolated PH 
domain. The ability o f the full-length 6xHis-tagged 
ARNO and its GST-Cys-tagged PH domain to bind 
a variety of phosphoinositides was analysed using a 
protein-lipid-binding assay. Serial dilutions of 
indicated phosphoinositides (200, 100, 50, 25,12.5 
and 6.25 pmol) were spotted on to Hybond-C extra­
membranes, which were then incubated with the 
purified recombinant ^xHis-tagged or Cys-tagged 
proteins. The membranes were washed, and the 
6xHis-tagged and Cys-tagged proteins bound to the 
membranes were detected using and anti-His or 
anti-GST antibody.
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Figure 4.8. Phosphoinositides-binding properties 
o f the full-length GRP-1 and its isolated PH 
domain. The ability of the full-length 6xHis-tagged 
GRP-1 and its GST-C's-tagged PH domain to bind 
a variety of phosphoinositides was analysed using a 
protein-lipid-binding assay. Serial dilutions of 
indicated phosphoinositides (200, 100, 50, 25, 12.5 
and 6.25 pmol) were spotted on to Hybond-C extra­
membranes, which were then incubated with the 
purified recombinant oxHis-tagged or Cys-tagged 
proteins. The membranes were washed, and the 
6xHis-tagged and Cys-tag0ed proteins bound to the 
membranes were detected u£;ng and anti-His or 
anti-GST antibody.
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Figure 4.9. Phosphoinositides-binding properties 
o f  the full-length cytohesin-1 and its isolated PH 
domain. The abil ity of the full-length 6xHis-tagged 
cytohesin-1 and its cytohesin-1-Cys-tagged PH 
domain to bind a variety of phosphoinositides was 
analysed using a protein-lipid-binding assay. Serial 
dilutions of indicated phosphoinositides (200, 100, 
50, 25, 12.5 and 6.25 pmol) T ,ere spotted on to 
Hybond-C extra-membranes, which were then 
incubated with the purified recombinant 6xHis- 
tagged or Cys-tagged proteins. The membranes 
were washed, and the 6xHis-tagged and Cys-tagged 
proteins bound to the membranes were detected 
using and anti-His or anti-GST antibody.
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4.3. Discussion
This chapter concentrates on the molecular basis o f the regulation o f  ARF 
proteins by the family o f small ARF-GEFs and polyphosphoinositides. All three 
members o f the small GEFs family i.e. ARNO, GRP-1 and cytohesin-1 described in 
this thesis stimulated with the same degree o f efficiency the guanine nucleotide 
exchange on the different forms o f ARF1 and ARF6 proteins.
The data showing that the deletion o f N  terminal o f ARF1 where myristate is 
post-transtionally added did not affect the rate o f GTP exchange either arising 
spontaneously or accelerated by the GEFs confirms previous observations (Pacheco- 
Rodriguez et al., 1998; Paris et al., 1997). These results indicate that the N-terminus- 
truncated mutant o f  ARF1 can still interact with the GEFs despite the fact that 
[A17JARF1 cannot bind to phospholipid vesicles on which the physical interaction 
between the ARF and GEF proteins are thought to occur (Jackson and Casanova, 
2000). This interaction with the GEFs does not involve the N-terminal o f the ARF 
protein. This observation was confirmed by structural studies in which a model o f the 
interaction between ARF 1-GDP and the Sec7 domain o f ARNO was proposed 
(Beraud-Dufour et al., 1998). According to this model, the N-terminal helix o f  ARF1 
did not physically interact with the ARNO-Sec7. The N-terminal helix o f ARF1 had in 
fact been shown to be buried in a pocket at the surface o f ARF1. Based on their own 
studies and those o f others (Betz et al., 1998; Cherfils et al., 1998; Goldberg, 1998; 
Mossessova et al., 1998), Beraud-Dufour et al. (1998) proposed a model for the 
mechanism o f the guanine nucleotide exchange catalyzed by ARNO-Sec-7 on 
[A17]ARF1. The GDP/GTP exchange is dependent on the interaction o f the switch
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regions o f ARF and the catalytic Sec7 domain o f the GEFs. A conserved glutamate 
residue (E l56) in the ARNO-Sec7 domain, located in a hydrophobic groove is 
strongly involved in the exchange mechanism because a mutation o f  glutamate to 
lysine (E —> K) or to aspartate (E —» D) resulted in a dramatic decrease in the 
exchange activity o f ARNO-Sec7 on ARF1 (Cherfils et al., 1998). This glutamate 
residue contributes to the release o f  the GDP by interacting with the Mg bound to 
ARF through the negatively charged carboxylate group o f  the glutamate side-chain. 
This interaction would result in the destabilization o f the Mg coordination with the 
(3-phosphate o f GDP leading to the removal o f the Mg2+. The spontaneous dissociation 
o f the nucleotide would then be brought about by electrostatic repulsion. Thus this 
model could be generalized to the other two ARF-GEFs, namely GRP-1 and 
cytohesin-1 since the glutamate and surrounding residues are conserved in all three 
proteins.
In vitro experiments comparing non-myristoylated, partially and fully 
myristoylated forms o f ARF proteins clearly demonstrated that myristoylation 
significantly increases nucleotide exchange efficiency on ARF proteins catalysed by 
the GEFs. However, this is achieved only when the ARF-GEF interactions occur in the 
presence o f phospholipid vesicles supplemented with PIP2 . This is in agreement with 
previous reports (Paris et al., 1997; Chardin et al., 1996). In the normal, physiological, 
cellular context, the fully-myristoylated form o f ARF is the only form o f the proteins 
found. Upon activation o f ARF by the GEFs, it is generally thought that the previously 
buried N-terminal a-helix o f ARF becomes exposed to the solvent. The subsequent 
binding o f ARF to the cellular membrane promoted by this increased surface
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hydrophobicity, due to the presence o f the myristoyl group, confers a high affinity for 
the lipid membrane. This initial binding would be further strengthened by the 
interaction o f the hydrophobic residues o f  the N terminal helix o f ARF-GTP with the 
lipid bilayer (Antonny et al., 1997).
The data presented in this thesis showed that ARNO, GRP-1 and cytohesin-1 
were all equally efficient in stimulating the nucleotide exchange on both ARF1 and 
ARF6 in vitro. ARNO was originally recognized as a GEF for ARF1 in vitro and was 
thought to be the principal GEF for ARF1 (Chardin et al., 1996). Subsequent in vitro 
nucleotide binding studies based on radio-labeled nucleotides and highly 
myristoylated ARF forms (= 80% myristoylated) also favoured ARNO as a GEF for 
ARF1 over ARF6 (Franco et al., 1998). These results support those reported by Macia 
et al. (2001) and Beraud-Dufour and Robineau (2001) who used a real-time assay to 
monitor the exchange activity on the myristoylated ARF1 and ARF6 proteins. This 
assay is based on the difference between the tryptophan fluroscence o f ARF-GDP and 
of ARF-GTP. Using this assay Macia et al. (2001) demonstrated that the nucleotide 
exchange catalysed by ARNO was 5 times greater on myristoylated ARF1 than 
myristoylated ARF6. By contrast, Frank et al. (1998) showed that ARNO was a better 
GEF for ARF6 than for ARF1 using a classical [35S]GTPyS exchange assay. This 
apparent discrepancy is most likely due to the fact that the ARF forms used in the in 
vitro assays differ in the degree o f myristoylation. Frank et al. (1998) used 20% 
myristoylated ARF1 and 50% myristoylated ARF6 whereas Franco et al. (1998) 
employed at least 80% myristoylated ARF1 and ARF6. The extent o f myristoylation 
o f the ARFs was not determined in the studies reported by Macia et al. (2001). Frank
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et al. (1998) further demonstrated that ARNO and ARF6 co-localized to the plasma 
membrane o f transfected cells. This observation was interpreted as evidence 
supporting a role for ARNO as a GEF for ARF6 rather than ARF1 in cells. Several 
other groups showed that ARNO can be expressed either at the Golgi (Lee et al., 2000; 
Monier et al., 1998) in which case ARNO would preferentially activate ARF1, or at 
the plasma membrane (Caumont et al., 2000; Venkateswarlu et al., 1998) or 
endosomal membranes (Maranda et al., 2001) where ARNO would probably associate 
with ARF6 since this isoform is thought to be enriched in this region (Cavenagh et al., 
1996, Peters et al., 1995). The detection o f in vivo nucleotide exchange on ARF6 
catalysed by ARNO (Santy et al., 2001) further corroborates the argument that ARNO 
is a suitable candidate in ARF6 activation in cells. Overall, the localisation o f ARNO 
and its substrate specificities depend on experimental conditions and the type o f  cells 
under investigation. There seems to be a consensus that in the absence o f the GEFs the 
in vitro spontaneous nucleotide exchange on ARF6 is faster than on ARF1 (Macia et 
al., 2001). This finding might indicate that a larger fraction o f ARF6 is spontaneously 
bound to membranes in vivo compared to ARF1.
In vitro studies demonstrated that GRP-1 is the principal GEF for ARF1 (Franco 
et al., 1998; Klarlund et al., 1998). The authors o f these studies showed that GRP-1 
could also function as a GEF for ARF5 to a lesser extent but failed to activate ARF6. 
Furthermore, Franco et al. (1998) overexpressed GRP-1 in mammalian cells. As a 
result, a disruption o f  the Golgi function was observed. This finding prompted these 
authors to propose that ARF1 is the major substrate for GRP-1 in vivo. However, in 
contrast to this view, Langille et al. (1999) showed that GRP-1 could activate ARF6
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using a similar in vitro nucleotide binding assay to that employed by Franco et al. 
(1998). In addition to the cell-free system, Langille et al. (1999) also used intact cells 
to demonstrate that GRP-1 could stimulate the nucleotide loading on both ARF1 and 
ARF6 in these cells. Because the co-localization of GRP-1 with ARF6 at the plasma 
membrane o f transfected cells was observed, the authors o f this report suggested a 
physiological role for GRP-1 in regulating ARF6 functions in cells.
Among the ARFs so far tested in vitro, cytohesin-1 was shown to activate ARF1 
(Ogasawara et al., 2000; Franco et al., 1998; Pacheco-Rodriguez et al., 1998; Meacci 
et al., 1997), ARF3 (Meacci et al., 1997), but had no effect on ARF6 (Pacheco- 
Rodriguez et al., 1998). The results described in this thesis clearly contradict these 
previous observations and show that cytohesin-1 can function as a GEF for ARF6 in 
vitro. This particular difference might be ascribed to the low degree o f myristoylation 
o f the ARF6 protein used in Pacheco-Rodriguez’s studies. However, cytohesin-1 has 
been shown to translocate to the plasma membrane following stimulation o f  PI 3- 
kinase in transfected cells (Venkateswarlu et al., 1999). Therefore, cytohesin-1 might 
very well interact with ARF6 in vivo using the same criteria o f inference as Langille et 
al. (1999).
Overall, the data presented in this thesis combined with past and recent reports 
reveal that ARNO, GRP-1 and cytohesin-1 can display activity for ARFs from all 
three classes in both in vitro and in vivo experiments. However, differences in in vitro 
assay conditions, such as Mg2+ concentration, the type o f assays used to monitor the 
nucleotide exchange, the methods used to produce lipid vesicles with or without the 
incorporated phosphoinositides, the degree o f myristoylation o f the purified ARFs, the
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types o f  cells used for in vivo experiments can account for the difficulty in identifying 
a precise physiological substrate for each o f the characterized GEFs.
The ARNO/GRP-1/cytohesin-1 family possess a C-terminal PH domain which is 
a common feature o f the GEFs. Therefore these GEFs are potential candidates for 
specific interaction with phosphoinositides which were widely shown to be implicated 
in the regulation o f PH-domain containing proteins (Jackson et al., 2000; 
Venkateswarlu et al., 1999; Klarlund et al., 1998; Venkateswarlu et al., 1998). The 
results presented in this thesis quantitatively and qualitatively demonstrate that both 
the full-length and the isolated PH domains o f the GEFs bind with equally high 
affinity and specificity to PI(3 ,4 )P2 , PI(4 ,5 )P2 , and PIP3 . However, these data seem to 
contradict previous reports showing for instance that the GRP-1 PH domain binds PIP3 
with high degrees o f affinity and selectivity over PI(3 ,4 )P2  and PI(4 ,5 )P2  in in vitro 
binding assays (Klarlund et al., 2001; Klarlund et al., 2000; Kavran et al., 1998; 
Klarlund et al., 1998; Klarlund et al., 1997) and structural studies (Ferguson et al., 
2000; Lietzke et al., 2000). Indeed, the soluble PIP3 head group, In s(l,3 ,4 ,5 )P4  
(Kavran et al., 1998) or soluble Cg PIP3 (Klarlund et al., 2001; Klarlund et al., 2000; 
Klarlund et al., 1998) were shown to bind with higher specificity to GRP-1 PH 
domain than to ARNO and cytohesin-1 PH domains in phosphoinositide binding and 
competition assays. Furthermore, Klarlund et al. (1998) had previously tested 
PI(3 ,4 )P2 , PI(4 ,5 )P2 , and PIP3 for their effects in stimulating GRP-1-mediated 
exchange activity o f ARF1. The selectivity o f PIP3 in enhancing ARF1 nucleotide 
exchange by GRP-1 over that observed for PI(3 ,4 )P2  or PI(4 ,5 )P2  had been detected at 
lower charge density in their phospholipid micelle-based assay. In addition, the same
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authors had shown that the PHVrnediated ARF1 nucleotide exchange through GRP-1 
was specifically inhibited by Ins(l,3 ,4 ,5 )P4  while the other polar head groups tested, 
including Ins(l,3 ,4 )P3 , Ins(l,4 ,5 )P3 , Ins(l,3 ,4 ,6 )P4  and Ins(l,2 ’,5 ,6 )P4  did not block the 
stimulation o f ARF1 exchange activity by GRP-1. A closer examination o f the amino 
acid sequence comparison o f the PH domain o f ARNO, GRP-1 and cytohesin-1 show 
that the three PH domains used in the experiments described in this thesis and those 
reported by Klarlund et a/.(2000) are almost identical (Figure 4.10). Indeed, the 
sequence alignment reveals that the GRP-1 PH domain possesses a diglycine m otif 
which differs from ARNO and cytohesin-1 PH domains which harbour a triglycine 
motif. As a consequence, Klarlund et al. (2000) suggested that the unusual diglycine 
m otif in the GRP-1 PH domain, as opposed to the triglycine in ARNO and cytohesin-1 
provides a possible explanation for the highly PIP3 binding selectivity displayed by 
GRP-1 PH domain. A point mutation in which an additional glycine was added to the 
GG m otif o f the GRP-1 PH domain greatly increased its binding affinity for PI(4 ,5 )P2  
compared with the native protein while it decreased its binding affinity for PIP3 . 
Conversely, a mutant ARNO PH domain in which a single glycine was deleted in the 
GGG m otif led to a reduced binding affinity for PIP2  but not for PIP3 . Therefore 
Klarlund et al. (2000) concluded that the binding selectivity o f GRP-1 PH domain 
towards PIP3 may be attributed to the unique presence o f the diglycine m otif as 
opposed to the triglycine in ARNO and cytohesin-1 PH domain.
The results presented in this thesis and those reported by other investigators are 
indeed contradictory. Different experimental conditions and different models used to 
investigate the binding properties o f the studied GEFs might provide an explanation
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cytohesin-1 1 MAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPE
ARNO 1 MAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPE
GRP-1 1 MAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPE
cytohesin-1 61 MLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDWLYMDPMCLDAFPKLVCFKKRIEAIPQ
ARNO 61 MLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDWLYMDPMCLDAFPKLVCFKKRIEAIPQ
GRP-1 61 MLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDWLYMDPMCLDAFPKLVCFKKRIEAIPQ
cytohesin-1 121 IDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSAEAAAREACCRECCAREAAARA 
ARNO 121 IDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSAEAAAREACCRECCAREAAARA
GRP-1 121 IDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSAEAAAREACCRECCAREAAARA
cytohes in-1 181 NSYESIKNEPFKIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYF
ARNO 181 NSYESIKNEPFKIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYF
GRP-1 181 NSYESIKNEPFKlPEDDGNDLTHTFFNPDREGWLLKLGG-RVKTWKRRWFILTDNCL^YF
cytohesin-1 241 EYTTDKEPRGIIPLENLSIREVEDSKKPNCFELYIPDNKDQVIKACKTEADGRWEGNHT
ARNO 241 EYTTDKEPRGIIPLENLSIREVEDSKKPNCFELYIPDNKDQVIKACKTEADGRWEGNHT
GRP-1 240 EYTTDKEPRGIIPLI i-JLSIREVEDPRKPNCFELYNPSHKGQVIKACKTEADGRWEGNHV
cytohesin-1 301 VYRISAPTPEEKEEWIKCIKAAIS RDPFYEMLAARKK KVS ST KRHZ —
ARNO 301 VYRI SAPTPEEKEEWIKCI KAAI SRDPFYEMLAARKK KVSSTKRHZ—
GRP-1 300 VYRISAPSPEEKEEWMKSIKASISRDPFYDMLATRKQGLPIKNRSTRAAASZ
Figure 4.10. Comparison o f  the sequences corresponding to the PH domains o f  cytohesin-1, 
ARNO and GRP-1. Comparison o f the sequences o f the PH domains correspond to residues 208 
to 324 o f the full-length ARF-GEFs. Small portions o f sequence corresponding to GST, from the 
PH-domain C-terminal fusion protein constructs prepared for experiments described in this 
thesis, are also included in the alignment, exactly as they were detected during sequencing. 
Diglycine (GG) and triglycine (GGG) motifs are visible between positions 218 and 220 as shown 
by asterisks. Alignment was generated by ClustalW and the printing o f the multiple alignment 
output was performed by Boxshade.
for this apparent discrepancy. The lipid binding assay described by Klarlund et al. 
(2000) was based on the use o f GST/PH domain fusion proteins bound to glutathione 
immobilized on agarose beads to which were added labeled or unlabeled 
phosphoinositides with eight carbon atoms in the fatty acyl chains. In contrast, the 
lipid-binding assay described in this thesis is based on the production o f large 
unilamellar liposomes as the “support” for the various phosphoinositides. These 
phosphoinositides carry fourteen carbon atoms in their hydrophobic chains. As a result 
the lipids used in my investigations were dispersed in a model membrane rather than 
as non-physiological monomers in bulk aqueous solvent. Notably, other investigators 
have examined di-glycine PH domain binding to large vesicles and found that any 
observed specificity for PIP3 over PIP2 was at most 3 to 4 fold enhanced rather than 
the 650-fold shown by Klarlund et al. (2000). Additionally, these investigations 
indicated the sensitivity o f binding to pH and salt concentration.
Whether the demonstrated differential polyphosphoinositide specificity is 
delivered exclusively by the PH domain, as Klarlund et al. (2000) suggest, remains to 
be firmly established. However, the data reported in this thesis clearly show that the 
full-length GEFs usually displayed the same binding characteristics as their respective 
isolated PH domains which exhibit very high sequence similarity. Therefore the 
distinct polyphosphoinositide binding selectivity reported for GRP-1 might not be 
located wholly in the PH domain. Despite these differences observed for the binding 
properties o f the GEFs for the major phosphoinositides, the general consensus is that 
the studied GEF PH domains can bind with high affinity to P(3,4)P2, PI(4,5)P2, PIP3 
and to a lesser extent PI(3,5)P2. Because some o f these phosphoinositides are
158
generated through the action o f a family o f PI 3-kinases (Rameh and Cantley, 1999; 
Toker and Cantley, 1997), it is therefore plausible to suggest a role for PI 3-kinases 
enzymes in the regulation o f the mechanisms o f recruitment and subsequent activation 
o f ARF proteins leading ultimately to the stimulation o f PLD activity (Rizzo and 
Romero, 2002). The activation o f isoforms o f type I PI 3-kinases such as p85cx/p- 
p l 1 Ocx/p/S and p i 10y type PI 3 kinases leads to rapid phosphorylation o f the inositol 
D-3 positions on PI, PI(4)P, and PI(4,5)P2 (Zvelebil et al., 1996). Receptor stimulation 
by insulin or growth factors that link to the PI 3-kinase pathway was shown to induce 
the recruitment o f the GRP-1 (Klarlund et al., 2000), ARNO (Venkateswarlu et al., 
1998) and cytohesin-1 (Venkateswarlu et al., 1999) to the plasma membrane. The 
observed PH domain-dependent translocation o f these GEFs to the plasma membrane 
was inhibited by chemically unrelated PI 3-kinase inhibitors wortmannin (Okada et 
al., 1994) and LY294002 (Vlahos et al., 1994).
Taken together, the data presented in this thesis and those mentioned above still 
support a participation o f the PI 3-kinase pathway in the activation o f PLD following 
the sequential recruitment and physical interaction o f the GEFs and ARFs on 
intracellular membranes. However, the ability o f newly generated 3-phosphorylated 
lipids to recruit these GEFs in the standing presence o f vastly greater amounts o f  the 
equally well-bound PI(4,5)P2 (from now on referred as PIP2 ) remains to be explained.
Interestingly, recent findings have complicated the common model mentioned 
above that GEFs translocate as a result o f binding to phosphoinositides generated by 
agonists binding to plasma membrane. Indeed, the GEFs have been shown to interact 
with partner proteins that modulate its localization and potentially their functions. For
159
instance, it has been demonstrated that GRP-1 could bind in particular to two novel 
proteins termed GRSP1 (GRP-1 signaling pamer 1) (Klarlund et al., 2001a) and 
GRASP also known as tamalin (Kitano et al., 2002; Nevrivy et al., 2000) in vitro. The 
interaction o f GRP-1 with these two proteins is mediated by its the N-terminal coiled- 
coil domain. In addition, GRP-1 was shown to interact with GRSP1 and GRASP in 
co-transfected mammalian COS-1 and HEK293 cells, respectively. In particular, these 
two interacting proteins co-localize with GRP-1 at the plasma membrane o f 
transfected cells. Interestingly, co-localization o f ARFs and GRASP was also 
observed at the plasma membrane o f transfected cells. This particular observation 
indicates a possible role o f GRASP in ARF signaling. In addition to GRP-1, ARNO 
and cytohesin-1 can also interact and co-localize with binding partners. Indeed, like 
GRP-1, ARNO strongly interacts with GRASP in vitro while cytohesin-1 has been 
shown to bind M uncl3-1, a presynaptic protein that is translocated to diacylglycerol- 
containing membranes in presynaptic active zones (Neeb et al., 1999). In the light o f 
these new findings, Klarlund et al. (2001) and Nevrivy et al. (2000) suggested that 
GRSP1 and GRASP function as adaptor proteins that selectively target the GEFs to 
discrete plasma membrane domains in response to stimulation by agonists. However, 
it is still unclear whether these novel interacting proteins further enhance the specific 
recruitment o f the GEFs to membranes mediated by phosphoinositides or act 
independently in response to the stimulation o f other signaling pathways.
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Chapter five
Efficient coupling of GEFs-ARFs-PLDl in 
permeabilized HL-60 cells is not preserved in vitro: 
role of guanine nucleotides (GDP, GTP) and 
polyphosphoinositides (PIP2, PIP3)
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5.1. Introduction
As discussed in Chapter 3, ARF1 turns out to be the preferred activator o f PLD 
over ARF6  both in permeabilized HL-60 cells and in a cell-free system. In vitro assays 
demonstrated that the efficient activation o f ARFs was enhanced by the presence o f 
the small ARF-GEFs as demonstrated in Chapter 4. These exchange factors effectively 
catalyzed the exchange o f GDP for GTP on ARFs with similar potency. In the two 
preceding chapters the interaction o f these two complexes (GEF + ARF, ARF + PLD) 
were studied independently, an approach similar to that taken by many other 
investigators. However, physiologically these two “half-reactions” may in reality form 
part o f a common pathway leading to the effective stimulation o f PLD activity in cells. 
Polyphosphoinositides are critical signalling molecules in the PLD pathway in that 
besides supporting basal PLD activity one o f their proposed functions is to recruit the 
PH domain-containing GEFs to membranes where they would in turn recruit ARFs.
The purpose o f the experiments described in this chapter is to attempt to 
conciliate these two “half-reactions” into one ternary complex both in permeabilized 
HL-60 cells and in cell-free assays and verify whether the tested GEFs display any 
specificity in activating PLD through ARF1 in these two systems. The role o f PIP2  and 
PIP3 was also assessed for their effects on the coupling between GEFs, ARFs and 
PLD.
To the best o f my knowledge, the properties o f the combined ternary complex 
• comprising GEF, ARF and PLD has never been examined in either permeabilized 
HL-60 cells or cell-free systems.
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5.2. Results
5.2.1. Stimulation o f  PLD activity by ARF1 is increased in the presence o f  the GEFs in 
permeabilized HL-60 cells but the same GEFs do not augment ARF-stimulated PLD 
activity in cell-free systems
The relative PLD activation efficiency of the GEFs was compared using two 
related experimental conditions. Concentrations o f the GEFs were normalized to each 
other using firstly the same absolute protein concentration (Figure 5.1/1) and secondly 
the same in vitro ARF1 guanine nucleotide exchange activity i.e. the same specific 
activity (Figure 5.1U). As shown in Figure 5A , the fully myristoylated ARF1 had very 
little effect on PLD activation at concentrations < 100 nM in the presence o f  1 mM 
GTP. The use o f GTP in these reconstitution assays is clearly a more physiologically 
relevant situation than one using GTPyS. This is because a single G-protein targeted 
by the GEFs plus GTP allows a more specific investigation o f PLD activation without 
the indescriminate co-activation o f other G-proteins that will occur with GTPyS 
present. The choice o f 1 mM GTP is based on the fact that this concentration is 
thought to be in the upper-end o f the range o f estimated levels o f GTP in cells. Thus 
the basal activation o f PLD was observed at 300 nM ARF1 and was slightly increased 
at 1 pM ARF1 stimulated by 1 mM GTP. The stimulation o f PLD by 300 nM ARF1 
was then significantly enhanced by ARNO (P = 0.04, n = 5), GRP-1 (P = 0.004, n = 5) 
and cytohesin-1 (P = 0.004, n = 5). The highest PLD activity was obtained at 1 pM 
ARF1 and in turn this was further improved by GRP-1 (P = 0.003, n = 5) and ARNO 
(P = 0.02, n = 5). Intriguingly, cytohesin-1 caused a slight inhibition o f PLD activity at 
1 pM ARF1 since the effects o f cytohesin-1 on PLD activity was not significantly
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Figure 5.1. Effects o f GEFs on the activation o f PLD by 
myristoylated ARF1 in permeabilized HL-60 cells. After 10 min 
permeabilization with SLO (0.4 IU/mL) at 37°C, [3H]choline- 
labelled and cytosol-depleted HL-60 cells were centrifuged and 
resuspended in buffer containing 3 mM MgATP and 3 mM 
Ca2+/EGTA (pCa5). The cells were then incubated for 20 min at 
37°C with increasing concentrations of myristoylated 
recombinant ARF1 in the presence 1 mM GTP. (A) GRP-1, 
ARNO and cytohesin-1 normalised to the same concentration 
and (B ) or to the same exchange activity were added to the 
reaction mixture. The assay was then performed as described in 
the Materials and Methods section. Data shown are mean ± 
S.E.M. of duplicate samples from 5 experiments. The 
significance of data was evaluated using Student t test.
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different from that o f GTP alone (P = 0.60, n = 5). However, there was no significant 
difference between the effect o f cytohesin-1 on PLD activity obtained at 300 nM 
ARF1 and that obtained at 1 pM ARF1 (P = 0.40, n = 5). Interestingly, GRP-1 (P = 
0.03, n = 5) and ARNO (P = 0.04, n = 5) exerted a significantly stronger effect on 
PLD activity than cytohesin-1 when 1 pM ARF1 was used in conjunction with GTP.
My earlier data showed that the small ARF-GEFs did not have the same degree 
o f efficiency in their ability to exchange GDP for GTP on ARF1 when assayed in in 
vitro, liposome-based nucleotide exchange assays. Indeed, my earlier data showed that 
ARNO was the most potent exchange factor on ARF1, followed by GRP-1 and then 
cytohesin-1. However, this order o f potency varied from batch to batch o f the different 
GEFs and it was not systematically observed. Sometimes GRP-1 and cytohesin-1 were 
also found to be equally efficient in their exchange activity on ARF1 or in some cases 
GRP-1 turned out to be the most efficient GEF. Therefore, in order to take account o f 
this variability, the amount o f each GEF used in the experiments was normalised to in 
vitro exchange activity (Figure 5.12?). Under these specified experimental conditions, 
the activation o f PLD detected at 300 nM ARF1 was again significantly improved by 
GRP-1 (P = 0.008, n = 5), ARNO (P = 0.02, n = 5) and cytohesin-1 (P = 0.01, n = 5). 
Again, the strongest PLD activity was observed at 1 pM ARF1 and further enhanced 
by ARNO (P = 0.02, n = 5) and GRP-1 (P = 0.03, n = 5). Again, cytohesin-1 
apparently became slightly inhibitory at 1 pM ARF1 although this effect was not 
significantly different from that obtained at 300 nM  ARF1 (P = 0.64, n = 5). In 
addition, the GEFs displayed no significant difference in their ability to enhance the 
ARF-mediated PLD activation when 1 pM ARF1 was used (P > 0.05, n = 5).
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Under both experimental conditions, all three recombinant GEFs significantly 
improved the stimulation o f PLD activity by ARF1 over the whole range o f ARF1 
concentrations. However, the GEFs did not show any statistically significant 
difference in potency between each other over the whole range o f ARF1 
concentrations (P > 0.05, n = 5). Unexpectedly, cytohesin-1 seemed to show an 
inhibitory effect at high ARF1 concentrations regardless o f whether the GEF 
concentration was normalised to protein mass or exchange activity and the effect o f 
cytohesin-1 on PLD activation reached a plateau at 1 pM ARF1. Whether this 
apparent but not conclusive inhibitory effect o f cytohesin-1 on PLD activity is 
physiologically relevant is not clear.
In contrast to the results obtained in the reconstitution system using 
permeabilized HL-60 cells, the studied GEFs did not substantiate the stimulatory 
effects induced by either ARF1 or ARF6 on PLD activity in a cell-free system (Figure 
5.2). The data shown in this figure clearly confirmed again what was already described 
in Chapter 3, that ARF1 is a stronger activator o f PLD than ARF6 in vitro. 
Furthermore, increasing the concentration o f GTP did not improve the activation o f 
PLD by ARF1 in the presence o f  GEF, cytohesin-1 is given as an example in 
Figure 5.3.
The observation that ARNO, GRP-1 and cytohesin-1 failed to enhance the 
activation o f PLD by ARFs in vitro could be explained by the fact that the GEF might 
have difficulty interacting with ARF and PLD under the specified experimental 
conditions. In particular, the purified GST-hPLDlb was recovered on glutathione 
sepharose beads. The activity o f the immobilised enzyme was then assayed in these
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Figure 5.2. Effects o f  GEFs on in vitro PLD activation mediated by myristoylated ARF 1 and ARF6 . Sf9 cells were infected with 
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hPLDlb on beads (20 pi) was incubated with a fixed concentration of mARFl (500 nM) or 238 nM mARF6  used with 1 mM GTP, 
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Figure 5.3. In vitro PLD activation mediated by myristoylated ARF1: effects o f  cytohesin-1 and various 
concentrations o f  GTP. Sf9 cells were infected with recombinant baculovirus for the expression of hPLD lb which 
was recovered on glutathione sepharose beads. A sample of the hPLDlb on beads (20 pi) was incubated with a 
fixed concentration of 500 nM mARFl at 37°C for 60 min in the presence of PC substrate (8 . 6  pM final 
concentration) and [3H]Choline-labelled PC ( 2 0 0 0 0 0  dpm per 10 pi substrate). GTP was added to the reaction 
mixtures at the indicated concentrations and along with 10 pM cytohesin-1. Reactions were stopped by transferring 
cells to ice and by adding methanol/chloroform (1:1, v/v). Phases were partitioned by addition of water. Release of 
[3H]choline was measured as described in the Materials and Methods section. Data shown are mean ± S.E.M. of 
duplicate samples from 3 experiments. The significance of data was evaluated using Student’s t test.
experiments. This procedure might conceivably hinder the access o f ARF and 
cytohesin-1 to PLD. To test this hypothesis, reduced glutathione was included in the 
assay in order to release PLD in the presence o f ARF1 and cytohesin-1. As shown in 
Figure 5.4, treatment o f PLD beads with 2.5 mM GSH improved the activation o f 
PLD by ARF1 plus GTP. The PLD activity was significantly higher after treatment 
with 2.5 mM GSH compared to 10 mM GSH (P = 0.02, n = 3) or to the control (P = 
0.03, n = 3). However, cytohesin-1 did not potentiate the stimulatory effect on PLD 
activity induced by ARF1 plus GTP, even though the treatment o f PLD beads with 
2.5 mM GSH prior to PLD activation did significantly increase PLD activity. This 
effect o f 2.5 mM GSH in improving PLD activity was again significantly stronger 
than that obtained with 10 mM GSH (P = 0.02, n = 3) or the control (P = 0.02, n = 3). 
Thus the results illustrated in Figure 5.3 clearly indicate that the failure o f  cytohesin-1 
to enhance PLD activity stimulated by ARF 1 cannot be attributed to the fact that the 
use o f glutathione sepharose beads to recover and then present PLD might have 
impeded the access o f the regulatory proteins to PLD.
5.2.2. Negative effects o f  GTP on the stimulation o f  PLD activity through the ARF- 
GEF pathway
The effects o f increasing concentrations o f GTP were examined in permeabilized 
HL-60 cells. As shown in Figure 5.5, cytohesin-1 alone had no effect on PLD activity 
over the whole range o f GTP concentrations. Interestingly, and not too surprisingly, 
given results described in Chapter 3, ARF1 alone could induce an activation o f PLD in 
the absence o f GTP. This increase in PLD activity was significant (P =0.007, n = 4) 
compared to the control. The most intriguing observation was the ability o f
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Figure 5.4. Effects o f  pretreatment o f  PLDlb on glutathione sepharose 
beads with GSH. The activity of recombinant PLD lb purified from sf9 
insect cells transfected with the hPLDlb baculovirus was determined 
either in the absence of GSH or in the presence o f 2.5 mM GSH and 
lO m M  GSH. Prior to incubation of PLD lb with recombinant ARF1 
(500 nM) and/or cytohesin-1 (10 pM), in the presence of GTP (1 mM), a 
sample o f the purified PLD lb recovered on glutathione sepharose beads 
was treated with the indicated concentrations of GSH for 30 min at 4°C. 
Pretreated PLD lb was then incubated with substrate prepared from PE, 
PIP2 and PC (C10) in the molar ratio 1 0 : 0.3: 1 . The final PC concentration 
was 8 . 6  pM. [3H]Choline-labelled didecanoyl PC was added to give 
approximately 200, 000 d.p.m. per 10 pL substrate. The reaction mixtures 
were transferred to a 37°C water bath and incubated for 1 hour. Release of 
[3H]Choline was measured as described in the Materials and Methods 
section. Data shown are mean ± S.E.M. of duplicate samples from 3 
experiments.
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Figure 5.5. Negative effects o f GTP on the activation o f PLD by fully 
myristoylated ARF1 and cytohesin-1 in permeabilized HL-60 cells. After 
10 min permeabilization with SLO (0.4 IU/mL) at 37°C, [3H]choline- 
labelled and cytosol-depleted HL-60 cells were centrifuged and 
resuspended in buffer containing 3 mM MgATP and 3 mM Ca +/EGTA 
(pCa5). The cells were then incubated for 20 min at 37°C with increasing 
concentrations of GTP (lithium salt) in the presence or absence of the 
indicated concentrations of myristoylated ARF1 and cytohesin-1. The 
assay was then terminated as described in the Materials and Methods 
section. Data shown are mean ± S.E.M. of duplicate samples from 4 
experiments.
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cytohesin-1 to significantly enhance ARF 1-mediated PLD activation without the 
requirement for exogenous GTP. Indeed, PLD was activated by the combined action 
o f ARF1 and cytohesin-1 in the absence o f any added GTP leading to 0.36% o f total 
lipids being hydrolyzed. This effect was significantly higher (P = 0.02, n = 4) than the 
one obtained in the presence o f ARF alone which induced 0.22% o f total lipids to be 
hydrolyzed. The observed ARFl-stimulated-PLD activity enhanced by cytohesin-1 in 
the absence o f exogenous GTP could be due to a preferred pool, or to other source o f 
endogenous GTP that cytohesin-1 could use to drive ARF1 into its active 
conformation. It is also possible that a nucleoside diphosphate kinase (NDPK) 
catalyzes the phosphorylation o f endogenous GDP molecules either free in solution or 
bound to ARFs (Randazzo et al., 1992; Randazzo et al., 1991; Kikkawa et al., 1990).
In addition, it was also found that adding increasing concentrations o f exogenous 
GTP gradually decreased the stimulatory effect o f cytohesin-1 on ARF 1-stimulated 
PLD activity. However, even at high concentrations o f GTP such as 1 mM GTP, 
cytohesin-1 could still significantly enhance PLD activity (P = 0.02, n = 4) as already 
observed in Figure 5.1. But at GTP concentrations > 1 mM, the stimulatory effect o f 
cytohesin-1 was completely abolished. In summary, it is not clear at this stage if  a 
guanine nucleotide is an absolute requirement for PLD activation in HL-60 cells and 
whether, if  one is required, if  it need be GTP.
5.2.3. The ARF 1-stimulated PLD activity that is enhanced by small ARF-GEFs 
preferentially uses GDP over exogenous GTP as a source o f  guanine nucleotide
As described above, the activation o f PLD through the ARF-GEF pathway does 
not seem to rely on bulk, soluble GTP for ARF activation. Bearing this in mind, one
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hypothesis is that the system can operate effectively using GDP. The following 
experiments were performed to test this hypothesis. Firstly, a range o f  concentrations 
o f GEFs were tested for their ability to enhance the activation o f PLD by ARF1 in the 
presence and in the absence o f GTP in permeabilized HL-60 cells. After cell 
permeabilization, the cells were resuspended in buffer containing a final concentration 
o f 100 pM GDP. As shown in Figure 5.6,4, the activation o f PLD by cytohesin-1 is 
concentration-dependent. Cytohesin-1 alone or combined with exogenous GTP did not 
have any effect on PLD activity. Interestingly, cytohesin-1 could significantly improve 
the ARF 1-stimulated PLD activity by two-fold at concentrations as low as 400 nM (P 
= 0.002, n = 3) compared to the PLD activity stimulated by ARF1 alone. 
Encouragingly, this GTP-independent effect was dependent on the concentration o f 
cytohesin-1. There is no significant difference between the basal PLD activity (control 
or GTP alone) and that observed in the presence o f ARF alone or ARF plus GTP in 
the absence o f cytohesin-1. The ARF 1-stimulated PLD activity seemed to be maximal 
between 12 and 40 pM cytohesin-1 where a significant three-fold increase was 
observed compared to the PLD activity stimulated by ARF1 alone (P = 0.007, n = 3). 
However, the enhancement o f the ARF 1-stimulated PLD activity by cytohesin-1 
observed in the presence o f the exogenously added GTP was not statistically 
significant (P > 0.05, n = 3) over the whole range o f concentrations tested, if  they were 
compared to the PLD response induced by ARF1 plus GTP in the absence o f 
cytohesin-1. A clear feature stands out: the improvement of the ARF 1-stimulated PLD 
activity by cytohesin-1 was significantly greater in the absence o f added GTP than in 
the presence o f  added GTP (P < 0.05, n = 3). This was true for the concentrations o f
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Figure 5.6. Concentration dependence o f GEF- 
induced PLD activation in permeabilized HL-60 cells: 
negative effects o f GTP. After permeabilization, cells 
were centrifuged and resuspended in buffer containing 
3 mM MgATP and 3 mM Ca2+/EGTA (pCa5) and 
100 pM GDP. The cells were then incubated for 
20 min at 37°C with increasing concentrations of (A) 
cytohesin-1, (B) GRP-1, (C) ARNO in the presence or 
absence of fully myristoylated ARF1 and GTP as 
indicated. The assay was then performed as described 
in the Materials and Methods section. Data shown are 
mean ± S.E.M. of duplicate samples from 3 
experiments for cytohesin-1 concentration-dependence 
effects.
cytohesin-1 ranging from 0.1 |uM to 40 pM. It is interesting to note that at high 
concentrations, cytohesin-1 showed a small inhibitory effect in the presence o f 
exogenous GTP. This effect was already noted in Figure 5.1.
Similarly, GRP-1 and ARNO also showed the same stimulatory effect on PLD 
activity as cytohesin-1. This effect was once again more potent in the absence o f GTP 
at concentrations o f GEFs > 1 pM. GRP-1 barely improved the activation o f PLD by 
ARF1 over the whole range o f concentrations tested in the presence of GTP 
(Figure 5.62?) whereas ARNO displayed a slightly more potent stimulatory effect on 
PLD activity in the presence o f GTP (Figure 5.6C).
Since the results shown above seem to strongly indicate a positive effect o f GDP 
in activating PLD via the ARF-GEF pathway, a range o f GDP concentrations was 
tested (Figure 5.7/4). Using permeabilised cells and by simply adding ARF1, with or 
without GTP, to cytohesin-1-containing reactions devoid o f added GDP produced a 
statistically significant increase in the basal PLD activity o f about three fold. GDP 
alone or in the presence o f 40 pM cytohesin-1 with or without the added GTP did not 
elicit a PLD response. However, concentrations o f GDP between 10 pM and 100 pM 
significantly increased PLD activation by ARF1 and cytohesin-1 (P < 0.05, n = 3). At 
these concentrations o f GDP, the addition o f  1 mM GTP decreased PLD activity by 
half. At concentrations > 100  pM, the effects o f GDP became inhibitory. Conceivably 
this inhibition by higher GDP concentrations could result from competition with 
endogenous GTP, present in the cells, for ARF. Thus the optimal GDP concentration 
found was 100 pM. This concentration was used in other experiments where a range 
o f concentrations o f  cytohesin-1 was tested in the presence o f ARF1 with or without
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Figure 5.7. The activation o f PLD in permeabilized 
HL-60 cells mediated by ARF1 and cytohesin-1 is 
dependent on GDP and is not inhibited by PAPS, an 
NDPK inhibitor. {A) Concentration dependence of 
GDP-induced activation of PLD, (B) concentration 
dependence o f cytohesin-1 and (C) effects of PAPS 
on the stimulation of PLD activity by ARF1 and 
cytohesin-1 in the presence and absence o f GTP. The 
standard PLD assay in permeabilized HL-60 cells 
was performed as described in the Materials and 
Methods section. 100 pM GDP was added to the 
resuspended HL-60 cells after permeabilization. Data 
shown are mean ± S.E.M. of duplicate samples from 
3 experiments.
Concentration o f PAPS (pM)
added GDP. As shown in Figure 5 .IB, cytohesin-1 alone or combined with added 
GDP was not effective over the whole range o f the indicated concentrations. Upon 
addition o f  300 nM myristoylated ARF1 in the presence o f GDP, cytohesin-1 
gradually increased its stimulatory effect on PLD activity with increasing 
concentration. The maximal effective concentration o f cytohesin-1 was 40 pM. This 
observed effect o f  cytohesin-1 can only be attributed to the presence o f GDP since in 
its absence the activation o f PLD by ARF1 was not observed over the whole range o f 
cytohesin-1 concentrations. Indeed, concentrations o f cytohesin-1 greater than 1 pM 
were required to reveal a GDP-dependent PLD response to ARF1 (P < 0.05, n =  3).
5.2.4. The NDPK competitive inhibitor, PAPS, has no effect on the GDP-sensitive 
activation o f  PLD by ARF1
The experiments described in Figures 5.7v4 and 5.IB  clearly show a critical role 
for GDP in mediating the activation o f PLD through the small ARF-GEF pathway. 
One possible explanation for this finding could be a role for NDPK. This enzyme 
converts GDP into GTP and was shown to be active in a related experimental system, 
permeabilized mast cells (Martin et al., 1995). However, the use o f PAPS as a 
competitive inhibitor o f the NDPK did not decrease the stimulatory effect o f  GDP 
(Figure 5.1C). The PLD response to ARF1 and cytohesin-1 with or without the added 
GTP was significantly higher than the basal PLD activity obtained in response to 
cytohesin-1 alone or in the presence o f GTP. The lack o f significant difference in PLD 
activation caused by ARF1 and cytohesin-1 in the absence and presence o f GTP at low 
PAPS concentration may be artefactual. For the experiments shown in Figures 5.1 A  
and 5.IB  clearly demonstrated that the PLD activity stimulated by ARF1 and
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cytohesin-1 was maximal in the presence o f 100 pM exogenously added GDP and 
decreased by half when GTP was added to the reaction mixtures. As PAPS was 
titrated in the reaction mixtures, PLD activity induced by ARF1 and cytohesin-1 
remained unchanged. One would expect PAPS to inhibit the production o f endogenous 
GTP from the added GDP catalysed by the NDPK. PAPS has been shown to bind 
NDPK with a Kd o f 10 pM in in vitro studies using a NDPK kinase from 
Dictyostelium amoeba (Schneider et al., 1998).
Although the activation o f PLD is GDP-sensitive in the permeabilized HL-60 cell 
system, presumably due to the presence o f a system responsible for the conversion o f 
GDP into GTP, the addition o f GDP in cell-free in vitro PLD assays containing 
recombinant PLD, ARF1 and cytohesin-1 failed to stimulate PLD (Figure 5.8). In the 
same fashion, this can only be attributed to the lack o f that mechanism, present in the 
cells, that allows GDP-dependent activation. The unidentified mechanism was 
obviously absent in the cell-free system where only GTP was effective in activating 
PLD in vitro.
These data seem to support the hypothesis that GDP is a better source o f guanine 
nucleotide for ARF activation through the small GEFs in permeabilized HL-60 cells. 
Taking advantage o f such unexpected stimulatory effects o f GDP, it was therefore 
reasonable to introduce a fourth element in the so far defined PLD signalling pathway 
comprising o f GEFs, ARFs and PLD. This fourth element is either PIP2  or PIP3 . These 
two polyphosphoinositide have already been shown to participate in the ARF- 
regulated PLD activity mostly in vitro (Hammond et al., 1997; Hammond et al., 1995; 
Pertile et al., 1995; Liscovitch et al., 1994; Brown et al., 1993).
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Figure 5.8. In vitro PLD activation mediated by myristoylated 
ARF1: comparison o f the effects GTP and GDP. Sf9 cells were 
infected with recombinant baculovirus for the expression of 
hPLDlb which was recovered on glutathione sepharose beads. A 
sample of the hPLDlb on beads (20 pi) was incubated with a 
fixed concentration of 500 nM mARFl at 37°C for 60 min in the 
presence of PC substrate (8 . 6  pM final concentration) and 
[3 H]Choline-labelled PC (200000 dpm per 10 pi substrate). GTP 
(100 pM) and GDP (100 pM) was added along with 10 pM 
cytohesin-1. Reactions were stopped by transferring cells to ice 
and by adding methanol/chloroform (1:1, v/v). Phases were 
partitioned by addition of water. Release of [3 H]choline was 
measured as described in the Materials and Methods section. 
Data shown are mean ± S. EM . of duplicate samples from 3 
experiments. The significance o f data was evaluated using 
Student’s t test.
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5.2.5. Both PIP2 and PIP3 enhance PLD activity in HL-60 cells and in vitro hut PIP3 is 
a better PLD activator
The effects o f further additions o f exogenous PIP2  and PIP3 on the coupling 
between GEFs, ARFs and PLD were investigated in cell-based and cell-free systems. 
As illustrated in Figure 5.9, under the “control” condition, the addition o f recombinant 
cytohesin-1 and PIP2  and PIP3 slightly augmented the basal PLD activity in HL-60 
cells. This small increase in PLD responsiveness to cytohesin-1 and the 
polyphosphoinositides was significant with PIP3 (P = 0.03, n = 3) but not with PIP2  (P 
= 0.06, n = 3). Under the “plus m A RFl” condition, the subsequent addition o f 
myristoylated ARF1 further enhanced the PLD basal activity found under the 
“control” condition. Not too surprisingly, PLD responsiveness to ARF1 alone was 
significantly increased by the addition o f cytohesin-1 alone (P = 0.01, n = 3), 
cytohesin-1 plus PIP2  (P = 0.006, n = 3), and cytohesin-1 plus PIP3 (P = 0.01, n = 3). 
More interestingly, the further enhancement o f PLD activity induced by the 
polyphosphoinositides in response to ARF1 plus cytohesin-1 was significant with PIP3 
(P = 0.03, n = 3) but not with PIP2 (P = 0.1, n = 3) although there is no significant 
difference between the enhancing effect o f these two polyphosphoinositides in 
comparison to the PLD activity elicited by ARF1 plus cytohesin-1 (P = 0.1, n = 3). 
Similar to the “control” condition, under the “plus GTP” condition, PIP3 appeared to 
be the most effective activator o f  PLD as it significantly increased the basal PLD 
response (P = 0.02, n = 3-). Under the “mARFl + GTP” condition, the presence o f 
GTP did not affect the potentiating effect o f either cytohesin-1 alone or cytohesin-1 
plus PIP2 /PIP3 . Indeed, under the “mARFl + GTP” condition, the basal PLD activity
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Figure 5.9. Effects o f PIP2 and PIP3 on PLD activity 
in permeabilized HL-60 cells. Activity of PLD was 
determined under standard assay conditions in 
previously permeabilized HL-60 cells in the presence 
or absence of 500 nM ARF1, 1 pM cytohesin-1, 
30 pM C8 PIP2, 30 pM C8 PIP3 , 100 pM GTP as 
indicated in the legend. After permeabilization, HL-60 
cells were centrifuged and resuspended in buffer 
containing 3 mM MgATP and 3 mM Ca2+/EGTA 
(pCa5) and 100 pM GDP. Release of [3H]Choline was 
measured as described in the Materials and Methods 
section. Data shown are mean ± S.E.M. of duplicate 
samples from 3 experiments. The significance of data 
was evaluated using Student t test.
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rose significantly when cytohesin - 1  alone (P = 0.03, n = 3), cytohesin- 1  plus PIP2 (P = 
0.007, n = 3), and cytohesin-1 plus PIP3 (P = 0.002, n = 3) were present. Although no 
significant difference was observed between the effects o f cytohesin- 1  alone and 
cytohesin-1 plus PIP2 , cytohesin-1 plus PIP3 significantly yielded stronger enhancing 
effects than those produced by cytohesin-1 alone (P = 0.01, n = 3) and cytohesin-1 
plus PIP2  (P = 0.0008, n = 3). Clearly, the results found in HL-60 cells indicate that 
the activation o f PLD by the combined actions o f ARFs and GEFs is undoubtedly 
further increased by the exogenous addition o f polyphosphoinositides such as PIP2 and 
PIP3 . However, PIP3 turns out to be the most effective activator o f PLD under these 
conditions. This observation was backed up to some extent by in vitro assays, again 
the exogenous effects o f PIP2 and PIP3 on recombinant GST-hPLDlb activity 
stimulated by ARF1 plus GTP.
Indeed, as shown in Figure 5.10, the basal activity o f PLD was substantially 
elevated in the presence o f PIP2 and PIP3 . PIP3 had a stronger effect than PIP2 . In the 
presence o f ARF1 plus GTP, the basal activity of PLD was stimulated approximately 
40-fold. This increase was further potentiated by the addition o f PIP2 and PIP3 . Again, 
PIP3 produced a stronger activation o f PLD mediated by ARF1 and GTP than PIP2 . 
Cytohesin-1 in combination with GTP did not trigger a marked PLD response 
although the basal PLD activity seemed to be slightly improved. However, cytohesin-1 
did not enhance the GTP plus ARF1-stimulated activity o f PLD either in the presence 
or absence o f  PIP2  and PIP3 . It is conceivable that in this in vitro PLD assay, 
cytohesin-1 sequesters some o f the exogenously added PIP2 and PIP3 thereby 
preventing these phosphoinositides from fully activating PLD.
182
PL
D 
ac
tiv
ity
 
(% 
tot
al 
PC 
hy
dr
ol
yz
ed
)
3.00 n
PLD + GTP PLD + ARF1+ PLD + PLD + ARF1 +
GTP cytohesin-1 + cytohesin-1 +
GTP GTP
Figure 5.10. Effects o f PIP2 and PIP3 on the 
activity o f  recombinant PLD lb  purified from  
sf9 insect cells transfected with the hPLDlb 
baculovirus. A sample of the purified PLD lb 
recovered on glutathione sepharose beads 
previously treated with 2.5 mM GSH for 
30 min at 4°C was incubated with substrate 
prepared from PE, PIP2 and PC (Ci0) in the 
molar ratio 10: 0.3: 1. The final PC
concentration was 8.6 pM. [3H]Choline- 
labelled didecanoyl PC was added to give 
approximately 200, 000 d.p.m. per 10 pL 
substrate. Recombinant ARF1 (500 nM), 
cytohesin-1 (10 pM), Cg PIP2 (10 pM) and C8 
PIP3 (10 pM) were added to the reaction 
mixture in the presence of GTP (1 mM). The 
reaction mixtures were transferred to a 37°C 
water bath and incubated for 1 hour. Release 
of [3H]Choline was measured as described in 
the Materials and Methods section. Data are 
representative of two experiments performed 
in duplicates.
■  PLD beads treated with 2.5 mM GSH
■  PLD beads treated with 2.5 mM GSH + PIP2 
□  PUD beads treated with 2.5 nM GSH + PIP3
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5.3. Discussion
This thesis is the first to examine the properties o f the reconstitution o f  a ternary 
complex consisting o f GEFs, ARFs, and PLD in both permeabilized HL-60 cells and 
in cell-free assays. In permeabilized HL-60 cells, PLD activation induced by ARF1 
was significantly promoted by the presence o f either ARNO, GRP-1 or cytohesin-1. 
The nucleotide used as an activator o f ARF was GTP. The concentration o f GTP used 
in the majority o f reconstitution assays was 1 mM. Even at this high concentration o f 
GTP, the GEFs were still able to significantly stimulate the ARF 1-mediated PLD 
activity with the same degree o f potency. The effects o f these GEFs on PLD activity in 
HL-60 cells were verified through the normalization to protein concentration and to 
the exchange specific activity. Under both experimental conditions, all three o f the 
GEFs tested were equally potent. The equipotency o f the GEFs was observed at 
relatively low concentrations o f ARF1 (300 nM). A minimum o f 100 nM ARF1 was 
required to observe any stimulation with the GEFs. ARNO and GRP-1 were still 
approximately equipotent, at higher concentrations, stimulating maximally at 1 pM 
ARF1. However, cytohesin-1 caused a slight inhibition o f PLD activity. This effect 
may be explained by the fact that at this particular concentration, the activation o f 
ARF1 by cytohesin-1 could be accompanied by the activation o f inhibitory pathways. 
By contrast, the same GEFs were unable to enhance the activation o f PLD by ARF1 or 
ARF6 in vitro using a recombinant PLD lb  purified from sf9 insect cells transfected 
with a hPLDlb-coding baculovirus and recovered on glutathione sepharose beads. 
This observation underlines major differences between the two model systems 
described in this thesis. Indeed, it seems very likely that cells possess other specific
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and/or non-specific components that cell-free systems do not necessarily have, even 
though rudimentary efforts have been made to mimic the “natural” environment o f  the 
cell.
The specific components could be specific protein activators and essential lipids. 
Protein activators could be residual members o f the small G protein family (i.e. Rho 
and Ral family proteins), PKC or other cytosolic factors present in the cells after 
permeabilization. These proteins may act in concert with ARFs and GEFs to bring 
about an effective and optimal activation o f PLD in HL-60 cells. For example, the 
membrane-associated RhoA, a member o f the Rho family o f  small G-proteins, and 
ARF were shown to synergistically activate PLD in HL-60 membranes (Siddiqi et al., 
1995) and partially purified rat brain PLD (Kuribara et al., 1995) in the presence o f  
GTPyS. Interestingly, Singer et al. (1996) reported that PLD in porcine brain was 
synergistically activated in vitro by PKC, ARF and RhoA in the presence o f GTPyS. 
Similarly, a combination o f PKCa, ARF1 and Cdc42 significantly stimulated PLD 
activity in the detergent-insoluble fraction of HL-60 membranes (Hodgkin et al., 
1999). Another member o f the small G protein, RalA, originally shown to directly 
interact with PLD1 (Luo et al., 1997), has been reported to synergistically stimulate 
bovine brain PLD activity in concert with ARF1 in vitro (Kim et al., 1998). Recently, 
Powner et al. (2002) have provided in vivo evidence for a co-localization o f PLD lb  
with R acl, ARF6, and PK C a in actin-rich structures at the plasma membranes 
following antigen-stimulation o f RBL-2H3 cells. Furthermore, a 50 kDa cytosolic 
factor in combination with either purified bovine brain ARF1 or ARF3 or purified
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recombinant human ARF1 was able to synergistically activate PLD in human 
peripheral blood neutrophils (Lambeth et al., 1995).
Thus it appears that the normal activation o f PLD is multifactorial and therefore 
it is likely that in a cellular environment those reported regulatory molecules would 
conspire to promote a complete activation o f PLD. However, the precise mechanism 
by which ARP synergizes with these co-regulatory molecules in cells remains unclear. 
Nonetheless, most in vitro studies seem to suggest that the mechanism o f the 
synergistic activation o f PLD is mediated by the direct and independent interaction o f 
the PLD-activating factors with PLD (Kim et al., 1998; Lee et al., 1997).
As already discussed in the previous chapter, phospholipids are closely involved 
in ARF and GEF functions. In the in vitro PLD assay described in this thesis, the 
substrate was prepared from a mixture o f PIP2 , and neutral phospholipids such as PC 
and PE. However, acidic lipids such as PS and PG might also be critical in the cellular 
environment. In addition to the critical role o f phosphoinositides, these acidic 
phospholipids might contribute to the optimal non-specific interaction between the 
GEFs and the cellular membranes to which they are recruited following receptor 
stimulation. Indeed, in vitro studies demonstrated, for instance, that the stimulation by
'i c
ARNO o f [ S]GTPyS binding on ARF1 in guanine nucleotide exchange assays and 
binding o f ARNO to lipid vesicles in sedimentation experiments were optimal under 
conditions where the PC vesicles were supplemented with either PG or PS in addition 
to PIP2  (Macia et al., 2000; Chardin- et al., 1996). Each o f these acidic phospholipids 
has a single negative charge that would presumably enhance the binding o f the GEFs 
to phosphoinositides in membranes, a process mediated by their positively charged PH
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domains, in a cellular context. The composition o f PS and PG is thought to be up to 
around 30% of the phospholipids on the cytoplasmic leaflets o f cellular membranes 
(Macia et al., 2000).
The permeabilization “model system” allows the leakage o f cytosolic 
components out o f the perforated cells but the integrity o f the non-specific 
components such as membranes o f cellular organelles including the nucleus, ER, 
Golgi apparatus, transport/secretory vesicles and plasma membrane generally remain 
intact when analysed by electron microscopy (Geraint Thomas, unpublished 
observation). The structural features o f these membranes such as their curvature and 
their lipid and protein composition are implicated in cellular functions involving 
internalization processes including endocytosis (Hurley and Wendland, 2002; Nossal 
and Zimmerberg, 2002), podocytosis (Anderson et al., 1992) and transcytosis 
(Ghitescu et al., 1986). For instance, PLD activity has been found in specific 
microdomains o f the plasma membranes identified as caveolae or lipid rafts (Severs, 
1988; Harder and Simons, 1997). These small vesicular invaginations are present in 
most cell types (Anderson, 1998; Parton, 1996) and have been suggested to be 
involved in the regulation o f PLD activity because they are enriched in critical 
PLD-regulatory molecules such as PIP2  (Hope and Pike, 1996; Pike and Casey, 1996), 
heterotrimeric GTP-binding proteins (Chang et al., 1994; Lisanti et al., 1994), the Ras- 
related GTP-binding proteins (Gingras et al., 1998; Senda et al., 1997; Chang et al., 
1994; Lisanti et al., 1994) and PKC (Kim et al., 2000; Kim et al., 1999). It has been 
suggested the PLD activity detected in caveolae was not PLD1 but PLD2 (Czamy et 
al., 2000; Czamy et al., 1999). However, this observation was restricted to cell types
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including HaCaT human keratinocytes and U937 promonocytes. Although there is no 
evidence for an ARF-activated PLD in caveolae in HL-60 cells, one cannot exclude 
the existence o f a phosphoinositide-dependent GEF-ARF-PLD pathway in the 
caveolar structures since these microdomains harbour essential signalling molecules 
required for PLD activity.
The specific and non-specific features evoked above are intrinsic components o f 
a cellular environment that are difficult to mimick in vitro and the lack o f  some o f 
these described cellular components in the cell-free assay might therefore explain the 
failure o f the GEFs to effectively potentiate the ARF-mediated activation o f PLD 
observed in the permeabilized model system. For example, my in vitro assays with 
recombinant PLD lb  cannot reproduce the caveolar micro environment.
As observed in permeabilized HL-60 cells, the GEFs were able to increase PLD 
responsiveness to ARF1. The initial failure to detect such stimulatory effects in vitro 
may be attributed to sub-optimal levels o f essential phosphoinositides such as PIP2 and 
PIP3 in the reaction mixtures. As a result, exogenous PIP2 and PIP3 were added to the 
recombinant PLD lb  in the presence o f recombinant ARF1. The in vitro experiment 
illustrated in Figure 5.10 clearly demonstrated that both basal and ARF 1-stimulated 
PLD activity was mostly enhanced by the addition o f exogenous phosphoinositides 
such as PIP2 and PIP3 . The addition o f cytohesin-1 had no further effects. However, in 
a cellular context, the same cytohesin-1 significantly augmented the activation o f  PLD 
by GTP-activated ARF1. O f similar interest is the observation that PIP2  and PIP3 
further potentiated the stimulatory effects o f cytohesin-1 on ARF 1-stimulated PLD 
activity when assayed in permeabilised cells. However, the observed higher potency
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displayed by PIP3 in permeabilized cells and in vitro assays seems to contradict earlier 
studies showing that PIP2  was somewhat more effective than PIP3 in activating PLD 
(Hammond et al., 1997; Liscovitch et al., 1994). But overall, these results are in 
agreement with previous reports on the requirement for polyphosphoinositides in 
ARF-regulated PLD activity. Indeed, The PHVdependent activation o f  PLD by ARF 
is well-established both in vitro (Liscovitch et al., 1994; Massenburg et al., 1994; 
Brown et al., 1993) and in permeabilized cells (Schmidt et al., 1996; Pertile et al., 
1995). The role o f PIP3 in elevating PLD activity has also been reported in vitro 
(Hammond et al., 1997; Liscovitch et al., 1994). The fact that exogenous PIP3 can 
participate in PLD activation in permeabilized HL-60 cells and in vitro further 
supports a possible role for the PI 3-kinase pathway in the activation o f PLD by 
agonists which cause transient increases in the levels o f PIP3 in cells. However, the 
mechanism by which these phosphoinositides activate PLD, or rather increase the 
activation o f PLD stimulated by ARF1 in vitro, is still unclear. It is possible that the 
presence o f either PIP2  or PIP3 increases the binding affinity o f the purified PLD to 
lipid vesicles via the proteins PX domain. Alternatively, either o f these two 
phosphoinositides may alter the substrate-containing phospholipid surface in a way 
that renders the PC substrate more accessible for the enzyme. Interestingly, the 
observed increase o f the basal activity o f PLD induced by PIP2  and PIP3 might 
indicate a direct interaction o f PLD with the phosphoinositides. Indeed, a short 
conserved sequence ( 2 1  residues) containing hydrophobic amino acids interspersed 
with basic arginine and lysine residues has been identified as a PHVbinding site in 
mammalian PLD2 (Sciorra et al., 1999). This binding m otif was also shown to be
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present in mammalian PLD1 and the yeast PLD, Spol4p. However, the identified 
phosphoinositide-binding m otif turned out to be absent from PLD enzymes that are 
not dependent on PIP2 for activity, such as bacterial PLD (Sciorra et al., 1999; Morris 
et al., 1996; Ponting and Kerr, 1996). Mutagenesis o f the first two conserved arginine 
residues o f the phosphoinositide-binding sequence in PLD2 significantly attenuated 
the catalytic activity o f the mutants as well as their binding to PfiVcontaining vesicles 
in vitro. The decrease in PLD activity was also observed in vivo (Sciorra et al., 1999). 
Based on their published data and those o f others (Chaudhary et al., 1998; Martin, 
1998; Lu and Chen, 1997), Sciorra et al. (1999) suggested that the direct interaction 
between the identified phosphoinositide-binding m otif in PLD and PIP2 is mediated by 
the conserved arginine and lysine residues that form electrostatic interactions with the 
phosphate groups on the inositol ring o f PIP2. Other phosphoinositide-binding 
domains such as the PH and PX domains are present at the N terminus o f PLD 
enzymes and these domains may also serve to bind either PIP2 or PIP3. However, the 
precise function o f the PX and PH domains in PLD is currently not well-defined 
although the PH domain has been shown to play no significant role in the activation o f 
PLD by PIP2 in vitro (Sciorra et al., 1999; Sung et al., 1999a; Sung et al., 1999b). On 
the other hand, it is conceivable that the mechanism o f activation o f PLD by PIP2 or 
PIP3 might be mediated through direct interaction o f the phosphoinositides with 
ARF1. Thus the newly formed complex would then interact with PLD. Evidence for a 
direct in vitro interaction between PIP2 and ARF1 has been reported (Randazzo, 1997; 
Terui et al., 1994). PIP2 has been suggested to act as an exchange factor on ARF1 by 
stimulating the rate o f  GDP dissociation from ARF1 and stabilizing the nucleotide-
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free form (Zheng et al., 1996; Terui et al., 1994). However, the role o f PIP2 in 
activating ARF is further complicated by the fact that it also potentially plays a role by 
recruiting ARF-GEF proteins to membranes.
More intriguing still is the fact that PIP3 is unquestionably a better activator o f 
PLD than PIP2  under the two experimental conditions described in this thesis. What is 
the significance o f such difference? It is well known that PIP2  is a stable, constituant 
o f several cell membranes, the levels o f which are maintained at some steady 
concentration. Consequently this lipid is always available in cells to participate in 
PLD-signaling pathway (Skippen et al., 2002; Fensome et al., 1996), the PLC- 
signaling pathway (Berridge, 1993) and the PI 3-kinase-signaling pathway (Rameh 
and Cantley, 1999). By contrast, the appearance o f significant amounts o f PIP3 is 
usually the result o f the stimulation o f cell surface receptors e.g. insulin receptors 
(Rizzo and Romero, 2 0 0 2 ). Therefore the levels o f  PIP3 fluctuates making its 
physiological actions transient as opposed to those o f PIP2 . Interestingly, even in the 
aftermath o f receptor stimulation, the levels o f PIP3 are still far smaller than those o f 
PIP2  (Czech, 2000) whose effective concentration in the cell is about 10 pM 
(McLaughlin et al., 2002). On the basis o f these considerations, one puzzling question 
arises. What are the cellular mechanism(s) that render PIP3 a more potent PLD 
activator than PIP2 ? Is there one specific element in the multi-component PLD 
pathway that would preferrentially use, for instance, PIP3 as a better binding partner 
over PIP2 ?- Traditionally such a component is believed to be the PH domains o f the 
ARF-GEFs. However, as already discussed in the previous chapter, I find that in 
contrast to other reports the GEFs cannot effectively discriminate between these two
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phosphoinositides. This probably excludes the GEFs as a potential single 
discriminatory element.
Taken together, the data described in this thesis and those previously reported 
underline the possible mechanisms o f activation o f PLD by phosphoinositides. These 
phosphoinositides are likely to be multifunctional in their regulation o f ARF- 
stimulated PLD activity.
As already discussed, ARF1 must ordinarily bind GTP to interact with target 
proteins such as PLD and this may reflect the need for translocation to membranes or 
specific interactions (see Chapter 3). Experiments in permeabilized HL-60 cells 
revealed inhibitory effects o f GTP on PLD activity at concentrations in the millimolar 
ranges. This observation may be due to an activation o f PIP2  breakdown through the 
well-known PLC pathway. Indeed, it is possible that GTP or ATP activate a purinergic 
receptor coupled to a heterotrimeric G protein, which is supported by GTP, that is also 
present in these cells. The G protein might then activate the PLC pathway leading to a 
decrease in the levels o f PIP2  as a result o f  its breakdown by PLC. The products o f this 
hydrolysis are the well-established second messengers, DAG and IP3 (Berridge, 1993). 
The subsequent reduction o f the levels o f PIP2 might decrease the responsiveness o f 
PLD to ARF. On the other hand, it is plausible that the high concentrations o f GTP 
support inhibitory enzymes. In addition, it is interesting to note that the form o f GTP 
used in the experiments described in this chapter is the lithium salt. It has been 
suggested that lithium could interfere with G protein function by inhibiting GTP 
binding (Avissar et al., 1988).
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The results presented in this chapter emphasize a critical and unexpected role for 
GDP in the activation o f PLD by ARF1 and its exchange factors ARNO, GRP-1 and 
cytohesin-1 in HL-60 cells. This important result possibly implies a role o f 
endogenously formed GTP which was preferentially effective in stimulating PLD 
activity compared to bulk exogenous GTP. Therefore an intracellular mechanism that 
converts either exogenous or endognous GDP into GTP might be involved in the 
efficient activation o f PLD by ARF1 in the presence o f any o f the GEFs studied. A 
potential candidate for this GTP-binding protein coupled effector regulation is the 
membrane-and-cytoskeleton-associated NDPK. NDPK was initially shown to catalyse 
the transfer o f phosphate from ATP to GDP that had been previously found bound to 
ras (Ohtsuki and Yokoyama, 1987), ARF (Randazzo et al., 1991) and trimeric GTP 
binding proteins (Kikkawa et al., 1990), thereby possibly activating G proteins 
without the need for nucleotide exchange. However, the suggested direct interaction o f 
these GTP-binding proteins with NDPK was subsequently dismissed on account o f 
flaws in the experimental design (Randazzo et al., 1992). Evidence for the activity o f 
NDPK in membranes o f HL-60 cells has been published (Wieland and Jakobs, 1992, 
Wieland et al., 1991; Seifert et al., 1988). Based on these considerations, it is tempting 
to hypothesize that the observed GDP-dependent PLD activity in HL-60 cells would 
be the result o f  the conversion o f GDP into GTP by NDPK. This hypothesis is further 
supported by the fact that the presence o f ATP is required in the permeabilized cells 
model system described in this thesis. In addition to its role in maintaining the levels 
o f intracellular PIP2 , ATP would serve as the phosphate donor in the conversion o f 
GDP to GTP by NDPK. The newly synthesized GTP would then be used by the GEFs
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to activate ARF. This mechanism would reconcile the previously proposed direct 
interaction between NDPK and GTP-binding proteins that was later called into 
question (Randazzo et al., 1992). In order to test this hypothesis, the effects o f an 
inhibitor o f NDPK were examined. Among various NDPK inhibitors employed in 
vitro and in permeabilized cells in previous studies (Schneider et al., 1998; Martin et 
al., 1995), PAPS is o f special interest because it was shown to bind relatively well to 
the NDPK in vitro binding assays (Schneider et al., 1998). However, PAPS was 
without effect on the GDP stimulation of PLD in the model system described in this 
thesis. The failure o f PAPS to inhibit NDPK and the presumed formation o f 
endogenous GTP from GDP and ATP in HL-60 cells might indicate a low specificity 
o f this inhibitor towards the particular type o f NDPK present in this type o f  cells. 
Alternatively, other systems responsible for the synthesis o f  GTP might be operating 
in HL-60 cells.
Interestingly, the stimulatory effect o f GDP was also observed in other signalling 
events relying on GTP-binding protein activation. For instance, the exocytotic 
mechanism o f permeabilized rat mast cells (Pinxteren et al., 2000; Martin et al., 1995; 
Lillie and Gomperts, 1992) and rat PC 12 (pheochromocytoma cells) cells (Vu and 
Wagner, 1993) was shown to be dependent on low concentrations o f GDP (< 100 pM) 
and was inhibited with the addition o f higher concentrations o f GDP. The positive 
effect o f GDP in the lower concentration range was suggested to be due to its 
conversion to GTP by the NDPK. The involvement of the NDPK in secretion was 
supported by the requirement for ATP in the permeabilized cells (Martin et al., 1995;
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Vu and Wagner, 1993) and also by the finding that the addition o f NDPK to ATP- 
depleted cells partially restored ATP[S]-stimulated secretion (Vu and Wagner, 1993).
Overall, the data presented in this chapter clearly lay emphasis on an exclusive 
reconstitution o f a ternary complex involving GEFs, ARFs and PLD in both standard 
permeabilized HL-60 cells and in in vitro model systems. The apparent discrepancy 
between these two systems revealed by the failure o f the same GEFs to substantially 
elevate the ARF-stimulated PLD in vitro strongly indicate the difficulty in mimicking 
the natural environment o f the cell in in vitro assays. This is further complicated by 
the multifunctional nature o f some the regulatory molecules such as 
polyphosphoinositides involved in PLD activation. Importantly, one o f the highlights 
o f the work presented in this chapter is the fact that the entire control sequence from 
PIPn —» ARF-GEF —> ARF —> PLD1 can be reproduced in permeabilized HL-60 cells. 
Morever, traditional views on the positive stimulatory effect o f bulk, diffuse guanine 
nucleotide are also challenged by the finding that GTP could exert inhibitory effects 
under specific conditions. In addition, it emerged that GDP seems to be preferentially 
used as a source o f GTP by ARFs and GEFs to effectively activate PLD in the 
permeabilized cells. The molecular basis for this observation will need further 
investigation.
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Chapter six
General discussion
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The principal theme o f this thesis is the coordinated regulation o f PLD by ARFs 
and its small exchange factors. This has been examined by using two different but 
complementary model experimental systems in order to allow direct comparisons. The 
requirement for such an investigation into the regulation o f PLD, at the molecular 
level, stems principally from the fact that there is still not a clear definition o f the 
discrete steps coupling receptor stimulation at the cell surface to the activation o f 
PLD. In addition, contentions over the specificity and selectivity o f the necessary 
protein-protein and protein-lipid interactions still exist in the published literature and 
are, on the whole, the norm. This thesis thoroughly addressed some o f the fundamental 
issues and generated new insights that will be useful for the understanding o f this 
complex type o f coordinated regulation common in cell physiology. This brief chapter 
will summarize the new findings, including their originality, and also further consider 
the value and the limitations o f the permeabilization/reconstitution system as a tool for 
the study o f the cell-signalling events that regulate PLD.
The data presented in this thesis indeed confirmed the well-established view that 
myristoylation at the N-terminus o f ARFs plays a crucial role in ARF functions i.e. 
recruitment on cellular membranes, guanine nucleotide binding property, interaction 
with effector and regulator proteins. Furthermore, this was done side-by-side, with 
identical materials, allowing the inferences drawn from one piece o f work to be 
extended confidently to be into others. I have proposed a largely collision-based 
mechanism as a feasible explanation for the intriguing guanine-nucleotide- 
independent ARF stimulation o f PLD activity in the permeabilised-cell model system. 
Alternatively, a pool o f endogenous GTP may be responsible for the activation o f
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ARP exogenous. The loading o f endogenous GTP on ARF may be catalyzed by 
residual endogenous ARF-GEFs. In addition, it is possible that endogenous NDPK 
converts the endogenous pool o f GDP into GTP leading to the activation o f 
recombinant ARF in the reconstituted cell-based system. Overall, the use o f a fully- 
myristoylated recombinant ARF protein in permeabilized cells makes it possible to 
reconstitute PLD activation without the need to add exogenous GTP.
The determination o f a full extent o f myristoylation the ARFs used made it 
possible to show a clear-cut difference between ARF1 and ARF6  in PLD regulation. 
Indeed, ARF1 turned out to be unequivocally a better activator o f PLD than ARF6  and 
this feature was observed in the two model systems used in this thesis. As a result, it is 
probable that these two proteins perform different non-redundant functions in vivo.
The data reported in this thesis clearly demonstrated that the small ARF-GEFs 
enhanced guanine nucleotide exchange on ARF1 and ARF6 , preferentially on ARF1. 
However, the same small ARF-GEFs did not preferentially interact with PIP3 over 
PIP2  in vitro. My rationalisation for this apparent contradiction o f the currently 
accepted view o f an ARF-GEF selectivity towards PIP3 is based on the different 
experimental conditions and different model systems used in each case. Notably, the 
fact that the small ARF-GEFs cannot discriminate between PIP3 and PIP2  under the 
experimental conditions described in this thesis cannot be readily attributed to the 
small differences in the PH domains. This would seem to imply that the small ARF- 
GEFS are functionally redundant in terms o f recognizing- changes in the levels o f these 
two specific phosphoinositide and transmitting this signal to PLD. Alternatively, the 
participation o f  other partner proteins, possibly interacting with the coiled-coil domain
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of the ARF-GEFs, might lend specificity and selectivity towards phosphoinositides. 
Conceivably, this would enhance protein targeting to the cell membranes and 
subsequent activation o f ARFs. In my work this hypothesis is confirmed by the 
observation that PIP3 supports PLD activation better than PIP2  in permeabilised HL-60 
cells. So, in accord with other models, the fact that either PIP3 or PIP2 are strongly 
involved in the regulation o f the interaction o f the small ARF-GEFs with phospholipid 
membranes indicates the possible participation o f upstream signalling pathways 
responsible for the synthesis o f these polyphosphoinositides. Ultimately, and 
conventionally, these signalling events may synergistically control the activation o f 
PLD in response to cell stimulation by extracellular factors.
Much o f the originality o f the work described here lies in the novel reconstitution 
of a ternary signaling system consisting o f GEFs, ARFs, and PLD in both cell-free and 
permeabilized cell assays. As far as I am aware, there have been no previous reports 
on the reconstitution o f such a ternary complex. The same is true o f the quaternary 
system that was established by mixing polyphosphoinositides, GEFs, ARFs and PLD 
in these model systems. Specifically, it was discovered that the small ARF-GEFs 
strongly enhanced PLD activation mediated by ARF1. By contrast, these small ARF- 
GEFs had no effects on PLD activity in vitro. Interestingly, polyphosphoinositides in 
both systems substantiated the ARF-regulated PLD activity and therefore implicating 
other pathways in the regulation o f PLD in vivo.
Thus the observation o f a coordinated regulation o f PLD that is not obvious in 
vitro but is clearly revealed in a cellular context, i.e. permeabilized cells, lays 
emphasis on the important concept o f emergent properties in biological systems. This
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concept is illustrated in my work by the finding that PIP3 , for which there is apparently 
no specificity expressed in vitro by the small ARF-GEFs, turned out to be a better 
activator o f PLD than PIP2 . It seems likely that in a larger, more complicated system 
than that available in cell-free assays, PIP3 does not act exclusively on any one 
individual step upstream o f PLD e.g. the ARF-GEFs, but probably modulates the 
combined, simultaneous effects o f several PLD regulators. Thus the selectivity o f the 
system emerges and clearly shows a preference for PIP3 over PIP2 . The emergent 
selectivity for PIP3 over PIP2  for PLD regulation is indeed puzzling since the level o f 
PIP2  is presumed to be considerably higher in cells, even if  the concentration o f PIP3 is 
transiently elevated in response to cell stimulation. It is probable that processes that 
stimulate PI 3-kinase also trigger a decrease in the level o f PIP2  by sequestering it into 
specialized cellular membranes compartments such as caveolae and membrane ruffles 
or causing its hydrolysis by PLC. Similarly, the results showing that at high protein 
concentrations ARF1 is a stronger PLD activator than ARF6  is o f special interest. This 
is because ARF1 is known to accumulate to extremely high concentrations in Golgi 
membranes, for example, where it is present in transport vesicle coats in 
stoicheometric ratios o f 3:1 to coatomer proteins.
The other original feature o f this work is the use o f two independent 
experimental systems namely the cell-free and cell-based systems to carry out the 
study o f PLD regulation. As shown in this thesis, the cell-free system allows the 
characterization o f molecular interactions but unfortunately lacks many details o f 
intracellular structure and regulation. I contend that this explains the absence o f the 
stimulatory effects o f the small-GEFs on PLD activity in vitro. By contrast, the second
200
system is a cell-based system and therefore more physiological. It essentially depends 
on the dual permeabilization/reconstitution process which has proven to be a valuable 
tool for the biochemical dissection o f signalling pathways that regulate PLD activity 
within neutrophil-related cell lines. Indeed, the gentle permeabilization step by the 
bacterial cytolysin, SLO, generates pores in the plasma membrane o f the cell, allowing 
the rapid efflux o f cytosolic proteins while maintaining o f  the general structural 
features. In such a system, I have confidently demonstrated, for instance, that the use 
o f exogenous GDP as a source for GTP is a more sensitive way to activate ARF 
proteins than the use o f either GTP or GTPyS. As a result, this novel observation 
should prove useful for any future investigation into the regulation o f PLD by small 
GTP-binding proteins in a permeabilization/reconstitution system. Finally, it is 
reasonable to think that the permeabilized HL-60 cell system may be adapted to other 
specialized cell types in order to help further clarify the complex mechanisms o f 
regulation o f PLD.
However, the use o f a permeabilization/reconstitution system has its own 
limitations. The permeabilization procedure allows the leakage o f a large proportion o f 
cytosolic components that may be crucial for the control and regulation o f the 
signalling pathway under investigation. In addition, cross-talk mechanisms probably 
operate under certain conditions which are difficult to assess in a cell permeabilization 
assay. The other disadvantage o f SLO permeabilization is the size restriction o f 
molecules that can pass through the lesions (molecules > 150 kDa cannot exit easily 
from the permeabilized cells). Thus the major concerns in using this cell-based 
reconstituted system remains that it has always been difficult to assess to which extent
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the permeabilized cells are a valid model for the intact cell. As already mentioned, cell 
permeabilization is an excellent step towards dissecting molecular processes but there 
is always a reasonable concern that important cellular structures, such as the 
cytoskeleton, or membrane organelles can be affected during permeabilization and 
therefore permeabilized cells are by no means perfect models for the living wild-type 
cells. However, this type o f reasonable concern about a perturbation to an 
experimental system must always be a part of modem cell biology. For example, the 
use o f transformed cell lines, the microinjection of recombinant proteins or o f RNA or 
DNA, the transfection and overexpression o f foreign DNA under strong promoters, all 
those techniques bring specific artifacts to any investigation. Hence, biological 
problems are best solved by bringing several complementary techniques to bear 
simultaneously.
Figure 6.1 schematically presents the different aspects o f the regulation o f PLD 
at the molecular level described in this thesis.
Continuation o f the work described here might focus on the following issues.
First, it would be interesting to characterize the discrepancy between ARF1 and 
ARF6  with respect to their interaction with polyphosphoinositides in order to 
determine whether the observed specificity o f ARF1 towards PLD could be due to 
specific interactions with polyphosphoinositdes. This protein-lipid interaction could be 
investigated by using the liposome-binding assay in which lipid vesicles supplemented 
with the polyphosphoinositdes o f interest would be exposed to the ARF proteins. In 
addition, a qualitative overlay assay using polyphosphoinositdes bound to 
nitrocellulose membranes could be carried out.
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Figure 6.1. Overview o f  the different signalling pathways leading to PLD activation in cells.
Second, localisation studies could be performed in permeabilized HL-60 cells to 
examine whether ARF1 and ARF6  are in fact differently localized in these cells. This 
would require the purification and expression of epitope-tagged ARF proteins. 
Because ARF proteins must be myristoylated to retain biological activity^ epitope 
tagging must be restricted to the carboxyl end o f the molecule. Small tags such as 
haemaglutinin (HA) and larger ones like green fluorescent protein (GFP) could be 
added to the carboxyl terminus. Detection and visualization could be performed by 
specific antibodies and fluorescence microscopy.
Third, it is crucial to elucidate the specific functional role(s) o f the different GDP 
and GTP-bound states o f ARF1 in the regulation o f PLD activity. One o f the 
hallmarks o f this project was the observation that ARF1 at high concentrations could 
activate PLD without the requirement for exogenous GTP. As a consequence, an 
important question arises as to whether a fully-myristoylated form o f ARF1 (T31N), a 
mutant that preferentially binds GDP, could activate PLD in the permeabilized cell 
system. This experiment would reveal whether the GTP-dependent reorganization o f 
the ARF switch regions is required for PLD activation. An answer to this question will 
undoubtedly bring more insight into the functions o f ARF in controlling PLD 
activation.
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